Patent abridgements Part 1 - Intellectual Property Office of New ...

INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND 

Complete Specifications Accepted 

Copies of the specification and drawings (if any) can be obtained 

from the IPONZ website www.iponz.govt.nz. 

At any time within 3 months from the date of issue of this Journal, any 

person interested may give notice of opposition to the grant of a patent 

on any of the applications relating to the accepted complete specification 

shown hereunder, by filing form 15 in duplicate accompanied by a statement 

of the case in duplicate and a fee of $300 plus GST where applicable, 

provided that if an application for extension on form 16 is made within the 

said 3 months, the Commissioner may extend the prescribed period for 

opposition to 4 months from the date of issue of this Journal. The grounds 

for giving notice of opposition are specified in section 21 of the Act, and 

prospective opponents should also refer to regulations 48 to 56 of the 

Patents Regulations 1954. 

(21) 554108 (22) 21 Dec 2005 

(54) Apparatus and method of diagnosis of Cheyne-Stokes breathing in 

a person 

(86) PCT/AU2005/001942 (87) WO06/066337 

(51) IPC2012.01:A61B5/08; G06F7/08, 20 

(71) ResMed Ltd 

(72) Armitstead, Jeffrey 

(31) 04 638169 (32) 23 Dec 2004 (33) US 

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, 

Hamilton, New Zealand 

(57) Disclosed is an apparatus, system, and method of diagnosis for 

detecting the presence of Cheyne-Stokes breathing in a person. The 

apparatus, system and method of diagnosis comprise the following: 

means for receiving data indicative of the person's respiratory flow 

or ventilation, computer processing means for calculating a frequency 

spectrum of said data, computer processing means for analysing said 

frequency spectrum to determine a first measure indicating presence 

of a peak in said frequency spectrum, computer processing means for 

analysing said data to detect the presence of an apnea or hypopnea, 

computer processing means for analysing said data to determine 

a second measure indicative of a rate of increase in the person's 

respiratory flow or ventilation following an apnea or hypopnea, and 

means for providing an output signal indicating that Cheyne-Stokes 

breathing has been detected when both said first measure is indicative 

of the presence of a peak and said second measure is indicative that 

the rate of increase of the respiratory flow or ventilation of the person 

is slow. 

(62) Divided out of 583557 

(21) 556261 (22) 26 Jan 2006 

(54) Animal feed compositions capable of reducing the incidence of fescue 

toxicosis in mammas containing a coated or encapsulated capsaicin 

product and an adsorbant 

(86) PCT/US2006/004870 (87) WO2006/081588 

(51) IPC2012.01:A23K1/18, 16 

(71) ADM ALLIANCE NUTRITION, INC. 

(72) Block, Stephanie S; Cecava, Michael J; Doane, Perry H 

(31) 05 648050 (32) 28 Jan 2005 (33) US 

(74) A J PARK, State Insurance Tower, Level 22, 1 Willis Street, Wellington 

6011, New Zealand 

(57) Disclosed is a method for feeding an animal comprising mixing a 

capsaicin containing product coated or encapsulated within a digestible 

matrix with an adsorbent and an animal feed product selected from the 

group consisting of feed matter, a mineral, a vitamin, an amino acid, 

an antibiotic, a plant extract, a plant botanical, and combinations of 

any thereof, thus producing an animal feed composition or animal feed 

supplement; and feeding the animal feed composition or animal feed 

supplement to an animal selected from the group consisting of bovines, 

equines, ovines, and caprines, wherein the animal is afflicted with a 

fescue toxicosis condition or located in an environment associated with 

fescue toxicosis. 

(21) 564069 (22) 26 Jun 2006 

(54) Prolonged release formulation of active principles having a pHdependent 

solubility 

(86) PCT/FR2006/001466 (87) WO2007/003746 

(51) IPC2012.01:A61K9/24, 36; A61K31/437; A61K47/12 

(71) Sanofi-Aventis 

(72) Alaux, Gerard; Andre, Frederic; Lewis, Gareth; Serre, Veronique 

(31) 05 0506539 (32) 28 Jun 2005 (33) FR 



(57) Disclosed is a prolonged-release formulation that can be used with 

zolpidem or an addition salt thereof having a pH-dependent solubility, 

comprising a matricial excipient based on a hydrophilic polymer 

selected from hydroxypropylmethylcellulose, hydroxyethylcellulose, 

hydroxypropylcellulose or carboxymethylcellulose, plant gums and 

derivatives thereof, alginic acid derivatives, and starch and derivatives 

thereof, the matricial excipient containing a given dose of zolpidem or 

an addition salt thereof, comprising one or more acidifying agents in 

the form of an acid salt of an organic acid wherein the acid salt of 

the acidifying agent is monopotassium tartrate, monosodium tartrate, 

monosodium citrate, bisodium citrate, and/or mixtures thereof. The 

disclosure further relates to formulations comprising a first immediaterelease 

layer comprising zolpidem or an addition salt thereof whose 

solubility is pH-dependent, and one or more binders, the first layer 

optionally containing one or more other excipients; and a second 

prolonged-release layer, adjacent to the first layer, comprising zolpidem 

or an addition salt thereof whose solubility is pH-dependent, one or more 

acidifying agents in the form of an acid salt, and one or more matricial 

excipients, the second layer optionally containing one or more other 

excipients. 

(21) 564510 (22) 28 Jun 2006 

(54) Plant treatment composition formulated as a liquid and comprising 

fludioxonil and one or more neonicotinoid insecticides selected from 

clothianidin, imidacloprid and thiamethoxam 

(86) PCT/US2006/025187 (87) WO2007/005470 

(51) IPC2012.01:A01N43/36, 30, 78, 50, 40, 88; A01G5/06; A01N25/00, 

26; A01N47/44; A01G1/00; A01C1/06 

(71) SYNGENTA PARTICIPATIONS AG 

(72) Torrent Parker, Marlene; Shetty, Kiran 

(31) 05 695143 (32) 29 Jun 2005 (33) US 



(57) Disclosed is a liquid composition for treating plant propagation 

material, and which comprises A) water; B) fludioxonil; C) one or 

more neonicotinoid insecticides selected from the group consisting of 

clothianidin, imidacloprid, and thiamethoxam; and D) a blend of the 

following components, by weight: i) 0.05-20% wetting agent selected 

from one or more lignosulfonic acid Na salt or naphthalenesulfonic acid 

sodium salt; ii) 0.05-10% dispersing agent selected from one or more 

of copolymer butanol PO/EO and acrylic graft copolymer in water and 

propyleneglycol; iii) 0.05-5% drying agent selected from one or more of 

inorganic oxides or polymer waxes and wherein the inorganic oxides are 

selected from the group consisting of silicon dioxide, titanium dioxide, 

aluminium oxide, zirconium oxide and fumed silica, and wherein the 

polymer waxes are selected from the group consisting of oxidized and 

non-oxidized polyethylene wax, polyethylene copolymer wax, Montan 

wax, and polyether wax; and iv) 0.01-20% suberization agent selected 

from at least one starch, alkyl triol, glycerol, alkyl diol, or octanoic acid. 

Further disclosed is a method for preventing pest infestation in useful 

crops comprising treating the plant propagation material of a useful crop 

with a pesticidally effective amount of a composition as defined above, 

wherein said plant propagation material is selected from seeds, roots, 

fruits, tubers, bulbs, or rhizomes. 

(21) 564868 (22) 7 Jun 2006 

(54) System for dynamic determination of disease prognosis 

(86) PCT/US2006/022327 (87) WO2006/133368 

(51) IPC2012.01:G06F19/00; G06Q50/00 

(71) CAREFUSION 303, INC. 

(72) Tabak, Ying P; Johannes, Richard S; Kurtz, Stephen G; Yamaga, 

Cynthia 

PATENT OFFICE JOURNAL 1594 27 April 2012 Page 46


(31) 05 688858 (32) 8 Jun 2005 (33) US 



(57) Disclosed is a system for determining a value for a prognosis 

parameter in real time, comprising: a communications system 

connected to a plurality of networked information sources comprising 

institutional systems and systems that administer and/or monitor 

delivery of medical therapy to patients in a care giving institution; a 

computer provided for: identifying predictor variables and estimating 

regression coefficients associated with the predictor variables in a 

multiple regression model, using a database of patients in a healthcare 

institution; inputting into the multiple regression model condition related 

information about a patient associated with the appropriate predictor 

variables, the condition related information being obtained from said 

plurality of networked sources; and calculating with the computer a value 

for a prognosis parameter with the model, using the predictor variables 

and the regression coefficients; wherein the computer is provided for 

identifying predictor variables and estimating regression coefficients 

associated with the predictor variables by: entering candidate variables 

into the multiple regression model sequentially; drawing random 

samples of the sequentially selected variables from the database of 

patients and fitting the model on these samples; and dropping the 

variables that change sign between samples or are not found to be 

significant. 


(21) 565957 (22) 22 Sep 2006 

(54) Capsule formulation of pirfenidone and pharmaceutically acceptable 

excipients 

(86) PCT/US2006/037057 (87) WO2007/038315 

(51) IPC2012.01:A61K9/48, 16, 28; A61K31/4412 

(71) InterMune, Inc. 

(72) Radhakrishnan, Ramachandran; Vladyka, Ronald; Sultzbaugh, 

Kenneth 

(31) 60/720257 (32) 22 Sep 2005 (33) US 

(74) WRAYS, Ground Floor, 56 Ord Street, West Perth, WA 6005, 

Australia 

(57) Disclosed is a capsule comprising 5-methyl-1-phenyl-2-(1H)pyridone, 

magnesium stearate, microcrystalline cellulose, and 

croscarmellose sodium. Further disclosed is the use of said capsule 

in the manufacture of a medicament for treating pulmonary fibrosis, 

hepatic fibrosis, cardiac fibrosis, keloid, dermal fibrosis, coronary 

restenosis, and post-surgical adhesions, multiple sclerosis, arthritis, 

asthma, chronic rhinitis, and edema. 


(21) 566045 (22) 24 Jul 2006 

(54) Compounds and their salts specific to the PPAR receptors and the 

EGF receptors and their use in the medical field 

(86) PCT/IE2006/000078 (87) WO2007/010516 

(51) IPC2012.01:C07C229/42; A61K31/136; A61P35/00 

(71) Giuliani International Limited 

(72) Naccari, Giancarlo; Baroni, Sergio 

(31) 05 RM A 000389 (32) 22 Jul 2005 (33) IT 



(57) Disclosed is an aromatic amine of the general formula (I) e.g. (±)-2ethoxy-3-(3'-aminophenyl)-propanoic 

acid in which: R1 and R2 which 

may be identical or different, are selected from the group consisting of: H 

and an alkyl group; Y is selected from the group consisting of: H, COOH, 

-OR3 and -CH(OR3)COOH; Z is CH(OR3)COOH and R3 is an alkyl 

group. Also disclosed is the use of said amine of chronic inflammation 

or tumours. 


(21) 566245 (22) 9 Aug 2006 

(54) Tcr-v-beta related peptides for treatment and diagnosis of 

autoimmune disease 

(86) PCT/GB2006/002977 (87) WO2007/017686 

(51) IPC2012.01:C07K16/28, 30 

(71) MATOSSIAN-ROGERS, Arpi 

(72) Matossian-Rogers, Arpi 

(31) 05 0516527 (32) 11 Aug 2005 (33) GB 

(31) 06 0609920 (32) 18 May 2006 (33) GB 

(31) 06 0609921 (32) 18 May 2006 (33) GB 

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins 

Centre, 342 Lambton Quay, Wellington 6011, New Zealand 

(57) Disclosed are peptides derived from antibodies with reactivity against 

a GPI linkage epitope and consisting of the sequence x-I-x-x-x-x-x-x-xx-Y-x-x-x-F-K-x. 

The peptides are used in the detection of autoimmune 

antibodies. Also disclosed is the treatment of diseases including those 

associated with autoimmune antibodies. 


(21) 566406 (22) 25 Oct 2006 

(54) Fermentive production of four carbon alcohols 

(86) PCT/US2006/041602 (87) WO2007/050671 

(51) IPC2012.01:C12P7/16; C12N1/19, 21; C12N15/52 

(71) BUTAMAX ADVANCED BIOFUELS LLC. 

(72) Donaldson, Gail K; Eliot, Andrew C; Flint, Dennis; Maggio-Hall, Lori 

Ann; Nagarajan, Vasantha 

(31) 05 30290 (32) 26 Oct 2005 (33) US 

(74) HOULIHAN2, Level 1, 70 Doncaster Road, Balwyn North, Victoria 

3104, Australia 

(57) A recombinant microbe capable of producing isobutanol, which 

comprises enzymes that can catalyse the reactions: (i) Pyruvate to 

acetolactate (step a); (ii) Acetolactate to 2,3-dihydroxyisovalerate (step 

b) (iii) 2,3-dihydroxyisovalerate to alpha-ketoisovalerate (step c) (iv) 

Alpha-ketoisovalerate to isobutyraldehyde (step d), or alternatively the 

reactions: a. alpha-ketoisvalerate to isobutyryl-CoA (step f); and b. 



Isobutyryl-CoA to isobutyraldehyde (step g); (v) Isobutyraldehyde to 

isobutanol (step e). 


(21) 567230 (22) 8 Sep 2006 

(54) A method of cell nuclear transfer involving a oocyte having at least a 

part of a modifed zona pellucida 

(86) PCT/DK2006/000498 (87) WO2007/028396 

(51) IPC2012.01:C12N15/87, 85 

(71) Aarhus Universitet 

(72) Du, Yutao; Vajta, Gabor; Bolund, Lars Axel; Kragh, Peter Michael 

(31) PA2005 01256 (32) 8 Sep 2005 (33) DK 

(31) PA2006 00316 (32) 3 Mar 2006 (33) DK 

(31) PA2006 00626 (32) 4 May 2006 (33) DK 

(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne, 

Victoria 3000, Australia 

(57) Disclosed is a method of cell nuclear transfer comprising the steps of 

a. establishing at least one pig oocyte having a zona pellucida, which is 

partly removed enzymatically b. separating the pig oocyte into at least 

two parts obtaining at least one cytoplast, c. establishing a donor pig 

cell or pig cell nucleus having desired genetic properties, d. fusing at 

least one pig cytoplast with the donor pig cell or membrane surrounded 

pig cell nucleus of step c e. obtaining a reconstructed pig embryo. Also 

disclosed is a method for producing a genetically modified or transgenic 

pig comprising: a. establishing at least one pig oocyte having a zona 

pellucida, which is partly removed enzymatically b. separating the pig 

oocyte into at least two parts obtaining a pig oocyte having a nucleus 

and at least one cytoplast, c. establishing a pig donor cell or pig cell 

nucleus with desired genetic properties, d. fusing at least one cytoplast 

with the donor cell or membrane surrounded cell nucleus of step c, e. 

obtaining a reconstructed pig embryo f. activating the reconstructed pig 

embryo to form a multi-cell pig embryo; g. culturing said non-human pig 

embryo; and h. transferring said cultured non-human pig embryo to a 

host pig such that the pig embryo develops into a genetically modified 

pig fetus. 

(21) 567483 (22) 4 Nov 2006 

(54) Use of complement pathway inhibitors to treat ocular diseases 

(86) PCT/US2006/043103 (87) WO2007/056227 

(51) IPC2012.01:C07K17/00; A61K38/00 

(71) GENENTECH, INC. 

(72) Fung, Sek Chung; Yao, Zhengbin 

(31) 05 733763 (32) 4 Nov 2005 (33) US 



(57) Provided is the use of a complement inhibitor in the preparation of a 

medicament for preventing or ameliorating an ocular disease associated 

with complement activation in a subject, wherein the complement 

inhibitor inhibits the alternative complement pathway, wherein the 

complement inhibitor inhibits the activity of Factor B, Factor Ba, Factor 

Bb or Factor D, wherein the complement inhibitor is an antibody or a 

binding fragment thereof and wherein the ocular disease is macular 

degeneration, diabetic retinopathy, or ocular angiogenesis. Further 

provided is an ATCC deposit of an antibody suitable for practising the 

invention. 


(21) 567656 (22) 20 Oct 2006 

(54) Methods of filtering a liquid stream produced from an in situ heat 

treatment process 

(86) PCT/US2006/040981 (87) WO2007/050446 

(51) IPC2012.01:B01D61/00; C10G11/00; E21B43/24; C10G45/00; 

C10G1/00, 02 

(71) SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. 

(72) Den Boestert, Johannes Leendert Willem Cornelis; Bond, Wim M; 

Nair, Vijay 

(31) 05 729763 (32) 24 Oct 2005 (33) US 

(31) 06 794298 (32) 21 Apr 2006 (33) US 



(57) Disclosed is a method for producing a hydrocarbon product, 

comprising: providing at least a portion of a liquid stream to a feed side 

of a membrane of a nanofiltration system to produce a permeate, and 

a retentate that comprises clogging compositions wherein: a formation 

fluid comprising mobilized fluids, visbroken fluids, pyrolyzed fluids, or 

mixtures thereof obtained by an in situ heat treatment process is 

separated to produce a gas stream and the liquid stream; the permeate 

is processed in one or more processing units downstream of the 

nanofiltration system to form one or more crude products; at least one 

of the processing units comprises a hydrotreating unit; and contacting 

the permeate with one or more catalysts in the presence of hydrogen 

to produce a product suitable for transportation and/or refinery use. 

Further disclosed is a hydrocarbon product when produced by the above 

method. 

(21) 567657 (22) 20 Oct 2006 

(54) Methods of hydrotreating a liquid stream to remove clogging 

compounds 

(86) PCT/US2006/041185 (87) WO2007/050477 

(51) IPC2012.01:C10G45/00; E21B43/24 

(71) SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. 

(72) Minderhoud, Johannes Kornelis; Nair, Vijay; Nelson, Richard Gene; 

Roes, Augustinus Wilhelmus Maria; Ryan, Robert Charles 

(31) 05 729763 (32) 24 Oct 2005 (33) US 

(31) 06 794298 (32) 21 Apr 2006 (33) US 



(57) Disclosed herein are methods for producing one or more crude 

products that includes producing formation fluid from a subsurface in situ 

heat treatment process; separating the formation fluid to produce a liquid 

stream and a gas stream; providing a liquid stream to a hydrotreating 

unit; hydrotreating at least a portion of the liquid stream at conditions 

sufficient for removal of at least a portion of clogging compositions 

that clog one or more processing units positioned downstream of the 

hydrotreating unit; and processing the hydrotreated liquid stream in one 

or more of the downstream processing units to form one or more crude 

products, wherein the in situ heat treatment process comprises heating 

a hydrocarbon containing formation with one or more heat sources 

which provide heat to at least a portion of the formation substantially by 

conductive and/or radiative heat transfer; and at least a portion of the 

liquid stream is filtered in a filtration system and then hydrotreated in 

the hydrotreating unit to remove the clogging composition; and further 

comprising processing at least a portion of the hydrotreated liquid 

stream in one or more of the downstream processing units to form the 

one or more crude products; and wherein the clogging compositions 

are di-olefins and hydrotreating converts at least a portion of the diolefins 

to mono-olefins; and wherein at least one of the processing 

units comprises a fractionation unit. Also disclosed is a crude product 



produced by the method as well as transportation fuel also produced by 

said method. 

(21) 567766 (22) 13 Nov 2006 

(54) Acetylated amino acids as anti-platelet agents, nutritional and vitamin 

supplements 

(86) PCT/US2006/044011 (87) WO2007/059047 

(51) IPC2012.01:A61K31/4015, 22 

(71) V. Ravi Chandran 

(72) Chandran, V Ravi 

(31) 05 735280 (32) 11 Nov 2005 (33) US 



(57) The disclosure relates to the use of an O-acetylated amino acid or 

pharmaceutically acceptable salt thereof or Zwitterion thereof for the 

manufacture of a medicament for treating or preventing a condition 

selected from stroke, heart attack, thromboembolism, or ischemia, 

wherein the O-acetylated amino acid is O-acetylated-L-hydroxyproline, 

O-acetylated-L-threonine, O-acetyl-L-serine or O-acetyl-L-tyrosine. 


(21) 567963 (22) 10 Nov 2006 

(54) Pharmaceutical combinations comprising testosterone in the 

treatment of female sexual dysfunction 

(86) PCT/NL2006/000542 (87) WO2007/055563 

(51) IPC2012.01:A61K31/4985, 519, 568; A61P15/00 

(71) EMOTIONAL BRAIN B.V. 

(72) Tuiten, Jan Johan Adriaan; Bloemers, Johannes Martinus Maria 

(31) 05077577.4 (32) 11 Nov 2005 (33) EP 



(57) Disclosed is the use of a combination of testosterone or an analogue 

thereof and tadalafil, in the preparation of a medicament for the 

treatment of female sexual dysfunction, wherein said testosterone or 

an analogue thereof and tadalafil are released at essentially the same 

time, or wherein said tadalafil is released prior to said testosterone or 

an analogue thereof, and wherein said testosterone or an analogue 

thereof is provided such that there is a short lasting peak of testosterone 

or an analogue thereof in the blood circulation of the subject to whom 

it is administered such that the peak effects of testosterone or an 

analogue thereof and tadalafil overlap at least in part. Also disclosed is 

a pharmaceutical formulation. 

(21) 567974 (22) 4 Oct 2006 

(54) Thermally enhanced solid-state generator 

(86) PCT/US2006/038789 (87) WO2007/044400 

(51) IPC2012.01:H01G9/21; H01M10/39 

(71) Thomas Beretich 

(72) Beretich, Thomas 

(31) 05 723696 (32) 5 Oct 2005 (33) US 

(74) PIPERS, Level 1, 5A Pacific Rise, Sylvia Park, Mt Wellington, 

Auckland, New Zealand 

(57) Disclosed is an energy conversion device, comprising; at least one 

cell, the cell comprising: a layer of electron-rich donor material in direct 

contact with a layer of a hole-rich acceptor material, and an ionic fluid 

in the donor and acceptor materials to facilitate the flow of electrons 

from the donor material to the acceptor material, thereby creating a cell 

with an electric potential across the junction of the donor and acceptor 

materials, the device being further characterised in that said electric 

potential is created by heat. Also disclosed is an energy conversion 

device, comprising: at least one cell, the cell comprising a carbon matrix 

formed of a stabilized mixture of carbon and an ionic material, an oxide 

matrix formed of a stabilized mixture of an oxide and an ionic material, 

the oxide matrix being in direct contact with the carbon matrix, and an 

electrolyte fluid absorbed into the carbon matrix and the oxide matrix; 

an anode in direct contact with the oxide matrix; and a cathode in direct 

contact with the carbon matrix, thereby creating a cell with an electric 

potential across the junction of the anode and cathode, the device being 

further characterized in that said electric potential is created by heat. 

Further disclosed is an energy conversion device for converting thermal 

energy to electrical energy, consisting of: a cell, the cell consisting of 

a stabilized mixture of carbon and an ionic material, and a stabilized 

mixture of an oxide and an ionic material; an anode in direct contact with 

the mixture of carbon and ionic material; and a cathode in direct contact 

with the mixture of oxide and ionic material, thereby creating a cell 

with an electric potential across the junction of the anode and cathode, 

the device being further characterized in that said electric potential is 

created by heat. 

(21) 568429 (22) 7 Dec 2006 

(54) Film-coated and/or granulated calcium-containing compounds and 

use thereof in pharmaceutical compositions 

(86) PCT/DK2006/000696 (87) WO2007/065441 

(51) IPC2012.01:A61K9/16, 20; A23L1/09, 303, 304; A61K33/06; 

A61K47/26 

(71) Nycomed Pharma AS 

(72) Piene, Jan Yngvar 

(31) 05 01736 (32) 7 Dec 2005 (33) DK 

(31) 06 01203 (32) 15 Sep 2006 (33) DK 

(31) 06 850130 (32) 6 Oct 2006 (33) US 

(74) FB RICE, Level 23, 200 Queen Street, Melbourne, Victoria 3000, 

Australia 

(57) Disclosed herein is a method for the preparation of a 

granulated calcium-containing compound wherein the calciumcontaining 

compound is selected from the group consisting of calcium 

carbonate, calcium citrate, calcium lactate, calcium phosphate including 

tricalcium phosphate, calcium gluconate, bisglycino calcium, calcium 

citrate maleate, hydroxyapatite including solvates thereof and mixtures 

thereof in a concentration of 50% w/w or more and in the form of 

particles and/or crystals, the method comprising applying a granulating 

composition comprising i) one or more water-soluble substances 

selected from the group consisting of polyols and carbohydrates, 

and ii) one or more polymeric substances selected from the group 

consisting of povidones and copovidones, and mixtures thereof, to a 

calcium-containing compound, and the water-soluble substance and 

the polymeric substance are dispersed or dissolved in a solvent. Also 

disclosed is a partly film-coated calcium-containing compound, wherein 

the calcium-containing compound is in the form of particles and/or 

crystals having at least part water-soluble film coating comprising i) one 

or more water-soluble substances selected from the group consisting of 

polyols and carbohydrates, and ii) one or more polymeric substances 

selected from the group consisting of povidones and copovidones, and 

mixtures thereof. 

(21) 568991 (22) 19 Dec 2006 

(54) Treating chronic fibrotic diseases by decreasing CCL21 activity 

(86) PCT/US2006/048282 (87) WO2007/075592 

(51) IPC2009.01:C12N5/06, 16; C12Q1/68 

(71) The Regents of the University of Michigan 

(72) Hogaboam, Cory M; Kunkel, Steven L 

(31) 05 753647 (32) 23 Dec 2005 (33) US 

(74) WRAYS, Ground Floor, 56 Ord Street, West Perth, WA 6005, 

Australia 

(57) Disclosed is the treatment of chronic fibrosis by decreasing the 

presence or activity of the chemokine CCL21 in fibrocytes and 

fibroblasts. The activity or presence of CCL21 can be decreased by 

using an antibody or siRNA either alone or in combination with an agent 

that decreases the activity or presence of the chemokine CCL19. The 

fibrosing disorder can be a chronic pulmonary fibrosis. 

(21) 569417 (22) 17 Jan 2007 

(54) A novel surface exposed haemophilus influenzae protein (protein E; 

pE) 

(86) PCT/SE2007/000034 (87) WO2007/084053 

(51) IPC2012.01:C07K14/285; C07K16/12; A61K39/102 

(71) Arne Forsgren 

(72) Forsgren, Arne; Riesbeck, Kristian 

(31) 06 758987 (32) 17 Jan 2006 (33) US 



(57) Disclosed is a vaccine composition comprising a surface exposed 

protein, which can be detected in Haemophilus influenzae, having an 



amino acid sequence as described in Sequence ID NO: 1, or a fragment 

thereof, wherein the fragment comprises an amino acid sequence 

having at least 50 contiguous amino acids from the amino acid sequence 

of SEQ ID NO: 1 which fragment, if necessary when coupled to a 

carrier, is capable of raising an immune response which recognises the 

polypeptide of SEQ ID NO: 1. 

(21) 569477 (22) 6 Dec 2006 

(54) Geopolymeric particles, fibers, shaped articles and methods of 

manufacture 

(86) PCT/IB2006/004268 (87) WO2007/119121 

(51) IPC2012.01:C04B28/00; C01B33/26; C04B14/04, 46 

(71) James Hardie Technology Limited 

(72) Biscan, Giang; Hojaji, Hamid; Melmeth, David Leslie; Pham, Thinh; 

Zhang, Huagang 

(31) 05 748037 (32) 6 Dec 2005 (33) US 

(74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, 

Australia 

(57) Disclosed is a shaped geopolymeric particle having a predetermined 

configuration, comprising a geopolymer functional building block, 

wherein the geopolymer functional building block is derived from 

geopolymerization of a selected precursor formulation comprising an 

amorphous silicate, an alkali activator, and a rheology modifier, wherein 

the geopolymerization of the precursor formulation occurs at a nonelevated 

temperature of between about 50 and 600 degrees F such 

that the non-elevated temperature in conjunction with the preselected 

precursor formulation modify the viscoelastic behaviour of the precursor 

formulation so that the rate of geopolymerization can be controlled 

to provide sufficient time for shaping the geopolymer particle into the 

predetermined configuration. Also disclosed is a shaped geopolymeric 

particle comprising a geopolymer, wherein the shaped geopolymeric 

particle has one or more voids therein, wherein the shaped geopolymer 

particle is derived from geopolymerization of a precursor formulation 

comprising an aluminosilicate source, an alkali source, and a blowing 

agent, wherein the precursor formulation has a preselected viscosity 

so that the configuration of the shaped geopolymeric particle can be 

controlled during geopolymerization. Further disclosed is a geopolymer 

with less than about 1.00 g/cc and how to make it and fibres 

incorporating the geopolymer. 

(21) 569562 (22) 28 Dec 2006 

(54) Placental stem cell populations, CD200 

(86) PCT/US2006/049491 (87) WO2007/079183 

(51) IPC2009.01:C12N5/06 

(71) ANTHROGENESIS CORPORATION 

(72) Abramson, Sascha Dawn; Edinger, James W; Faleck, Herbert; Hariri, 

Robert J; Labazzo, Kirsten S; Pereira, Marian; Wang, Jai-lun; Ye, Qian 

(31) 05 754968 (32) 29 Dec 2005 (33) US 

(31) 06 846641 (32) 22 Sep 2006 (33) US 

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand 

(57) Provided is a method of producing a cell population comprising 

isolating from other cells placental stem cells that adhere to a substrate, 

and determining that said placental stem cells express CD200; wherein 

said isolated placental stem cells constitute said cell population, and 

wherein said placental stem cells are not totipotent stem cells or 

trophoblasts. The stem cells can differentiate to chondrocytes or 

osteogenic cells. 


(21) 570106 (22) 26 Jan 2007 

(54) Influenza vaccines containing hemagglutinin and matrix proteins 

(86) PCT/IB2007/001150 (87) WO2007/085969 

(51) IPC2012.01:A61K39/145 

(71) Novartis Vaccines and Diagnostics GmbH & Co. KG 

(72) Broeker, Michael; Kost, Holger 

(31) 06 0601733 (32) 27 Jan 2006 (33) GB 

(31) 06 0620175 (32) 11 Oct 2006 (33) GB 


Australia 

(57) Disclosed is a purified surface antigen or split virion influenza vaccine 

comprising influenza virus haemagglutinin and a fragment of M1 matrix 

protein which co-purify, wherein said matrix protein fragment comprises 

a T cell epitope of said M1 matrix protein and has a molecular weight 

that is less than or equal to 10kDa, and wherein the composition does 

not contain ovalbumin. 

(21) 570213 (22) 6 Feb 2007 

(54) Device for treating snoring by passing the device through the tongue 

and anchoring it under and at the back of the tongue 

(86) PCT/US2007/061721 (87) WO2007/092865 

(51) IPC2012.01:A61F2/02; A61F5/56 

(71) LINGUAFLEX, INC. 

(72) Sanders, Ira 

(31) 06 765638 (32) 6 Feb 2006 (33) US 

(74) DAVIES COLLISON CAVE-Melbourne, 1 Nicholson Street, 

Melbourne, Victoria, Australia 

(57) Methods and devices to prevent or treat sleep apnea and snoring. One 

aspect of this invention is a tongue retractor (LTR) that indirectly retracts 

tongue base by its implant site in the frenulum area. This simplifies the 

insertion, adjustment and maintenance of the device. Another aspect 

of this invention describes a highly localized and fully implantable LTR 

that is inserted into the base of tongue to stiffen lax surface mucosa or 

mechanically couple it to internal tongue structures. Another aspect of 

this invention is an LTR inserted in or around the pharyngoglossal fold. 

This site allows retraction and stiffening of tongue base tissue as well 

as the soft palate and lateral pharyngeal wall. 


(21) 571087 (22) 8 Dec 2006 

(54) Cellulolytic enzymes, nucleic acids encoding them and methods for 

making and using them 

(86) PCT/US2006/046919 (87) WO2007/094852 

(51) IPC2012.01:C12N9/42 

(71) Verenium Corporation 

(72) Gray, Kevin A; Zhao, Lishan; Cayouette, Michelle 

(31) 06 772786 (32) 10 Feb 2006 (33) US 



(57) Provided are cellobiohydrolase sequences and their variants, which 

can be used in expression vectors and transgenic organisms to 

manipulate cellulose metabolism. Further provided are corresponding 

antisense and RNAi oligonucleotides for inhibiting the translation of a 

cellulase message in cells and various other cellulose related food and 

fibre industry applications. 


(21) 571696 (22) 1 Mar 2007 

(54) Regulation of immune responses by modulation of the function of 

antigen presenting cells 

(86) PCT/AU2007/000254 (87) WO2007/098557 

(51) IPC2012.01:A61K38/16; A61P37/02 

(71) CBio Limited 

(72) Johnson, Barbara Jane; Dobbin, Caroline Amanda; Flesch, Inge E A 

(31) 2006901058 (32) 2 Mar 2006 (33) AU 

(74) SPRUSON & FERGUSON, St Martins Tower, Level 35, 31 Market 

Street, Sydney, New South Wales 2000, Australia 

(57) Provided is the use of chaperonin 10 (Cpn10) in the manufacture of 

a medicament for treating or preventing a disease or condition arising 

from an infection by a viral or bacterial pathogen in a subject, wherein the 

disease or condition is selected from cancer, an autoimmune disorder, 

inflammation, allergy, and asthma. The Cpn10 modulates the level of 

cell surface expression of at least one MHC molecule in the subject, 

particularly HLA-DR, HLA-DP and HLA-DQ. Further provided is an 

in vitro method of identifying compounds that modulate an immune 

response by screening for MHC molecule modulation in the presence 

of Cpn10. 

(21) 571788 (22) 25 Apr 2007 

(54) Fungicidal compositions comprising sodium lauryl sulfate and/or 

thyme oil and methods of using the same 

(86) PCT/US2007/009958 (87) WO2007/127211 

(51) IPC2012.01:C14C1/00 



(71) BUCKMAN LABORATORIES INTERNATIONAL, INC. 

(72) Stockman, George B; Oppong, David 

(31) 06 795864 (32) 28 Apr 2006 (33) US 



(57) Disclosed is a method of preventing or inhibiting putrefaction, 

degradation, and/or deterioration of a surface of wet, tanned animal 

hide or skin, the method comprising applying a composition consisting 

of sodium lauryl sulfate and/or thyme oil and optionally at least one 

inert ingredient to the surface or to a solid, liquid or gas that comes 

in contact with the surface, in an effective amount to inhibit or prevent 

putrefaction, degradation, and/or deterioration of said surface, wherein 

the composition is applied in an amount of from about 0.25 to about 100 

pounds (about 0.1 to about 45.4 kg) of said composition per about 3,000 

pounds (about 1360 kg) of wet, tanned hides or skins. 


(21) 572365 (22) 27 Apr 2007 

(54) COATING COMPOSITIONS WITH POLYMERIZABLE 

ETHYLENICALLY UNSATURATED COMPOUNDS SUITABLE FOR 

USE AS A WOOD STAIN AND/OR TONER 

(86) PCT/US2007/067581 (87) WO2007/130849 

(51) IPC2012.01:B05D7/08; C09D133/00; C09D15/00 

(71) PPG INDUSTRIES OHIO, INC. 

(72) DEAN, Roy E; DUDIK, John M; DUFFY, Shawn P; FOUKES, Richard 

J; ZIEGLER, Michael J 

(31) 06 797441 (32) 4 May 2006 (33) US 

(31) 07 737854 (32) 20 Apr 2007 (33) US 



(57) Disclosed is a radiation curable wood stain or wood toner composition 

comprising: (a) a film-forming resin, (b) a colorant, (c) a long chain alkyl 

group containing polymerizable ethylenically unsaturated compound 

comprising a (meth)acrylate. (d) a diluent. 

(21) 572386 (22) 4 Apr 2007 

(54) A teatcup liner with a flexible engagement member arranged to 

engage with a shell to form a teatcup 

(86) PCT/SE2007/050218 (87) WO2007/139481 

(51) IPC2012.01:A01J5/08 

(71) DeLAVAL HOLDING AB 

(72) Kassibrahim, Jan 

(31) 0601203-3 (32) 31 May 2006 (33) SE 


(57) Disclosed is a teatcup liner adapted to be mounted in a shell to 

form a teatcup to be applied to a teat of an animal. The teatcup liner 

has an inner space with an upper head for receiving the teat and an 

outer side with a barrel. The barrel has an end portion on the outer 

side of which a primary engagement member is arranged. The primary 

engagement member is adapted to be in engagement with a secondary 

engagement member arranged on the shell. The primary engagement 

member is bendable relative to a length axis of the liner. A hindering 

member is arranged on the outer side of the teatcup liner on a side 

of the primary engagement member distant from the upper head so 

as to restrict bending of the primary engagement member away from 

the upper head whilst permitting bending of the primary engagement 

member towards the upper head. When the primary engagement 

member is engaged with the secondary engagement member, the 

primary engagement member is located intermediate the secondary 

member and the hindering member. Methods for mounting the teatcup 

liner in a shell are also disclosed. 

(21) 573370 (22) 20 Jun 2007 

(54) Sealing insert with a coloured adhesive layer sandwiched between 

support layer and transparent laminated film 

(86) PCT/EP2007/056143 (87) WO2008/000673 

(51) IPC2012.01:B65D53/04; B32B7/02; C09J7/02 

(71) Alfelder Kunstoffwerke Herm. Meyer GmbH 

(72) ROTHWEILER, Peter 

(31) 06 06030116 (32) 28 Jun 2006 (33) DE 

(31) 06 06048009 (32) 9 Oct 2006 (33) DE 

(74) LESICAR MURRAY TRENTO, 58 Rundle Street, Kent Town, South 

Australia 5067, Australia 

(57) Disclosed is a container closure that is in combination with a 

sealing insert. The sealing insert is inserted into the container closure. 

The sealing insert comprises a support layer (10) and a transparent 

lamination film (20). The transparent lamination film is connected to the 

support layer (10) via a coloured adhesive layer (30). 

(21) 573646 (22) 12 Jun 2007 

(54) SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH 

EFFECTOR FUNCTION 

(86) PCT/US2007/071052 (87) WO2007/146968 

(51) IPC2012.01:C07K16/28; A61K39/395; A61P31/00; A61P35/00 

(71) Wyeth LLC; Emergent Product Development Seattle, LLC 

(72) THOMPSON, Peter, Armstrong; LEDBETTER, Jeffrey, A; HAYDEN- 

LEDBETTER, Martha, Susan; GROSMAIRE, Laura, Sue; BADER, 

Robert; BRADY, William; TCHISTIAKOVA, Lioudmila; FOLLETTIE, 

Maximillian, T; CALABRO, Valerie; SCHULER, Alwin 

(31) 06 813261 (32) 12 Jun 2006 (33) US 

(31) 06 853287 (32) 20 Oct 2006 (33) US 



(57) Provided is a multivalent single-chain binding protein comprising 

from amino to carboxy terminus: a. a first binding domain derived 

from an immunoglobulin-like molecule or the variable regions 

of an immunoglobulin; b. a constant sub-region comprising an 

immunoglobulin CH2 domain and a CH3 domain; c. a scorpion linker, 

wherein said scorpion linker comprises an amino acid sequence derived 

from a hinge of an immunoglobulin or immunoglobulin-like molecule 

or an extracellular stalk region of a type 2 membrane protein in 



the C-type lectin family; and d. a second binding domain derived 

from an immunoglobulin-like molecule or the variable regions of an 

immunoglobulin. 


(21) 573845 (22) 12 Jul 2006 

(54) PRESERVED SLICES OF VEGETABLES AND FRUITS AND 

PROCESSING METHODS 

(86) PCT/EP2006/006825 (87) WO2008/006388 

(51) IPC2012.01:A23B7/02; A23L1/212 

(71) Nestec S.A. 

(72) ERLE, Ulrich; LERMER, Roland 

(31) (32) 12 Jul 2006 (33) EP 



(57) Provided is a method of preparing a dehydrated slice of a vegetable or 

a fruit, the method comprising the steps of: - cutting a vegetable or fruit 

in a plurality of slices, - heat-treating said slices by one or more waterbased 

heating methods selected from the group consisting of blanching, 

boiling and steaming, - contacting said slices with carbohydrate, which 

is a non-reducing disaccharide, either during or after the heat-treating 

step to provide carbohydrate uptake by the slices and/or a coating of the 

surface of said slices, - pre-drying said heat-treated slices, wherein each 

slice is placed on an air-permeable surface such that the slices do not 

overlap each other, and wherein the slices contact said air-permeable 

surface such that a shrinking of the circumference is substantially 

prevented, and - final air drying, whereby a dehydrated slice is obtained, 

said dehydrated slice comprising; - a circumference being substantially 

the same as a circumference of the respective slice of the raw vegetable 

or fruit; - a thickness reduced by 20 to 95 % in comparison to the 

thickness of the respective slice of the raw vegetable or fruit, and having 

a planar surface, - a coloured peel or skin and said peel or skin is 

not visibly discoloured in comparison to the peel or skin colour of the 

respective raw vegetable or the raw fruit, and - adapted to be rehydrated 

by a rehydration process. 

(21) 574108 (22) 12 Jul 2007 

(54) IMPROVEMENTS IN AND RELATING TO PLANT PROTECTION 

(86) PCT/GB2007/002611 (87) WO2008/007100 

(51) IPC2012.01:A01N37/42, 44 

(71) PLANT BIOSCIENCE LIMITED 

(72) ROBERTS, Michael Richard; PAUL, Nigel Duncan; TAYLOR, Jane 

Elizabeth; CROFT, Patricia; MOORE, Jason Paul 

(31) 0613901.8 (32) 13 Jul 2006 (33) GB 



(57) Provided is a method of treating a seed with a seed treatment 

composition to induce a plant resistance mechanism against one or 

more pests in a plant grown from said seed so as to restrict plant damage 

by pests, the method including applying the treatment composition 

to a seed, wherein the seed is a non-germinated seed, and wherein 

the treatment composition includes a treatment agent selected from 

jasmonic acid (JA) or its jasmonate salts wherein said salts are selected 

from the group consisting of potassium or sodium jasmonate; jasmonic 

acid methyl ester; jasmonic acid- L-amino acid amide-linked conjugates 

selected from the group consisting of the conjugate with L-isoleucine 

or the conjugates with L-valine, L-leucine and L-phenylalanine; 12-oxophytodienoic 

acid; coronatine; coronafacoyl-L-serine and coronafacoyl- 

L-threonine; methyl esters of 1-oxo-indanoylisoleucine and 1-oxoindanoyl-leucine; 

coronalon; or combinations thereof, wherein the 

resistance mechanism is induced due to the treatment of the nongerminated 

seed rather than due to carry over of treatment composition 

from the seed onto a germinating plant. 

(21) 574173 (22) 20 Jul 2007 

(54) METHODS AND COMPOSITIONS FOR THE TREATMENT AND 

PREVENTION OF INFECTIONS 

(86) PCT/US2007/016485 (87) WO2008/011164 

(51) IPC2012.01:A61K9/00 

(71) Advanced Vision Research, Inc. 

(72) GILBARD, Jeffrey P 

(31) 06 490917 (32) 21 Jul 2006 (33) US 

(74) Pizzeys Patent and Trade Mark Attorneys, Level 20, ANZ Centre, 324 

Queen Street, Brisbane, Queensland 4000, Australia 

(57) Disclosed is an ophthalmologic preparation comprising chlorine 

dioxide as an oxidizing antibacterial agent and a xanthine as a 

heterocyclic compound wherein the heterocyclic compound improves 

the antibacterial effect of the oxidizing agent. The preparation is used 

for treating a microbial colonization or infection of the ocular surface or 

eyelid. 

(21) 574228 (22) 12 Apr 2010 

(54) Milk headspace sensing techniques 

(51) IPC2012.01:A01J5/00 

(71) Lely Patent N.V. 

(72) Wilson, Allan Walter 



(57) Provided is a method of analysing milk components having the steps 

of: a) collecting a milk sample from a milk stream of a milking system; 

b) ionising the milk sample, and c) using an ion mobility spectrometer to 

detect components of interest within the ionised milk sample the method 

characterised in that the ion mobility spectrometer is positioned within 

the milking system from which the milk sample was taken, and the milk 

sample is collected in a gaseous form. Further provided is a device 

configured to perform the method using milk sampled from a headspace 

above milk liquid in a milking system. 

(21) 574390 (22) 27 Jun 2007 

(54) FATTY ACID BLENDS AND USES THEREFOR IN FUEL 

(86) PCT/US2007/015017 (87) WO2008/002643 

(51) IPC2012.01:C07B53/00; C07C53/00; C12N15/82; C10L1/02 

(71) COH Inc. 

(72) KNUTH, Mark, E; BEETHAM, Peter, R; WALKER, Keith, A; GOCAL, 

Gregory, Francis William 

(31) 06 817558 (32) 28 Jun 2006 (33) US 



(57) A mixture of fatty acid alkyl esters that comprises: (i) At least 50 

percent by weight of saturated medium chain fatty acid alkyl esters that 

have 6-14 carbons, myristoleic acid alkyl ester and monosaturated long 

chain fatty acid alkyl esters having more than 18 carbons; and (ii) Less 

than 10 percent by weight myristic acid alkyl ester and saturated long 

chain acid alkyl esters. The mixture comprises either (1) lauric acid alkyl 

ester (C12:0) at 5 to 20 percent by weight of the mixture or (2) the mixture 

comprises 15 to 40 percent fatty acid alkyl esters having 6-14 carbons 

and 60 to 85 percent monosaturated fatty acid alkyl esters having more 

than 18 carbons. The mixture can be used as a fuel for an internal 

combustion engine; in particular the mixture is used in a biodiesel blend. 


(21) 574423 (22) 26 Jul 2007 

(54) IMMUNOGENIC COMPOUNDS AND PROTEIN MIMICS 

(86) PCT/NL2007/050374 (87) WO2008/013454 

(51) IPC2012.01:C07K14/48, 49, 495, 52, 59, 61; A61K39/00; C07K1/04; 

A61K47/42; C07K7/54; G01N33/68 

(71) PEPSCAN SYSTEMS B.V. 

(72) TIMMERMAN, Peter; PUIJK, Wouter, Cornelis; MELOEN, Robbert, 

Hans 

(31) 06 06076478 (32) 26 Jul 2006 (33) EP 



(57) Disclosed is a method for inducing and/or enhancing immunogenic 

reproducibility and/or immunogenicity of an amino acid sequence, 

comprising a. coupling said amino acid sequence via at least two 

linkages at a site outside an epitope to a (hetero)aromatic molecule 

with at least two benzylic halogen substituents wherein each of the at 

least two linkages is formed by reacting a benzylic halogen substituent 

of the (hetero)aromatic molecule with a nucleophilic functionality within 

the peptide structure; and b. forming at least one internal bond within 

said amino acid sequence at a site outside an epitope after coupling of 



the amino acid sequence to the (hetero)aromatic molecule, wherein the 

at least one internal bond is a disulphide bond or a diselenium bond. 

Further disclosed are immunogenic compounds comprising an amino 

acid sequence bound to a (hetero)aromatic molecule via at least two 

linkages at a site outside an epitope, wherein said at least two linkages 

are at a benzylic position of said (hetero)aromatic molecule, wherein 

said amino acid sequence comprises at least one internal bond, and 

wherein said internal bond is a disulphide bond or a diselenium bond. 

(21) 574447 (22) 24 Aug 2007 

(54) TAMPER RESISTANT ORAL PHARMACEUTICAL DOSAGE 

FORMS COMPRISING AN OPIOID ANALGESIC 

(86) PCT/IB2007/002515 (87) WO2008/023261 

(51) IPC2012.01:A61K31/485; A61K9/22, 32 

(71) Purdue Pharma L.P. 

(72) MANNION, Richard, Owen; O'DONNELL, Edward, Patrick; 

McKENNA, William, Henry; HUANG, Haiyong, Hugh 

(31) 06 840244 (32) 25 Aug 2006 (33) US 


Australia 

(57) Disclosed is a process of preparing a solid oral extended release 

pharmaceutical dosage form, comprising combining (a) combining (1) 

at least one polyethylene oxide and (2) at least one active agent 

selected from i) opioid analgesics ii) therapeutically active agents 

iii) combinations of i) and ii); and iv) benzodiazepines, barbiturates, 

amphetamines, stimulants, combinations with respective antagonists, 

pharmaceutically acceptable salts, hydrates, and solvates and mixtures 

thereof to form a composition; (b) shaping the composition to form 

an extended release matrix formulation; and (c) curing said extended 

release matrix formulation 


(21) 574469 (22) 26 Jun 2007 

(54) SEASONING AND METHOD FOR SEASONING A FOOD PRODUCT 

WHILE REDUCING DIETARY SODIUM INTAKE 

(86) PCT/US2007/014801 (87) WO2008/005237 

(51) IPC2012.01:A23L1/22, 237, 221, 29, 304 

(71) ConAgra Foods RDM, Inc. 

(72) JENSEN, Michael; SMITH, Gordon; FEAR, Shawn; 

SCHILMOELLER, Lance; JOHNSON, Clinton 

(31) 06 817993 (32) 30 Jun 2006 (33) US 

(31) 06 847724 (32) 27 Sep 2006 (33) US 

(31) 06 847725 (32) 27 Sep 2006 (33) US 

(31) 06 847734 (32) 27 Sep 2006 (33) US 

(31) 07 708667 (32) 20 Feb 2007 (33) US 

(31) 06 847739 (32) 27 Sep 2006 (33) US 



(57) Disclosed is a flowable solid seasoning composition to reduce dietary 

sodium intake, comprising small particle sodium chloride salt having 

a mean particle size greater than or equal to 5 microns and less 

than 20 microns to reduce the sodium content of the solid seasoning 

composition, wherein the salt intensity of the seasoning composition 

is greater than or equivalent to the salt intensity of a flowable solid 

seasoning comprising a greater percent by weight of sodium chloride. 

Also disclosed is a food product containing the seasoning composition; 

a method for making the food product and the use of the seasoning 

composition for a reduced salt diet. 

(21) 574644 (22) 14 May 2007 

(54) VITAMIN D COMPOSITIONS AND METHOD OF ADMINISTRATION 

TO A HUMAN BEING 

(86) PCT/CA2007/000844 (87) WO2008/031188 

(51) IPC2012.01:A61P3/02; A61J7/00; A61K9/08; A61K31/59; 

A61J17/00; A23D9/007; A61K47/14 

(71) Elaine Vieth; Reinhold W Vieth 

(72) VIETH, Reinhold, W; VIETH, Elaine 

(31) 06 2558202 (32) 14 Sep 2006 (33) CA 

(31) 07 2578881 (32) 16 Feb 2007 (33) CA 

(74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street, 

Melbourne, Victoria 3000, Australia 

(57) Provided is a composition for application to an object surface to 

provide a therapeutic or nutritional amount of vitamin D in a single drop 

to a human being who is to suck said composition directly from said 

object surface. wherein said composition oomprises vitamin D and a 

compound selected from the group consisting of caprylic acid, caprylic 

monoglyceride and monocaprylin, in a liquid, biologically-acceptable oil 

medium, wherein the concentration of vitamin D is between 9 to 9000 

mcg/ml. 


(21) 574760 (22) 25 Jul 2007 

(54) OSCILLATING WATER COLUMN POWER GENERATOR 

(86) PCT/GB2007/002827 (87) WO2008/012530 

(51) IPC2012.01:F01D1/30, 02; F01D5/14; F03B13/14; F15D1/12 

(71) Dresser-Rand Company Limited 

(72) FREEMAN, Christopher; HERRING, Steven, James; BANKS, Kevin 

(31) 06 0614916 (32) 25 Jul 2007 (33) GB 



(57) A bi-directional flow impulse type turbine arrangement (120) for use 

with a bi-directional reversing flow (F, Fl, F2)., and in particular for 

use with an oscillating water column power plant (110). The turbine 

arrangement has a rotor (132), and first and second sets of guide vanes 

(140, 142) located on an opposite axial sides of the rotor for directing the 

bi-directional reversing flow to and from the rotor. The guide vanes are 

disposed at a greater radius and radially offset from the rotor blades. The 

turbine arrangement further comprises first and second annular ducts 

disposed respectively between the first and second sets of guide vanes 

and the rotor for directing fluid from the guide vanes to the rotor blades. 

In addition, the vanes have a profile to maintain a constant flow passage 

between the vanes over a turning section of the vanes, and the rotor 

blades of the rotor have a higher turning angle, and producing a nonaxial 

outlet downstream flow. The turbine may also incorporate vanes 

with a slot and a boundary layer blowing arrangement to re-energise 

and improve the reverse flow over the vanes. 

(21) 574809 (22) 1 Feb 2010 

(54) Biomimetic mechano-sensitive actuator array 

(51) IPC2012.01:F03G7/00; H01L41/09 

(71) Auckland UniServices Limited 

(72) Anderson, Iain Alexander; O'Brien, Benjamin Marc; Gisby, Todd; 

Calius, Emilio Patricio; Xie, Shane 



(57) A biomimetic actuator array adapted for sequential actuation by 

way of mechanosensitivity propagating actuation through the array, a 

mechano-sensitive actuator adapted for use in a biomimetic actuator 

array, and a method of controlling an actuator in a biomimetic actuator 

array is disclosed. An array of actuators is provided which is adapted 

for sequential actuation by way of mechanosensitivity propagating 



actuation through the array, triggering each actuator upon deformation 

thereof caused by an adjacent actuator or a load in the form of a 

fluid or a solid object. Actuation is thus coordinated with minimal 

computational overhead. The mechano-sensitive actuator for use in 

a biomimetic actuator array comprises: (a) manipulation means for 

selectively manipulating a fluid or solid object; (b) sensing means for 

sensing deformation of the manipulation means; and (c) triggering 

means for actuating the manipulation means upon sensing deformation 

thereof where the actuator propagates actuation through the array by 

way of mechano-sensitivity. 

(21) 574846 (22) 29 Aug 2007 

(54) USE OF DPA(n-6) OILS IN INFANT FORMULA 

(86) PCT/US2007/077150 (87) WO2008/027991 

(51) IPC2012.01:A23L1/29, 30; A61K31/202, 66 

(71) MARTEK BIOSCIENCES CORPORATION 

(72) ARTERBURN, Linda; BARCLAY, William; FLATT, James; VAN 

ELSWYK, Mary; ZELLER, Samuel G 

(31) 06 823875 (32) 29 Aug 2006 (33) US 



(57) Disclosed is an infant formula composition, wherein, when ready for 

consumption by the infant, the composition includes long chain n-3 fatty 

acids and long chain n-6 fatty acids; wherein the long chain n-3 fatty 

acids include docosahexaenoic acid (DHA); wherein the long chain n-6 

fatty acids include docosapentaenoic acid (DPA(n-6)) and arachidonic 

acid (ARA); wherein the ratio of ARA:DHA is greater than 0.4:1 and less 

than 3:1, and wherein the DHA:DPA(n-6) ratio is from 10:1 to 0.5:1. 

(21) 574895 (22) 19 Jul 2007 

(54) METABOLICALLY ENGINEERED CELLS FOR THE PRODUCTION 

OF PINOSYLVIN 

(86) PCT/EP2007/057484 (87) WO2008/009728 

(51) IPC2012.01:C12P7/22 

(71) Fluxome Sciences A/S 

(72) KATZ, Michael; FORSTER, Jochen; DAVID, Helga; SCHMIDT, 

Hans Peter; SENDELIUS, Malin; BJORN, Sara Petersen; DURHUUS, 

Thomas Thomasen 

(31) 06 0614442 (32) 20 Jul 2006 (33) GB 


Australia 

(57) Disclosed is the use of a micro-organism for the production of 

pinosylvin, wherein said micro-organism has an operative metabolic 

pathway comprising at least one enzyme activity, said pathway 

producing pinosylvin from cinnamic acid, wherein cinnamoyl-CoA is 

formed from cinnamic acid in said pathway in a reaction catalysed 

by a 4-coumarate-CoA ligase or a citmamoyl-CoA ligase expressed in 

said micro-organism and said pinosylvin is produced from cinnamoyl- 

CoA by a stilbene synthase expressed in said micro-organism. Further 

disclosed is a method for producing pinosylvin comprising culturing a 

micro-organism cell having a pinosylvin producing metabolic pathway 

under pinosylvin producing conditions, wherein said pathway comprises 

a phenylalanine ammonia lyase (PAL) accepting phenylalanine as a 

substrate and producing cinnamic acid therefrom, said PAL being such 

that if the PAL also accepts tyrosine as a substrate and forms coumaric 

acid therefrom, the ratio Km, (phenylalanine) I Km, (tyrosine) for said 

PAL is less than 1:1 , and wherein if said micro-organism produces a 

cinnamate-4-hydroxylase enzyme (C4H), the ratio Kcat (PAL) I Kent 

(C4H) is at least 2:1. 

(21) 575007 (22) 15 Jun 2007 

(54) DISPERSANT COATED WEIGHTING AGENTS 

(86) PCT/US2007/071338 (87) WO2008/033591 

(51) IPC2012.01:C09K8/03, 02; C09K3/00; C22B43/00 

(71) M-I L.L.C. 

(72) MASSAM, Jarrod 

(31) 06 825156 (32) 11 Sep 2006 (33) US 

(31) 07 741199 (32) 27 Apr 2007 (33) US 



(57) Disclosed is a method of formulating a wellbore fluid comprising: 

dry coating a weighting agent with a dispersant to form a sized 

weighting agent coated with the dispersant, wherein the dry coating 

comprises at least one of thermal adsorption of the dispersant onto 

the weighting agent, heating a sized weighting agent to a temperature 

sufficient to react a monomeric dispersant onto a weighting agent to 

form a polymer coated weighting agent, or spray drying; providing 

a base fluid; and adding the sized weighting agent coated with the 

dispersant to the base fluid; wherein the weighting agent is at least one 

selected from barite, calcium carbonate, dolomite, ilmenite, hematite, 

olivine, siderite, manganese oxide, and strontium sulfate; wherein 

the dispersant comprises at least one selected from polyacrylate 

esters, poly(meth)acrylic acid, a homopolymer or copolymer of any 

monomer selected from acrylic acid, itaconic acid, maleic acid or 

anhydride, hydroxypropyl acrylate vinylsulphonic acid, acrylamido 2propane 

sulphonic acid, acrylamide, styrene sulphonic acid, acrylic 

phosphate esters, methyl vinyl ether and vinyl acetate or salts thereof, 

carboxylic acids of molecular weight of at least 150 Daltons such as oleic 

acid and polybasic fatty acids, alkylbenzene sulphonic acids, alkane 

sulphonic acids, linear alphaolefin sulphonic acid, phospholipids such 

as lecithin, including salts thereof and including mixtures thereof; and 

wherein the base fluid is at least one selected from an oleaginous fluid, 

a nonoleaginous fluid, or mixtures thereof. 

(21) 575018 (22) 5 Sep 2007 

(54) COMPOSITIONS FOR THE TREATMENT OF ANTIBODY 

MEDIATED NEUROPATHIES 

(86) PCT/US2007/019416 (87) WO2008/030505 

(51) IPC2012.01:C07K16/08; A61P21/00 

(71) Alexion Pharmaceuticals, Inc. 

(72) HALSTEAD, Susan; WILLISON, Hugh; ROTHER, Russell, P. 

(31) 06 842296 (32) 5 Sep 2006 (33) US 


Australia 

(57) Disclosed are recombinant antibodies of human origin specific for 

the C5 component of the activated complement and characterised by 

the ability to inhibit the conversion of the C5 alpha chain to C5a and 

C5b. Moreover the present invention refers to the nucleotide sequences 

coding for such antibodies and to the therapeutic use of both polypeptide 

and nucleotide sequences, in particular for the therapy of diseases 

involving tissue damage deriving from uncontrolled activation of the 

complement system. 

(21) 575093 (22) 12 Sep 2007 

(54) HUMAN ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND 

ANTIBODY FRAGMENTS FOR THE RADIOIMMUNOTHERAPY OF 

OVARIAN CARCINOMA 

(86) PCT/EP2007/007944 (87) WO2008/031577 

(51) IPC2012.01:C07K16/30 



(71) DOMPE PHA.R.MA S.P.A.; ISTITUTO NAZIONALE PER LO 

STUDIO E LA CURA DEI TUMORI 

(72) MARTIN, Franck; CATTOZZO, Margherita; MAURIZI, Giovanni; DI 

CIOCCIO Vito; FIGINI, Mariangela; CANEVARI, Silvana 

(31) 06 06019399 (32) 15 Sep 2006 (33) EP 



(57) Provided is an antibody or fragment thereof, which specifically 

binds to folate receptor-alpha (FRa), wherein said antibody or 

fragment thereof comprises a light chain, whose variable region 

comprises the complementarity-determining regions (CDRs) having the 

following amino acid sequences : - RASESVSFLGINLIH, QASNKDT, 

LQSKNFPPYT, and wherein the constant region of said light chain is a 

kappa constant region and a heavy chain comprising the CDRs having 

the following amino acid sequences DYAMI , SISSSSSYIYYADSVKG , 

ERYDFWSGMDV. The medicament can be used to treat cancers. 

(21) 575118 (22) 30 Aug 2007 

(54) LOCAL TOPICAL ADMINISTRATION FORMULATIONS 

CONTAINING INDOXACARB AND A CRYSTALLIZATION INHIBITOR 

(86) PCT/US2007/019096 (87) WO2008/030385 

(51) IPC2012.01:A01N47/38; A01N25/02; A01P7/00 

(71) E. I. DU PONT DE NEMOURS AND COMPANY 

(72) GUERINO, Frank; FREEHAUF, Keith, Alan; SARGENT, Roger, 

Mervyn; O'NEIL, Peter, Andrew; SIMMONS, Robert, D.; WANG, Chen- 

Chao 

(31) 06 841846 (32) 1 Sep 2006 (33) US 

(74) HOULIHAN2, Level 1, 70 Doncaster Road, Balwyn North, Victoria 

3104, Australia 

(57) Provided is a local, topical, spot-on formulation for control of 

Indoxacarb-sensitive ectoparasites on a domestic animal comprising 

an ectoparasitically effective amount of Indoxacarb and a veterinarily 

acceptable carrier; wherein the concentration of Indoxacarb in said 

formulation is at least 100g/L; wherein said veterinarily acceptable 

carrier comprises a crystallization inhibitor and a solvent; wherein said 

solvent is selected from the group consisting of a glycol ether and 

an alkyl acetate; wherein Indoxacarb-sensitive ectoparasites consist of 

parasites, in any stage of life, that live on the outside of an animal's body; 

and wherein the formulation is applied to an area less than or equal to 

10% of the total surface area of the animal's body to effectively control 

i ndoxacarb-sensitive ectoparasites. 

(21) 575141 (22) 31 Aug 2007 

(54) METHOD OF ELICITING OR INDUCING AN IMMUNE RESPONSE 

(86) PCT/AU2007/001277 (87) WO2008/025095 

(51) IPC2012.01:A61K39/02, 08, 112, 118, 12, 145; A61K47/26; 

A61P31/04, 12, 18; A61P35/00 

(71) CSL Limited; THE UNIVERSITY OF MELBOURNE 

(72) EDWARDS, Stirling, John; PEARSE, Martin, John; SCHEERLINCK, 

Jean-Pierre, Yves; SUTTON, Phil 

(31) 06 904796 (32) 1 Sep 2006 (33) AU 



(57) Disclosed is the use of a composition consisting essentially 

of a protein, polypeptide or peptide antigen, a saponin-based 

adjuvant, and optionally one or more adjuvants selected from the 

group consisting of liposomes, oil-in-water adjuvants, aluminium salt 

adjuvants, lipopolysaccharide adjuvants, oligonucleotide adjuvants and 

mucosal adjuvants, in the manufacture of a medicament wherein the 

medicament if formulated for intra-lung administration to a human or 

animal subject to elicit an immune response in the subject. 

(21) 575154 (22) 3 Oct 2007 

(54) LOCKABLE JOINT FOR SURGICAL TABLE COMPRISING GAS 

CARTRIDGE 

(86) PCT/EP2007/008582 (87) WO2008/040537 

(51) IPC2012.01:A61B19/00; F16C11/10; F16M11/14; A61B17/00, 02 

(71) Orion Surgical GmbH 

(72) FRICKE, Helmut; GRIFFITH, Lawrence, E. 

(31) 06 850090 (32) 6 Oct 2006 (33) US 

(31) 07 932127 (32) 29 May 2007 (33) US 

(31) 07 963699 (32) 29 Jun 2007 (33) US 



(57) Disclosed is a lockable joint that includes a first arm having a 

swivel head which is pivotably mounted to a socket and a locking 

device arranged for locking the swivel head with respect to the socket. 

The locking device has a piston, a pressure gas source and an 

actuating device arranged for reversibly disconnecting the piston from 

the pressure gas source. The pressure gas source is a gas cartridge. 

(21) 575159 (22) 25 Sep 2007 

(54) 2-METHYLENE-(20S,25S)-19,27-DINOR-(22E)-VITAMIN D 

ANALOGS 

(86) PCT/US2007/079381 (87) WO2008/039751 

(51) IPC2012.01:A61P3/04; A61P29/00; A61K31/59; C07C401/00; 

A61P17/00, 06; A61P35/00, 02; A61P37/06 

(71) Wisconsin Alumni Research Foundation 

(72) DELUCA, Hector, F.; CLAGETT-DAME, Margaret; PLUM, Lori, A.; 

CHIELLINI, Grazia; GRZYWACZ, Pawel 

(31) 06 848805 (32) 28 Sep 2006 (33) US 



(57) Disclosed are 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D 

analogs, in particular the compound is 2-methylene-(20S,25S)-19,27dinor-(22E)-1alpha,25- 

dihydroxyvitamin D3. This compound can be 

used as an anti-cancer agent and for the treatment of skin diseases 

such as psoriasis as well as skin conditions such as wrinkles, slack 

skin, dry skin and insufficient sebum secretion. This compound also 

has little, if any, calcemic activity and therefore may be used to treat 



autoimmune disorders or inflammatory diseases in humans as well 

as renal osteodystrophy. This compound may also be used for the 

treatment or prevention of obesity. 

(21) 575171 (22) 29 Aug 2007 

(54) DRUG DELIVERY SYSTEMS COMPRISING SOLID SOLUTIONS 

OF WEAKLY BASIC DRUGS 

(86) PCT/US2007/077153 (87) WO2008/027993 

(51) IPC2012.01:A61K9/14 

(71) Aptalis Pharmatech, Inc. 

(72) VENKATESH, Gopi; BOLTRI, Luigi; COLOMBO, Italo; LAI, Jin-wang; 

FLABIANI, Flavio; MAPELLI, Luigi 

(31) 06 841760 (32) 31 Aug 2006 (33) US 

(31) 06 841893 (32) 31 Aug 2006 (33) US 



(57) Disclosed is a pharmaceutical composition comprising timed pulsatile 

release (TPR) beads, wherein said TPR beads comprise: a solid 

dispersion of at least one active pharmaceutical ingredient in at 

least one solubility-enhancing polymer; and a TPR coating comprising 

a water insoluble polymer and an enteric polymer; wherein the 

active pharmaceutical ingredient comprises a weakly basic active 

pharmaceutical ingredient having a solubility of not more than 100 

ìg/mL at pH 6.8 and wherein the active pharmaceutical ingredient is 

substantially amorphous. 

(21) 575212 (22) 9 Oct 2007 

(54) TREATING SEWAGE SLUDGE BY TUMBLING AND HEATING IN 

DRUM MOUNTED ON WEIGHT-RESPONSIVE MEMBER 

(86) PCT/US2007/080785 (87) WO2008/045857 

(51) IPC2012.01:A61L2/04; C02F11/00; F26B11/16; F26B25/22 

(71) RDP TECHNOLOGIES, INC. 

(72) CHRISTY, Richard, W; VANBRAMER, Robert; QUICI, Michael 

(31) 06 539903 (32) 10 Oct 2006 (33) US 

(31) 07 867951 (32) 5 Oct 2007 (33) US 



(57) An apparatus, method and system is provided for treating sewage 

sludge by heating the same in a drum (D) to drive off pathogens and/ 

or pasteurize the sewage sludge while the material is tumbled in the 

drum, and with moisture gases being evaporated therefrom and drawn 

off from the drum. There is provided at least one weight-responsive 

member (107, 108, 110, 111) on which the drum is mounted, and a 

control is provided connected to the one or more weight-responsive 

member whereby the solids content of the treated material can be 

determined by measuring the difference in weight of material in the 

container, before and after moisture is drawn off from the material and 

prior to its discharge from the drum. The control is preferably effected 

by means of a computer. 


(21) 575228 (22) 23 Aug 2007 

(54) METHODS AND APPARATUS FOR INFORMATION 

MANAGEMENT SYSTEMS 

(86) PCT/US2007/076621 (87) WO2008/024900 

(51) IPC2012.01:G06F15/173; H04L12/28; H04L29/08 

(71) Raytheon Company 

(72) LAIL, Joesph, Bryan 

(31) 06 823439 (32) 24 Aug 2006 (33) US 

(31) 07 843 266 (32) 22 Aug 2007 (33) US 



(57) A method and an information management system (100) of 

providing services from a legacy defense system (140) are disclosed. 

The information management system includes a communications 

subsystem to a defense network (150) including a plurality of nodes. 

The legacy defense system is not adapted to operate in conjunction with 

the defense network. The information management system comprises 

a system interface configured to connect to the legacy defense system 

and responsive to communications with the legacy defense system; 

a network interface configured to communicate with the nodes of 

the defense network to effect communication between the legacy 

defense system and the defense network via the communications 

subsystem; and a data processing system in communication with the 

system interface and the network interface. The data processing system 

responds to a service request from a node received via the network 

interface by requesting a service response according to the service 

request from the legacy defense system via the system interface; 

receiving the service response from the legacy defense system via 

the communications subsystem; translating the service response to a 

format useable by the node; and transmitting the translated service 

response to the node via the network interface. 



(21) 575336 (22) 18 Oct 2007 

(54) BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS 

(86) PCT/US2007/081841 (87) WO2008/051808 

(51) IPC2012.01:C07D487/04; A61K31/5025, 53; A61P35/00 

(71) SGX PHARMACEUTICALS, INC. 

(72) BOUNAUD, Pierre-Yves; SMITH, Christopher Ronald; JEFFERSON, 

Elizabeth Anne 

(31) 06 862552 (32) 23 Oct 2006 (33) US 

(31) 06 870309 (32) 15 Dec 2006 (33) US 

(31) 07 913766 (32) 24 Apr 2007 (33) US 

(31) 07 952840 (32) 30 Jul 2007 (33) US 



(57) Disclosed are bicyclic triazole compounds 

such as 3-[1-(1-ethyl-azetidin-3-yl)-1H-pyrazol-4-yl]-6-(6-methyl- 

[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl)-quinoline. The disclosed 

bicyclic triazole compounds are used to treat cancer. 

(21) 575451 (22) 12 Sep 2007 

(54) GENOMIC MARKER FOR MEAT TENDERNESS 

(86) PCT/EP2007/059585 (87) WO2008/031846 

(51) IPC2012.01:C12Q1/68 

(71) INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE; APIS 

GENE 

(72) BERNARD, Carine; CASSAR-MALEK, Isabelle; HOCQUETTE, Jean- 

Francois 

(31) 06 060300943 (32) 12 Sep 2006 (33) EP 



(57) Disclosed is method for the identification of a tender meat. The 

method involves the quantification of the expression level of a DNAJA1 

gene in a muscle sample and matching said expression level of the 

sample to that of a control gene wherein the lower expression level 

of the DNAJA 1 gene of the muscle sample with regard to that of the 

expression level of the control gene is an indication of the tenderness 

of the meat. 

(21) 575535 (22) 10 Sep 2007 

(54) A PORTABLE DEVICE FOR USE IN ESTABLISHING TRUST 

(86) PCT/AU2007/001337 (87) WO2008/031148 

(51) IPC2012.01:H04L9/00; G06F21/00 

(71) Commonwealth Scientific and Industrial Research Organisation 

(72) ZIC, John, Joseph; NEPAL, Surya 

(31) 06 905001 (32) 11 Sep 2006 (33) AU 



(57) A process for establishing trust between a host machine and a 

remote machine and a portable device for use in establishing trust are 

disclosed. The portable device (100) includes a communications module 

for communicating with an untrusted host machine (102); embedded 

trusted data; a virtual machine module for instantiating a virtual machine 

on the host machine; and a security module for including a secure 

application in the virtual machine to perform an attestation process using 

the embedded trust data to authenticate the host machine to establish 

trust. Also disclosed is a method of producing a portable device for use 

in establishing trust including generating an endorsement cryptographic 

public/private key pair; generating an endorsement credential digital 

certificate using the public key of the key pair and credential data; 

generating an endorsement credential digital signature using the private 

key of the pair and the endorsement credential certificate with the 

endorsement key pair, endorsement credential digital certificate, digital 

signature and credential data being trusted data for storage in the 

device; embedding the trusted data in the portable device which 

includes a communications module for communicating with a host 

machine; storing in the portable device a virtual machine module for 

instantiating a virtual machine on a host machine; and storing in the 

portable device a security module for including a secure application 

in the virtual machine to perform an attestation process using the 

embedded trust data to authenticate the host machine. 

(21) 575631 (22) 1 Oct 2007 

(54) IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS 

(86) PCT/US2007/021174 (87) WO2008/054603 

(51) IPC2012.01:C07K16/28; A61K39/395; A61P37/02 

(71) Amgen Inc. 

(72) TOCKER, Joel; PESCHON, Jacques, J; FITZPATRICK, David; 

SMOTHERS, James, F; MEHLIN, Christopher; LIM, Ai Ching 

(31) 06 827882 (32) 2 Oct 2006 (33) US 

(31) 06 873072 (32) 5 Dec 2006 (33) US 

(31) 07 969895 (32) 4 Sep 2007 (33) US 



(57) Disclosed is an isolated human monoclonal antibody, comprising a 

variable heavy chain that is at least 90% identical to SEQ ID NO:14 and 

a variable light chain that is at least 90% identical to SEQ ID NO:40, 

wherein said antibody specifically binds human IL-17 receptor A and 

inhibits the biological activity of human IL-17A. The disclosed antibodies 

comprise: a. a heavy chain CDR1 comprising an amino acid sequence 

of X1YGIS, wherein X1 is selected from the group consisting of R, S 

and G; b. a heavy chain CDR2 comprising an amino acid sequence of 

WISX1YX2GNTX3YAQX4X5QG, wherein X1 is A, X2 is N, S or K, X3 is 

N or K, X4 is K or N, and X5 is L or F; c. a heavy chain CDR3 comprising 

an amino acid sequence of X1QLX2X3DY, wherein X1 is R or K, X2 is 

Y, V or A, and X3 is F or L; d. a light chain CDR1 comprising an amino 

acid sequence of RASQSX1X2X3X4LA, wherein X1 is V or I, X2 is I or 

S, X3 is S or T, X4 is N or S, and X5 is A or N; e. a light chain CDR2 

comprising an amino acid sequence of X1X2STRAX3, wherein X1 is G 

or D, X2 is A or T, and X3 is T or A, and f. a light chain CDR3 comprising 

an amino acid sequence of QQYDX1WPLT, wherein X1 is N, T or I. 

(21) 575685 (22) 4 Oct 2007 

(54) NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND 

USES THEREOF 

(86) PCT/AU2007/001475 (87) WO2008/040057 

(51) IPC2012.01:C07D307/78, 79, 82, 86; A61K31/343; A61P3/10; 

A61P37/06 

(71) Bionomics Limited 



(72) FLYNN, Bernard, Luke; BAELL, Jonathan, B; HARVEY, Andrew, J; 

CHAPLIN, Jason, Hugh; PAUL, Dharam; MOULD, Jorgen, Alvar 

(31) 06 849488 (32) 4 Oct 2006 (33) US 



(57) Disclosed is a substituted benzofuran compound of 

formula (I) where the substituents are as disclosed in the 

specification. Examples of compounds of formula (I) are 5- 

Acetyl-4, 7 -dimethoxy-6-(3-(phenyl)propoxy)benzofuran; 5-Acetyl-4, 

7 -dimethoxy-6-( 4-(phenoxy)butoxyl)benzofuran and 5-Acetyl-6- 

(3-phenylpropoxy)benzofuran. Also disclosed is a pharmaceutical 

composition comprising a compound of formula (I), the use of a 

compound of formula (I) in the manufacture of a medicament for treating 

or prevention of autoimmune or chronic inflammatory diseases, or 

the prevention of rejection of foreign organ transplants and/or related 

afflictions and a method of intentionally modulating potassium ion 

channel activity of T-cells ex-vivo by the application of a compound of 

formula (I) or a pharmaceutically acceptable salt thereof, to said T -cells. 

(21) 575829 (22) 30 Aug 2007 

(54) SPERM CELL SEPARATION METHODS AND COMPOSITIONS 

CONTAINING APTAMERS OR NUCLEIC ACID SEQUENCES FOR 

USE THEREIN 

(86) PCT/US2007/077300 (87) WO2008/028081 

(51) IPC2012.01:A61K31/70; C07H21/02; C12Q1/68 

(71) Biocern, Inc. 

(72) OKSENBERG, David, A; KRYLOV, Sergey; MUSHEEV, Michael 

(31) 06 824069 (32) 30 Aug 2006 (33) US 



(57) Disclosed is an isolated non-naturally occurring nucleic acid sequence 

that binds to a target molecule accessible from the surface of a 

mammalian sperm cell comprising a nucleotide sequence selected 

from the group consisting of SEQ ID NOS: 3-35. Further disclosed 

are methods of separating a mixture of mammalian sperm cells by 

contacting a mixture of sperm cells with a composition comprising at 

least one nucleic acid as described above. 


(21) 575900 (22) 2 Oct 2007 

(54) NON-MUCOADHESIVE FILM DOSAGE FORMS 

(86) PCT/EP2007/008579 (87) WO2008/040534 

(51) IPC2012.01:A61K31/445; A61K9/70 

(71) LABTEC GESELLSCHAFT FUR TECHNOLOGISCHE 

FORSCHUNG UND ENTWICKLUNG MBH; APR APPLIED PHARMA 

RESEARCH SA 

(72) BREITENBACH, Armin; LEHRKE, Ingo; LEICHS, Christian; 

GALFETTI, Paolo 

(31) 06 848965 (32) 2 Oct 2006 (33) US 



(57) Disclosed herein is a non-mucoadhesive orally disintegrating film, 

able to disintegrate upon contact with saliva in the buccal cavity 

within about sixty seconds, said film comprises ondansetron or 

a pharmaceutically acceptable salt thereof in combination with a 

hydrophilic binder and a water-soluble diluent selected from the group 

consisting of polyvinyl alcohol, polyethylene glycol, propylene glycol, 

polyethylene oxide, starches, celluloses or gelatines and means for 

retarding absorption of said ondansetron through the oral mucosa said 

retarding means are selected from the group of: · an ion exchange resin, 

that bind the ondansetron and prevent its ionization and dissolution 

upon integration of the film, wherein said ion exchange resin is selected 

from the group consisting of polymers and copolymers of acrylic acid, 

methacrylic acid, sulfonated styrene, sulfonated divinylbezene, modified 

cellulose and dextrans, silica gel modified by the addition of ionic groups; 

· pH adjusting agents ionizing the ondansetron to a less permeable 

state, selected from the group consisting of cyclodextrin or acrylate 

polymers; · ondansetron in base form; wherein said retarding means 

result in a gastrointestinal absorption of at least 60% of said ondansetron 

when the film is placed on the tongue, allowed to disintegrate, and 

subsequently swallowed. 

(21) 575901 (22) 12 Sep 2007 

(54) ALPHAVIRUS REPLICON PARTICLES MATCHED TO PROTEIN 

ANTIGENS AS IMMUNOLOGICAL ADJUVANTS 

(86) PCT/US2007/078331 (87) WO2008/033966 

(51) IPC2012.01:A61K39/39, 145; C12N15/86; C12N7/04 

(71) ALPHAVAX, INC. 

(72) SMITH, Jonathan, F; HUBBY, Bolyn; COPP, Laura 

(31) 06 825395 (32) 12 Sep 2006 (33) US 



(57) Disclosed is the use of an immunogenic protein and alphavirus 

replicon particles expressing said immunogenic protein in the 

manufacture of one medicament or separate medicaments to be 

administered to a subject for enhancing the immune response to the 

immunogenic protein in said subject, wherein the particles and the 

immunogenic protein are to be administered simultaneously and at the 

same location. 

(21) 575935 (22) 8 Oct 2007 

(54) TWISTED RUDDER BLADE 

(86) PCT/EP2007/008704 (87) WO2008/043504 

(51) IPC2012.01:B63H25/38 

(71) Mr Aloys Wobben 

(72) WOBBEN, Aloys; ROHDEN, Rolf; HOLTKAMP, Dirk 

(31) 06 06047755 (32) 6 Oct 2006 (33) DE 



(57) A twisted rudder blade adapted to be arranged at the stern of a ship 

for steering the ship. The twist of the blade at a rudder position of zero 

degrees is adapted to the configuration of the flow of the water resulting 

from a straight ahead travel of the ship through the water in the region 

of the respective rudder blade. 

(21) 576008 (22) 8 Oct 2007 

(54) APPARATUS FOR PARI-MUTUEL RACING GAME WITH FINISH 

ORDER BETTING 

(86) PCT/US2007/080683 (87) WO2008/043096 

(51) IPC2012.01:A63F13/00; G07F17/32; G06Q50/34 

(71) CFPH, LLC 

(72) ALDERUCCI, Dean, P; GELMAN, Geoffrey, M 

(31) 06 828516 (32) 6 Oct 2006 (33) US 





(57) An apparatus (500) for pari-mutuel racing game with reverse betting 

comprises a computing device operable to receive at least one bet 

that the respective participant will win the race for each of the plurality 

of participants in a race; offer to bettors a bet that the plurality of 

participants will finish the race in a potential order, in which the potential 

order includes a least favoured participant finishing the race first, a next 

least favoured participant finishing the race second, and a favoured 

participant finishing the race last; receive from a bettor a bet that 

the potential order will transpire; determine, based on the plurality of 

received bets, a potential order in which the plurality of participants 

might finish the race; determine an actual order in which the plurality of 

participants finished the race; and determine a payment amount to the 

bettor based on the actual order and the bettor’s bet on the potential 

order. 


(21) 576016 (22) 26 Sep 2007 

(54) INDIVIDUAL HEALTH RECORD SYSTEM AND APPARATUS 

(86) PCT/US2007/079609 (87) WO2008/039880 

(51) IPC2012.01:G06F17/30; G06N5/02; G06F19/00 

(71) RALPH KORPMAN; CINDY A POST; RUBY R HILADO; W RANDAL 

CLEGG 

(72) KORPMAN, Ralph; POST, Cindy, A; HILADO, Rudy, R; CLEGG, W. 

Randal 

(31) 06 826967 (32) 26 Sep 2006 (33) US 

(74) Patent Attorney Services, Suite 4, 26 Ellingworth Parade, Box Hill, 


(57) A computer based method of handling and transforming health care 

data and a system of processing, storing and handling health care 

information are disclosed. The system comprises a persistent data 

storage device; an information input component; a central health record 

component and a user interface component. The information input 

component is adapted to receive health care information from one 

or more health care information sources. The central health record 

component is adapted to create or modify abstract health care objects 

from that information. The abstract health care objects are objectoriented. 

The user interface component is adapted to provide access by 

one or more users to the system wherein the creation or modification of 

the abstract health care objects comprises the processing of the health 

care information using a health care ontology. 

(21) 576115 (22) 9 Oct 2007 

(54) METHOD AND SYSTEM OF CONDUCTING AN AUCTION 

(86) PCT/AU2007/001528 (87) WO2008/043138 

(51) IPC2012.01:G06Q30/00, 08 

(71) CommoditiesOne Pty Ltd 

(72) STUART, Gavin 

(31) 06 905625 (32) 10 Oct 2006 (33) AU 

(31) 06 850967 (32) 10 Oct 2006 (33) US 

(74) DAVIES COLLISON CAVE - Sydney, Level 14, 255 Elizabeth Street, 

Sydney, New South Wales, Australia 

(57) A system (300) for conducting an auction having a plurality of online 

bidders and a site bidder (340) comprises a plurality of client processing 

systems (320) used by a respective plurality of online bidders (330) 

and the below described server processing system (310). A server 

processing system for conducting an auction having a plurality of online 

bidders and a site bidder is disclosed. The server processing system 

is in data communication with a respective client processing system for 

each online bidder and configured to receive one or more online bids 

from one of the plurality of online bidders for acceptance prior to a first 

event via the respective client processing system; restrict online bids 

from being accepted from the plurality of online bidders in the auction in 

response to the first event whilst the site bidder is able to place an onsite 

bid in the auction; and allowing one or more of the plurality of online 

bidders to submit one or more online bids in response to a second event 

occurring after the first event. Each online bidder is able to submit more 

than one online bid to compete in the auction. 

(21) 576132 (22) 26 Oct 2007 

(54) ANTIBODIES AND IMMUNOCONJUGATES AND USES 

THEREFOR 

(86) PCT/US2007/082726 (87) WO2008/052187 

(51) IPC2012.01:A61K39/395; A61P35/00; C12N5/10; A61K47/48; 

A61K51/10; C07K16/30; C12N15/13 




(72) DENNIS, Mark, S; RUBINFELD, Bonnee; POLAKIS, Paul; 

JAKOBOVITS, Aya 

(31) 06 863295 (32) 27 Oct 2006 (33) US 

(31) 06 868707 (32) 5 Dec 2006 (33) US 

(31) 07 921300 (32) 30 Mar 2007 (33) US 

(31) 07 937857 (32) 29 Jun 2007 (33) US 



(57) Disclosed is a humanized antibody that binds to STEAP-1 and 

immunoconjugates thereof. Also disclosed is a method of detecting 

STEAP-1 and the use of the antibody and immunoconjugates in the 

manufacture of a medicament for treating cancer. 

(21) 576195 (22) 10 Oct 2007 

(54) COMPLEMENT INHIBITION FOR IMPROVED NERVE 

REGENERATION 

(86) PCT/NL2007/050490 (87) WO2008/044928 

(51) IPC2012.01:A61K38/08, 10, 17; A61K39/395; A61K31/19, 245, 727; 

A61P25/00; A61K45/06 

(71) ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN 

AMSTERDAM 

(72) BAAS, Frank; RAMAGLIA, Valeria 

(31) 06 850277 (32) 10 Oct 2006 (33) US 


(57) Disclosed are medicaments used for treating conditions that require 

axonal regeneration, e.g. in mammals affected by injury or disease 

of the central or peripheral nervous system. The medicaments used 

in these methods facilitate axonal regeneration by inhibition of the 

complement system. Conditions requiring axonal regeneration that may 

be treated in accordance with the invention include physical injuries as 

well as neurodegenerative disorders of the peripheral or central nervous 

system. 

(21) 576223 (22) 10 Oct 2007 

(54) INTRA-MAMMARY TEAT SEALANT FORMULATION AND 

METHOD OF USING SAME TO REDUCE OR ELIMINATE VISUAL 

DEFECTS IN AGED CHEESES 

(86) PCT/US2007/080911 (87) WO2008/045920 

(51) IPC2012.01:A61K33/30, 00, 24; A61K45/06; A61P15/14; A61P31/04 

(71) Wisconsin Alumni Research Foundation 

(72) RANKIN, Scott, A 

(31) 06 850572 (32) 10 Oct 2006 (33) US 



(57) Disclosed is a method of forming a physical barrier in the teat canal of 

a non-human animal and simultaneously preventing black spot defect in 

dairy products made with milk from the animal, the method comprising: 

infusing an amount of a teat seal formulation into the teat canal of 

the animal, wherein the teat seal formulation comprises a bismuthfree, 

non-toxic amount of titanium dioxide, zinc oxide, barium sulphate, 

combinations thereof. 


(21) 576226 (22) 24 Oct 2007 

(54) PATIENT INCLINE DEVICE WITH A CENTERLINE SPINAL 

SUPPORT 

(86) PCT/US2007/022621 (87) WO2008/057239 

(51) IPC2012.01:A61G7/10, 07 

(71) Patient Transfer Systems, Inc 

(72) WEEDLING, Robert, E; WEEDLING, James, E 

(31) 06 855874 (32) 1 Nov 2006 (33) US 

(31) 06 860044 (32) 20 Nov 2006 (33) US 

(31) 07 732184 (32) 3 Apr 2007 (33) US 

(74) Mallesons Stephen Jaques, Level 50 Bourke Place, 600 Bourke 

Street, Melbourne, VIC 3000, Australia 

(57) A patient incline device 10 includes an incline ramp 12 and a 

centreline spinal support 14 located on a base member 12. The incline 

ramp 12 supports the upper torso and head of a patient such that the 

upper torso and head are elevated with respect to the base member 

12. The centreline support 14 is located adjacent the inline ramp 12 for 

contact with a central portion of the patient's back located adjacent the 

spine to elevate the central back portion. The width of the spinal support 

14 is less than that of the incline ramp 12 to define lateral spaces along 

opposite sides of the centreline support 14 to receive the arms and side 

portions of the patient for lateral extension of the chest wall. 

(21) 576242 (22) 5 Oct 2007 

(54) STABILIZED PROSTAGLANDIN E COMPOSITION 

(86) PCT/US2007/021374 (87) WO2008/045309 

(51) IPC2012.01:A61K31/19, 20, 201, 5575; A61K9/08 

(71) Nexmed Holdings, Inc. 

(72) FRANK, Daniel, W; WANG, Yiping 

(31) 06 546196 (32) 11 Oct 2006 (33) US 



(57) Disclosed is a storage stable prostaglandin E group composition 

which comprises: (a) a prostaglandin E group compound (such as 

alprostadil); (b) a (C1-C4)-alkyl (C8-C22) carboxylic ester (such as 

ethyl laurate); (c) an N,N-di(C1-C8) alkylamino substituted, (C4-C18) 

alkyl (C2-C18)carboxylic ester, a pharmaceutically acceptable addition 

salt thereof, or a combination thereof (such as dodecyl 2-(N,Ndimethylamino)-propionate 

- DDAIP); and (d) optionally, a viscosity 

enhancing agent (such as guar gum); the composition containing no 

more than 0.5 percent by weight of a C1-C4 alcohol. 

(21) 576248 (22) 18 Oct 2007 

(54) Valve actuator for a container containing a pressurized fluid 

(86) PCT/EP2007/061173 (87) WO2008/046897 

(51) IPC2012.01:B65D83/14, 16 

(71) GLAXOSMITHKLINE CONSUMER HEALTHCARE GMBH & CO KG 

(72) KRAEMER, Hans; GEIBERGER, Christoph 

(31) 06 0620943 (32) 20 Oct 2006 (33) GB 

(31) 06 0624674 (32) 11 Dec 2006 (33) GB 


(57) A valve actuator 10 for a container containing a pressurised fluid and 

having an operable valve via which the fluid is dispensed, comprises 

a mounting 11 attachable to the container, a control part 20 moveably 

mounted on the mounting, the control part 20 incorporating a valve 

operator 21 operably connectable to the valve when the mounting 11 

is attached to the container, and incorporating an outlet conduit via 

which fluid may flow from the valve to an outlet opening, the control part 

20 being moveable in a first direction to operate the valve to release 

fluid from the container, and being moveable in a second direction after 

use to thereby operate the valve to cease the flow of fluid, a variable 

volume post-expansion chamber 24 provided in communication with the 

outlet conduit via an expansion opening 27 and in which residual fluid 

remaining in the outlet conduit after use can expand, and a variable 

volume suction chamber 212 in communication with the outlet conduit 

via a suction opening which is more constricted relative to the flow of 

the fluid than is the expansion opening 27. The volume of the variable 

volume post expansion chamber 24 and the suction chamber 212 are 

reduced on movement of the control part 20 in the first direction and 

increased on movement of the control part 20 in the second direction 

such that the increase in volume of the suction chamber 212 creates an 

air pressure which is less than atmospheric. This reduced pressure is 



communicated via the suction opening to the outlet conduit to thereby 

suck residual fluid in the outlet conduit back from the outlet opening. 

(21) 576259 (22) 14 Sep 2007 

(54) METHOD AND SYSTEM FOR CROSS-ISSUER REGISTRATION 

OF TRANSACTION CARDS 

(86) PCT/US2007/078537 (87) WO2008/034083 

(51) IPC2012.01:G06Q20/24 

(71) VISA International Service Association 

(72) SHEETS, John, Foxe 

(31) 06 825733 (32) 15 Sep 2006 (33) US 



(57) A computer implemented method of providing cross-issuer 

registration of transaction cards issued by the same association and a 

system of providing cross-issuer registration of transaction cards issued 

by an issuer are disclosed. The system comprises an Internet server 

means for receiving a registration code sent from a client representing 

a transaction card holder. The registration code is associated with the 

transaction card and an issuer thereof. The system also comprises 

an Internet server means for determining the issuer of the transaction 

card based on at least a portion of the registration code; an Internet 

server means for transmitting the registration code to the issuer of the 

transaction card and an Internet server means for receiving account 

information sent from the issuer. The account information is associated 

with the registration code and with the transaction card. The system 

further comprises an Internet server means for transmitting for delivery 

to and display by the client representing the transaction card holder 

of at least a portion of the account information and a description of 

one or more services in which to enroll the transaction card holder; an 

Internet server means for receiving a verification value corresponding 

to the account information and being sent from the client representing 

the transaction card holder; an Internet server means for determining 

if the verification value is valid; and an Internet server means, if 

the verification value is valid, for receiving a selection of the one or 

more services in which to enroll sent from the client representing the 

transaction card holder. The selected one or more services applies 

to multiple the transaction cards issued by the issuer that were each 

issued to the transaction card holder. A computer implemented method 

of providing cross-issuer registration of transaction cards issued by the 

same association is also disclosed where account setup information 

sent from a client representing a transaction card holder is received via 

a website facilitated by an Internet server system. A registration code 

sent from a client representing a transaction card holder is received via 

the website facilitated by the Internet server system. The registration 

code is associated with the transaction card and an issuer thereof, 

includes a digest created by a hashing algorithm performed upon a 

Primary Account Number (PAN) for the transaction card less the bank 

identification number (BIN) and includes an issuer code corresponding 

to the issuer of the transaction card. The issuer of the transaction card 

based on at least a portion of the registration code is determined via the 

website facilitated by the Internet server system. The registration code to 

the issuer of the transaction card is transmitted via the website facilitated 

by the Internet server system. Account information sent from the issuer 

is received via the website facilitated by the Internet server system. The 

account information is associated with the registration code and with 

the transaction card; cannot be determined from the registration code; 

includes an account identifier; and is in encrypted form. At least a portion 

of the account information; and a description of one or more services in 

which to enroll the transaction card holder is transmitted via the website 

facilitated by the Internet server system, for delivery to and display by 

the client representing the transaction card holder. A transaction Card 

Verification Value (CVV) for the transaction card that corresponds to the 

account information is receiving via the website facilitated by the Internet 

server system and is sent from the client representing the transaction 

card holder. If the verification value is valid is determined via the website 

facilitated by the Internet server system and if the verification value is 

valid a selection of the one or more services in which to enroll sent from 

the client representing the transaction card holder is received via the 

website facilitated by the Internet server system. The selected one or 

more services applies to multiple the transaction cards offered by the 

issuer that were each issued to the transaction card holder and to each 

which the registration code is also associated. 

(21) 576260 (22) 8 Nov 2007 

(54) GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising 

one of more substitutions as compared to h[Gly2]GLP-2 

(86) PCT/GB2007/004273 (87) WO2008/056155 

(51) IPC2012.01:C07K14/605; A61K38/26 

(71) Zealand Pharma A/S 

(72) LARSEN, Bjarne Due; PETERSEN, Yvette Miata 

(31) 06 01456 (32) 8 Nov 2006 (33) DK 

(31) 06 859313 (32) 15 Nov 2006 (33) US 


Australia 

(57) GLP-2 analogues are disclosed which comprise one of more 

substitutions as compared to h[Gly2]GLP-2 and which may have 

the property of an increased small intestine/colon and stomach/colon 

selectivity. More particularly, preferred GLP-2 analogues disclosed 

herein comprise substitutions at one or more of positions (11, 16, 20, 24) 

and/or (28) of the wild-type GLP-2 sequence, optionally in combination 

with further substitutions at position (2) and one or more of positions (3, 

5, 7), and (10), and/or a deletion of one or more of amino acids (31) to 

(33) and/or the addition of a N-terminal or C-terminal stabilizing peptide 

sequence. The analogues are particularly useful for the prophylaxis or 

treatment of stomach and bowel-related disorders and for ameliorating 

side effects of chemotherapy. 


(21) 576355 (22) 19 Oct 2007 

(54) PROCESS FOR MAKING CRYSTALLINE ANHYDROUS 

DOCETAXEL 

(86) PCT/US2007/022309 (87) WO2008/051465 

(51) IPC2012.01:A01N43/02; A61K31/335 

(71) ScinoPharm Singapore PTE, Ltd. 

(72) LIAO, Yuan-xiu; HO, Meng-fen; CHEN, Shu-ping; LIN, Chia-ning; LIN, 

Yu-li; HSIAO, Tsung-yu 

(31) 06 853341 (32) 20 Oct 2006 (33) US 



(57) Disclosed is crystalline N-debenzoyl-N-tert-butoxycarbonyl-10deacetyl 

taxol trihydrate. Also disclosed is a process of producing 

docetaxel trihydrate comprising a) combining docetaxel and acetonitrile; 

b) heating the mixture of step (a) to about 30-45 degrees C; c) adding 

water to the mixture of the heated mixture of step b); d) cooling the 

mixture of c) to about 10-300 degrees C to obtain a slurry; and e) filtering, 

washing, and drying the slurry of step (d) to obtain docetaxel trihydrate. 


(21) 576402 (22) 22 May 2007 

(54) Method for producing titanium by reducing titanium tetrachloride in an 

arc furnace in a vacuum 

(86) PCT/LV2007/000002 (87) WO2008/039047 

(51) IPC2012.01:C22B34/12; F27B3/08, 19 

(71) Ervins Blumbergs; Baltic Titan Limited 



(72) BLUMBERGS, Ervins 

(31) 06 P 111 (32) 25 Sep 2006 (33) LV 



(57) A method and device for the continuous production of metallic titanium 

and metallic titanium alloys by the metallothermic reduction of titanium 

tetrachloride is disclosed. The method characterized in that the reaction 

of titanium tetrachloride reduction by the reducing agent and the melting 

of obtained spongy titanium are conducted simultaneously in vacuum 

in an electric-arc furnace. The device for continuous producing metallic 

titanium or metallic titanium alloy is characterized in that to accomplish 

the reaction of reduction of titanium tetrachloride by the reducing agent 

in vacuum with simultaneous melting of spongy titanium for producing 

metallic titanium or its alloy. The reactor is executed in the form of 

electric-arc furnace (1), which is connected with the vacuum pump (14) 

and is supplied with consumable electrode (6), which functions as a 

cathode. The anode is the liquid bath of titanium or titanium alloy, which 

is located in the cooled crystallizer (11) at the upper part of dummy bar 

(12), to which voltage is supplied. 

(21) 576408 (22) 16 Oct 2007 

(54) P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O- 

ACETYL-3'-DEOXY-Beta-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5- 

D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION 

(86) PCT/US2007/081526 (87) WO2008/140549 

(51) IPC2012.01:A01N43/78; A61K31/425 

(71) Anadys Pharmaceuticals Inc 

(72) KUCERA, David; HALEY, Gregory, J; RUEDEN, Erik, J; WANG, 

Tingmin; BLATTER, Fritz; VIERTELHAUS, Martin 

(31) 06 852002 (32) 17 Oct 2006 (33) US 

(31) 07 899405 (32) 5 Feb 2007 (33) US 

(31) 07 953597 (32) 2 Aug 2007 (33) US 



(57) Disclosed herein is p-toluene sulfonic acid salt 

of 5-amino-3-(2’-O-acetyl-3’-deoxy-â-D-ribofuranosyl)-3H-thiazolo[4,5d]pyrimidin-2-one, 

methods for its preparation, compositions comprising 

said acid salt and uses thereof in the manufacture of a medicament for 

treating Hepatitis B virus infection, Hepatitis C virus infection, a tumor 

or cancer in a patient. 

(21) 576425 (22) 23 Oct 2007 

(54) FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS 

ALK AND C-MET INHIBITORS 

(86) PCT/US2007/022496 (87) WO2008/051547 

(51) IPC2012.01:C07D405/12, 14; C07D417/12, 14; A61K31/495; 

A61P35/00; C07D403/12, 14; C07D413/12; C07D239/48 

(71) Cephalon, Inc 

(72) AHMED, Gulzar; BOHNSTEDT, Adolph; BRESLIN, Henry, Joseph; 

BURKE, Jason; CURRY, Matthew, A; DIEBOLD, James, L; DORSEY, 

Bruce; DUGAN, Benjamin, J; FENG, Daming; GINGRICH, Diane, 

E; GUO, Tao; HO, Koc-Kan; LEARN, Keith, S; LISKO, Joseph, G; 

LIU, Rong-Qiang; MESAROS, Eugen, F; MILKIEWICZ, Karen; OTT, 

Gregory, R; PARRISH, Jonathan; THEROFF, Jay, P; THIEU, Tho, 

V; TRIPATHY, Rabindranath; UNDERINER, Theodore, L; WAGNER, 

Jason, C; WEINBERG, Linda; WELLS, Gregory, J; YOU, Ming; 

ZIFICSAK, Craig, A 

(31) 06 853562 (32) 23 Oct 2006 (33) US 

(74) Watermark Patent and Trade Marks Attorneys, Level 2, 302 Burwood 

Road, Hawthorn, Victoria 3122, Australia 

(57) Disclosed herein are fused bicyclic 2,4-diaminopyrimidine derivatives 

of formula I, wherein the substituents are as defined within the 

specification, processes for their preparation, compositions comprising 

said compounds and uses thereof. Said compounds are useful as 

Anaplastic Lymphoma Kinase (ALK) and c-MET inhibitors and as 

such are useful in the treatment of proliferative disorders such as 

colon cancer, breast cancer, renal cancer, lung cancer, hemangioma, 

anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, 

squamous cell carcinoma, myeloid leukaemia, melanoma, glioblastoma 

and astrocytoma. 

(21) 576428 (22) 3 Nov 2007 

(54) DIAGNOSIS OF METASTATIC MELANOMA AND MONITORING 

INDICATORS OF IMMUNOSUPPRESSION THROUGH BLOOD 

LEUKOCYTE MICROARRAY ANALYSIS 

(86) PCT/US2007/083555 (87) WO2008/100352 

(51) IPC2012.01:G06F19/00; C12Q1/68; G11C17/00 

(71) BAYLOR RESEARCH INSTITUTE 

(72) PALUCKA, Anna, Karolina; BANCHEREAU, Jacques, F; 

CHAUSSABEL, Damien 

(31) 06 856406 (32) 3 Nov 2006 (33) US 



(57) Provided is a method of identifying a subject with melanoma 

comprising: determining a level of expression of one or more melanoma 

expression vectors in a previously obtained sample, wherein a level 

of expression is determined using at least one technique selected 

from the group consisting of polymerase chain reaction, heteroduplex 

analysis, single stand conformational polymorphism analysis, ligase 

chain reaction, comparative genome hybridization, southern blotting, 

northern blotting, western blotting, enzyme-linked immunosorbent 

assay, fluorescent resonance energy-transfer and sequencing; and 

displaying each of the melanoma expression vectors with a separate 

identifier, wherein the one or more melanoma expression vectors 

comprise three or more genes. Further provided are corresponding 

microarrays for diagnosis. 


(21) 576500 (22) 19 Oct 2007 

(54) A RAT TRAP 

(86) PCT/DK2007/000449 (87) WO2008/046424 

(51) IPC2012.01:A01M27/00 

(71) PAF HOLDING APS 

(72) FRITZBOGER, Preben 

(31) 06 01357 (32) 19 Oct 2006 (33) DK 

(31) 06 678687 (32) 26 Feb 2007 (33) US 


(57) A rat trap comprising a plate with a first side and a second side and 

with a number of through-going openings from the first to the second 

side; a number of spikes secured to an anchoring plate, said anchoring 

plate being arranged on the first side of said plate, and wherein each 

spike is adapted to the individual openings in the plate to the effect that a 

spike is able to slide through such opening from the first side of the plate 

to the second side of the plate; an energy supply; a release mechanism; 

a sensor adapted to detect the presence of a rat within the reach of 

the spikes on the second side of the plate; a firing mechanism which is 

capable of ejecting one or more of these spikes through the openings 

when the presence of a rat is detected by the sensor, characterised 

in that the rat trap further comprises a withdrawal mechanism which, 

following a given period of time, withdraws the spikes through the 

openings in the plate, whereby the plate serves as stop means and 



hence releases a rat spiked by one or more spikes, said plate with a first 

side and a second side and with a number of through-going openings 

from the first to the second side is constituted of a member adapted to 

engage a sewer pipe. 

(21) 576522 (22) 15 Nov 2007 

(54) PUTTING AN ABSORBENT MATERIAL AND LIQUID SETTABLE 

MATERIAL INTO CABLE GLAND 

(86) PCT/IB2007/054655 (87) WO2008/059455 

(51) IPC2012.01:H02G3/18; H05K5/06 

(71) PRATLEY INVESTMENTS (PROPRIETARY) LIMITED 

(72) PRATLEY, Kimleigh George Montague 

(31) 06 09508 (32) 15 Nov 2006 (33) ZA 



(57) A method of forming a seal 62 between and around conductors 

12A, 12B and 12C of an electrical power cable 10 that has particular 

application as a safety measure in potentially explosive applications, 

includes passing the conductors 12A, 12B and 12C through an opening 

in a body 26 such as a cable entry gland so as to define a cavity within 

the body between and around the conductors, introducing an absorbent 

material 64 and a liquid settable material 66 into the cavity, and allowing 

the settable material 66 to be absorbed by the absorbent material 64 and 

to set thereby to seal the cavity between and around the conductors. 

The absorbent material may be in the form of powder, granules or fibres 

and the settable material may be an acrylic or epoxy resin with a reaction 

catalysed by the absorbent material and which fuses, during setting, 

with the insulation of the cable conductors. 

(21) 576591 (22) 26 Oct 2007 

(54) CANCER SUSCEPTIBILITY VARIANTS ON CHR8Q24.21 

(86) PCT/IS2007/000019 (87) WO2008/050356 

(51) IPC2012.01:C12Q1/68 

(71) deCODE genetics efh 

(72) GUDMUNDSSON, Julius; SULEM, Patrick; KONG, Augustine; 

MANOLESCU, Andrei; AMUNDADOTTIR, Laufey 

(31) 06 068560 (32) 27 Oct 2006 (33) IS 



(57) Provided is a method of diagnosing a susceptibility to prostate cancer 

in a human individual, comprising detecting in the individual at least 

one allele of one or more polymorphic marker, within a specific genomic 

region of human chromosome 8 with a specified sequence, selected 

from the group consisting of DNA marker rs16901979, and markers in 

linkage disequilibrium therewith, wherein different alleles of the one or 

more marker are associated with different susceptibilities to prostate 

cancer, and determining a susceptibility to prostate cancer from the 

presence or absence of the at least one allele. Further disclosed are 

corresponding oligonucleotides as diagnostic reagents. 

(21) 576606 (22) 25 Oct 2007 

(54) NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, 

THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR 

THERAPEUTIC APPLICATIONS 

(86) PCT/IB2007/003209 (87) WO2008/053301 

(51) IPC2012.01:C07D487/04; A61P35/00; A61P25/00; A61P33/00; 

A61K31/41, 4196, 53 

(71) HYBRIGENICS SA 

(72) GUEDAT, Philippe; JACQ, Xavier; COLLAND, Frederic; 

DAVIET, Laurent; FORMSTECHER, Etienne; RAIN, Jean-Christophe; 

COLOMBO, Matteo 

(31) 06 06291686 (32) 30 Oct 2006 (33) EP 

(31) 06 554056 (32) 30 Oct 2006 (33) US 



(57) Provided are tetracyclic inhibitors of cysteine proteases of 

Formula (I), with defined substituents. An exemplary compound is 

3-Methyl-1,2,3a,4,10-pentaaza-cyclo-penta[b]fluoren-9-one O-methyloxime. 

The compounds can be used for various diseases, including 

cancers, inflammations, cardiovascular diseases and viral diseases. 

(21) 576650 (22) 7 Nov 2007 

(54) Machine having swappable tools for different tasks covered by a 

housing rotatable to different positions for different tasks 

(86) PCT/EP2007/009616 (87) WO2008/055660 

(51) IPC2012.01:E01H5/04; A01D42/00, 08, 04, 02 

(71) Andrew Manson Lau 

(72) LAU, Andrew, Manson 

(31) 06 06016981 (32) 7 Nov 2006 (33) DE 



(57) A combination device (1) for carrying out various work tasks, such 

as cutting snow, mowing, scarifying or soil breaking is disclosed. The 

device has a plurality of interchangeable work implements (60) whose 

respective design is tailored to the respective work task. A basic frame 

is provided in which the work implement is fixed and driven in rotation. 

The installed work implement is partially enclosed by a housing (23) 



extending parallel to the axis of rotation of the work implement. In order 

to tailor the combination device optimally to the respective work task, 

provision is made for the housing (23) to be able to rotate about an axis 

parallel to the axis of rotation of the respective work implement (60) and 

to be fastened in various operating positions. 

(21) 576734 (22) 25 Oct 2007 

(54) Cool drying of gas by passing the gas through a heat exchanger 

(86) PCT/BE2007/000116 (87) WO2008/055322 

(51) IPC2012.01:B01D53/26; B01D5/00; F25B49/02; G05D23/19 

(71) ATLAS COPCO AIRPOWER, NAAMLOZE VENNOOTSCHAP 

(72) VAN DIJCK, Wouter, Denis, Ann; VAN NEDERKASSEL, Frederic, 

Daniel, Rita 

(31) 06 060544 (32) 10 Nov 2006 (33) BE 



(57) Method for cool drying gas, in particular air containing water vapour, 

where the gas is led through the secondary part of a heat exchanger 

2, whose primary part is the evaporator of a cooling circuit which also 

comprises a compressor 6 that is driven by a motor 5, a condenser 7, 

and an expansion means between the outlet of the condenser 7and the 

inlet of the above-mentioned evaporator. First the temperature or the 

dew point is measured in the environment of the place where, when cool 

drying, the temperature of the gas to be dried is the lowest. Then when 

the decrease of the lowest measured gas temperature or the dew point 

over a predetermined period of time amounts to less than a preset value 

the cooling circuit is switched off. 

(21) 576736 (22) 5 Nov 2007 

(54) Pitch and stickies control in pulp and papermaking processes using 

a combinantion of a lipase and a nonionic polymeric detackifier 

(86) PCT/US2007/023290 (87) WO2008/057492 

(51) IPC2012.01:D21C9/08; D21H17/26; D21H21/02 

(71) HERCULES INCORPORATED 

(72) CAREY, William, S; XU, Zu-Feng 

(31) 06 856996 (32) 6 Nov 2006 (33) US 



(57) Disclosed is a method for inhibiting the deposition of one or more 

organic contaminants in pulp and papermaking systems. The method 

comprises treating one or both of the pulp or the process equipment 

surfaces in a pulp and papermaking system with an effective inhibiting 

amount of a combination of: 1) one or more lipases; and 2) one or more 

non-ionic polymeric detackifiers, wherein the one or more non-ionic 

polymeric detackifiers comprise hydrophobically modified hydroxyethyl 

cellulose ether or a poly[vinyl acetate] having from about 50% to 100% 

hydrolysis of the acetate groups to hydroxyl groups. Also disclosed is 

a composition for inhibiting the deposition of organic contaminants on 

process equipment surfaces in pulp and papermaking systems. The 

composition comprises one or more lipases and one or more non-ionic 

polymeric detackifiers, wherein the one or more non-ionic polymeric 

detackifiers comprise hydrophobically modified hydroxyethyl cellulose 

ether or a poly[vinyl acetate] having from about 50% to 100% hydrolysis 

of the acetate groups to hydroxyl groups. 

(21) 576880 (22) 11 Oct 2007 

(54) A post support for a ground spike made from folded sheet metal with 

reinforcement ribs 

(86) PCT/CA07/001814 (87) WO2008/046200 

(51) IPC2012.01:B21D21/00; B21K25/00; E04H12/22; B23P15/00; 

E02D5/74, 80 

(71) Peak Innovations Inc. 

(72) WALKER, Simon; ZHU, Jianzhong 

(31) 2573995 (32) 16 Jan 2007 (33) CA 

(31) 2563135 (32) 11 Oct 2006 (33) CA 

(74) Peak Innovations Inc., 203 - 11782 Hammersmith Way, Richmond 

BC V7A 5E2, Canada 

(57) A metal post support ground spike (40) is disclosed. The support 

includes a post receiving socket (50), and a flat plate (60). The flat plate 

is welded to at least two of the four walls of the post receiving socket. 

The post support may also comprise a blades portion (41) welded to 

the flat plate. The blades portion, post receiving socket and flat plate 

may all have reinforcement lines (46, 47, 55) stamped therein and may 

comprise metals of varying thickness and rigidity. The flat plate may 

comprise the thickest and most rigid metal, whereas the post receiving 

socket and/or the blades may be made from a thinner and/or less rigid 

metal. Clamps in the form of tabs (56) may assist to hold a post in the 

socket by the use of fasteners passing through holes (58) and being 

tightened. 



(21) 576923 (22) 24 Oct 2007 

(54) A stopper cap with a multilayer joint for a bottle neck and a method 

for making such 

(86) PCT/FR2007/001759 (87) WO2008/056057 

(51) IPC2012.01:B32B27/08; B65D41/04; B65D53/04; B67B3/12, 18 

(71) AMCOR FLEXIBLES CAPSULES FRANCE 

(72) GRANGER, Jacques; BOURREAU, Jean Marie 

(31) 06 0609289 (32) 24 Oct 2006 (33) FR 



(57) Disclosed is a stopper cap (1'), having an axial direction (10'), 

comprising a shell (2'), with a head (20') a skirt (21') and a seal (3) 

arranged in the shell. The stopper cap is configured to tightly seal the 

neck of a recipient by axially and laterally compressing the seal between 

the cap and the neck. The seal is a shaped seal having a center part with 

an inner surface configured to face the recipient. The shaped seal is a 

multilayer seal comprising at least a resilient layer and a set of adjacent 

layers. The adjacent layer comprising at least a layer made of a material 

to form a barrier against the diffusion of gases, a malleable support layer, 

and an outer layer made of plastic material. 

(21) 577058 (22) 4 May 2007 

(54) COMPOSITIONS AND METHODS FOR TREATING A NEOPLASM 

(86) PCT/US2007/068300 (87) WO2008/073509 

(51) IPC2012.01:A61K39/395; A61P35/00 


(72) MASS, Robert, D; PLOWMAN, Gregory, D 

(31) 06 874460 (32) 11 Dec 2006 (33) US 



(57) Use of an antagonist anti-VEGF antibody in the manufacture of a 

medicament for treating multiple myeloma in a patient relapsed from or 

refractory to bortezomib therapy. 


(21) 577150 (22) 14 Dec 2007 

(54) IMIDAZOPYRIDINE INHIBITORS OF IAP 

(86) PCT/US2007/087532 (87) WO2008/079735 

(51) IPC2012.01:C07D471/04; A61K31/437, 4188; A61P35/00 


(72) KOEHLER, Michael F.T. 

(31) 06 870821 (32) 19 Dec 2006 (33) US 



(57) Disclosed are 2-(imidazo[1,2-a]pyridin-2-yl)pyrrolidine derivatives as 

represented by the general formula (I), wherein: X1 and X2 are each 

independently O or S; Y is CH2; Z is H, alkyl, a carbocycle or a 

heterocycle which may be substituted; Q is H, halogen, hydroxyl, 

carboxyl, amino, nitro, cyano, alkyl, a carbocycle or a heterocycle; 

wherein said alkyl, carbocycle and heterocycle may be substituted; R1, 

R3’, R4’, R5, R6 and R6’ are each hydrogen; R2 is morpholino or 

cyclohexyl; R3 and R4 are methyl; R7 is H, cyano, hydroxyl, mercapto, 

halogen, nitro, carboxyl, amidino, guanidino, alkyl, a carbocycle, a 

heterocycle or -U-V; R8 is H, alkyl, a carbocycle or a heterocycle wherein 

one or more CH2 or CH groups of said alkyl is optionally replaced 

with -O-, -S-, -S(O)-, S(O)2, or -C(O)-; and said alkyl, carbocycle and 

heterocycle is optionally substituted; and m is 0 to 4; or a salt or 

stereoisomer thereof. Representative compounds include those where 

the 2-(imidazo[1,2-a]pyridin-2-yl)pyrrolidine moiety is substituted on the 

1-position with N-methyl-L-alanine-L-cyclohexylglycine or N-methyl-Lalanine-L-morpholin-4-ylglycine. 

Further disclosed is a pharmaceutical 

composition which comprises a compound as defined above and a 

carrier, diluent or excipient for the treatment of cancer. 


(21) 577209 (22) 20 Dec 2007 

(54) ACYLAMINOPYRAZOLES AS Fibroblast Growth Factor Receptor 

INHIBITORS 

(86) PCT/GB2007/004917 (87) WO2008/075068 

(51) IPC2012.01:C07D487/04; A61P35/00; C07D403/12; C07D413/12; 

A61K31/415; C07D231/40; C07D471/04; C07D405/06; C07D409/12; 

C07D401/06, 12, 14 

(71) ASTRAZENECA AB 

(72) FOOTE, Kevin, Michael; THEOCLITOU, Maria-Elena; THOMAS, 

Andrew, Peter; BUTTAR, David 

(31) 06 871190 (32) 21 Dec 2006 (33) US 

(31) 07 985542 (32) 5 Nov 2007 (33) US 



(57) Disclosed are acylaminopyrazole compounds according to 

the structure of Formula I, wherein A is a substituted 

aryl group and B comprises an aryl or heteroaryl ring 

bonded to a heterocycle. Specific examples of compounds of 

Formula I include: N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3yl]benzamide, 

N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4- 

(3,5-dimethylpiperazin-1-yl)benzamide, 4-(4-Cyclobutylpiperazin-1-yl)- 

N-[5-[(3,5-dimethoxyphenyl)methoxy]-2H-pyrazol-3-yl]benzamide, and 

N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-2-(4-methyl-3oxopiperazin-1-yl)pyrimidine-5-carboxamide, 

The disclosed 

compounds are used in the treatment of cancer and other therapies 

involving the production of a fibroblast growth factor receptor inhibitory 

effect. 



(21) 577284 (22) 20 Nov 2007 

(54) AN AEROSOL DEVICE 

(86) PCT/GB2007/004432 (87) WO2008/062172 

(51) IPC2012.01:B65D83/14; A61M15/00 

(71) Cipla Limited 

(72) LULLA, Amar; RAO, Xerxes 

(31) 1914/MUM/2006 (32) 20 Nov 2006 (33) IN 

(31) 1635/MUM/2007 (32) 24 Aug 2007 (33) IN 



(57) Provided is an aerosol device comprising a container with an opening 

at one end, a valve assembly supported within the container, and 

sealing means for providing a seal between the valve assembly and the 

container, and a cap member for retaining the valve assembly in the 

container, said cap member being separate from said sealing means; 

wherein said seal is provided between the outside of the valve assembly 

and the inside of the container and the cap member is secured to the 

outside of the container. The sealing may be made by crimping or by 

snap-fitting. 

(21) 577318 (22) 30 Oct 2007 

(54) NOVEL COMPOUNDS WITH AFFINITY FOR AMYLOID 

(86) PCT/JP2007/071121 (87) WO2008/059714 

(51) IPC2012.01:C07D471/04; A61K51/00 

(71) Nihon Medi-Physics Co., Ltd. 

(72) TANIFUJI, Shigeyuki; NAKAMURA, Daisaku; TAKASAKI, Shinya; 

OKUMURA, Yuki 

(31) 06 311203 (32) 17 Nov 2006 (33) JP 



(57) Disclosed are imidazo-pyridine compounds represented by general 

formulae (1), (2), (3) and (4). Examples of the compounds 

include 6-tributylstannyl-2-(4'-fluorophenyl)imidazo[1,2-a]pyridine and 

2-(4'iodophenyl)-6-methoxyimidazo[1,2-a]pyridine. The compounds are 

used in the diagnosis of Alzheimer’s disease. 

(21) 577348 (22) 20 Dec 2007 

(54) INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE 

(86) PCT/US2007/088319 (87) WO2008/083027 

(51) IPC2012.01:A01N43/58; A61K31/495, 50; C07D237/32; C07D403/10 

(71) ABBOTT LABORATORIES 

(72) GANDHI, Viraj B; GIRANDA, Vincent L; GONG, Jianchun; PENNING, 

Thomas D; ZHU, Gui-dong 

(31) 06 882317 (32) 28 Dec 2006 (33) US 



(57) Disclosed is a poly(ADP-ribose)polymerase compound of 

formula (Ik), wherein the substituents are as defined within 

the specification. An example of a compound of formula 

(Ik) includes 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1yl)methyl)phenyl)pyrrolidine-2,5-dione. 

Further disclosed is a 

pharmaceutical composition comprising a compound of formula (Ik), and 

the use of a compound of formula (Ik) for treating cancer and reducing 

tumour volume. 


(21) 577467 (22) 16 Nov 2007 

(54) COMBINATION OF PEMIROLAST AND A STATIN FOR USE IN THE 

TREATMENT OF INFLAMMATORY DISORDERS 

(86) PCT/GB2007/004408 (87) WO2008/074975 

(51) IPC2012.01:A61P9/00; A61P29/00; A61P37/00; A61K31/366, 22, 40, 

405, 47, 505, 517; A61K45/06 

(71) CARDOZ AB 

(72) RAUD, Johan 

(31) 06 875377 (32) 18 Dec 2006 (33) US 

(31) 07 000743 (32) 29 Oct 2007 (33) US 



(57) A combination or kit thereof comprising (A) pemirolast and (b) a statin 

selected from rosuvastatin and atorvastatin. The combination can be 

used to treat inflammatory conditions in particular: migraine, asthma, 

chronic obstructive pulmonary disease, Crohn’s disease, multiple 

sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, 

ulcerative cololitis or a cardiovascular disease. In particular the 

cardiovascular disease is atherosclerosis or an associated disorder 

selected from aortic aneurysm, arteriosclerosis, peripheral arterial 

occlusive disease, a coronary artery disease, a coronary disease, 

plaque rupture, atheroma rupture, vascular disease, arterial disease, 

ischemic disease, ischemia and stroke. 

(21) 577472 (22) 16 Oct 2007 

(54) RFID LABEL WITH COUPLING ANTENNA AND CARRIER FILM 

(86) PCT/EP2007/008948 (87) WO2008/055579 

(51) IPC2012.01:G06K19/077; H01L23/498; H01Q1/22 

(71) BIELOMATIK LEUZE GMBH + CO. KG 

(72) BOHN, Martin; NITSCHKO, Harry; SCHAFFRATH, Kai 

(31) 10 2006 052 517.5 (32) 6 Nov 2006 (33) DE 



(57) Disclosed is a self-adhesive label (1) made of an RFID chip (3) and 

a coupling antenna (4) on a carrier film (5). The RFID chip (3) is fixed 

directly onto and galvanically connected to the coupling antenna (4). 

The RFID chip (3) and coupling antenna (4) are arranged in a plane 

with the carrier film (5). The underside of the label (1) has an adhesive 

layer covered by a strippable web- or sheet-type separating material. 

This layer is located on the carrier film (5). The thicknesses of the carrier 



film (5) and adhesive layer are set so that, when the label (1) is attached 

to an additional RFID antenna (6), the coupling antenna (4) and the 

additional RFID antenna (6) are inductively coupled. The label (1) can 

be attached to the additional RFID antenna (6) by adhesive bonding 

using the adhesive layer. 

(21) 577511 (22) 16 Aug 2007 

(54) 2-Phenyl-imidazo[1,2-a]pyridine derivatives substituted with a 

radioactive halogen substituent 

(86) PCT/JP2007/065955 (87) WO2008/065785 

(51) IPC2012.01:C07D471/04; A61K49/04; A61K31/437, 4188 

(71) Nihon Medi-Physics Co., Ltd. 

(72) TANIFUJI, Shigeyuki; NAKAMURA, Daisaku; TAKASAKI, Shinya; 

OKUMURA, Yuki 

(31) 06 324701 (32) 30 Nov 2006 (33) JP 



(57) Disclosed are 2-phenyl-imidazo[1,2-a]pyridine derivatives as 

represented by the following formula (1), or a salt thereof: wherein: 

all of A1, A2, A3 and A4 represent carbons, R1 is a radioactive 

halogen substituent; R2 is a group selected from the group consisting 

of hydrogen, cyano, hydroxyl, methoxy, or is a carboxyl, amino, 

N-methylamino or N,N-dimethylamino group; p is an integer of 0 

to 2. Further disclosed are representative compounds of formula 

(1) such as 2-(4’-ethoxyphenyl)-6-[123I]iodoimidazo[1,2-a]pyridine, 2- 

[4’-(2-hydroxyethoxy)phenyl]-6-[125I]iodoimidazo[1,2-a]pyridine, 2-[4’- 

(3-hydroxypropoxy)phenyl]-6-[131I]iodoimidazo[1,2-a]pyridine. Further 

disclosed is a diagnostic agent for Alzheimer’s disease, which 

comprises a compound as defined above, or a salt thereof. 

(21) 577563 (22) 5 Feb 2008 

(54) METHOD FOR CONFIGURING THE LINK MAXIMUM 

TRANSMISSION UNIT (MTU) IN A USER EQUIPMENT (UE) 

(86) PCT/SE2008/050142 (87) WO2008/115124 

(51) IPC2012.01:H04L12/46; H04W28/16; H04L29/06 

(71) TELEFONAKTIEBOLAGET L M ERICSSON (PUBL) 

(72) KUNINGAS, Tarmo 

(31) 07 0700725 (32) 22 Mar 2007 (33) SE 



(57) A user equipment (UE) is adapted to connect to a System Architecture 

Evolution / Long Term Evolution (SAE/LTE) radio network. The UE 

comprising means for receiving data. The means for receiving data 

comprises the link maximum transmission unit (MTU) supported by the 

SAE/LTE network. The means comprises one of means for receiving 

the link MTU in a Non Access Stratum (NAS) message and means for 

receiving the link MTU in a Radio Resource Control (RRC) message. 

A method of configuring the link maximum transmission unit (MTU) in 

a user equipment (UE) adapted to connect to an System Architecture 

Evolution / Long Term Evolution (SAE/LTE) radio network and a node 

in a System Architecture Evolution/Long Term Evolution (SAE/LTE) 

radio network is disclosed. The node comprises means for signalling 

the MTU supported by the SAE/LTE network to a User Equipment (US) 

connected to the network. The means comprises one of means for 

signalling the link MTU in a Non Access Stratum (NAS) message and 

means for signalling the link MTU in a Radio Resource Control (RRC) 

message. 

(21) 577601 (22) 28 Nov 2006 

(54) An ocean power generator using the relitive motion of to nuetraly 

bouyant parts to generate electricity 

(86) PCT/IT2006/000825 (87) WO2008/065684 

(51) IPC2012.01:F03B13/20 

(71) 40SOUTH ENERGY LIMITED 

(72) GRASSI, Michele 



(57) A wave energy converter apparatus is disclosed. The apparatus 

has at least two members (1, 2) mutually connected by connection 

means (4) and movable for allowing the mutual displacement of the 

members (1, 2) in response to waves in the water where the apparatus 

is placed. The apparatus further comprising energy conversion means 

(6) for converting the motion of the connection means (4) into electric 

energy, and means for storing and/or transporting elsewhere the energy 

produced. The members (1, 2) are non-floating, completely submerged 

members making the apparatus, taken as a whole, neutrally buoyant. 

Means is provided for keeping the position of each one of the submerged 

members substantially at rest with respect to the surrounding water with 

which they are in direct contact, so that the members (1, 2) will move 

under the wave action substantially in the same way as an undisturbed 

water particle placed in the same region, the at least two submerged 

members (1, 2) being mutually spaced by the connection means (4) 

so as to assume respective positions affected differently by the water 

motion induced by the waves. 



(21) 577603 (22) 10 Dec 2007 

(54) PROCESS FOR THE PREPARATION OF PIPERAZINYL AND 

DIAZEPANYL BENZAMIDE DERIVATIVES 

(86) PCT/US2007/086936 (87) WO2008/076685 

(51) IPC2012.01:C07D241/04; A61P25/00; A61K31/4965, 5377; 

C07D403/10; C07D413/10; C07D401/10 

(71) JANSSEN PHARMACEUTICA N.V. 

(72) CHOUDHURY, Anusuya; GRIMM, Jeffrey S.; SORGI, Kirk L.; 

PALMER, David; LIU, Jing 

(31) 60/870003 (32) 14 Dec 2006 (33) US 



(57) Disclosed is a process for the preparation of formula (Ia) or a 

pharmaceutically acceptable salt, ester, tautomer, solvate or amide 

thereof, wherein reacting a compound of formula (Xa) with a compound 

of formula (XIa) in the presence of a peptide coupling agent, in an 

organic solvent or mixture of organic solvents, to yield the corresponding 

compound of formula (Ia). Further disclosed is a process for the 

preparation of formula (Ib) or a pharmaceutically acceptable salt, ester, 

tautomer, solvate or amide thereof, wherein reacting a compound of 

formula (Xb) with a compound of formula (XIb) in the presence of a 

peptide coupling agent, in an organic solvent or mixture of organic 

solvents, to yield the corresponding compound of formula (Ib). 

(21) 577674 (22) 16 Nov 2007 

(54) System for dealing with duress transactions at e.g. an ATM 

(86) PCT/IB2007/054676 (87) WO2008/059464 

(51) IPC2012.01:G06Q20/00, 40 

(71) NET 1 UEPS TECHNOLOGIES, INC. 

(72) BELAMANT, Serge, Christian, Pierre 

(31) 06 09535 (32) 16 Nov 2006 (33) ZA 



(57) An electronic financial transaction system and a method of controlling 

an electronic financial transaction are disclosed. The system includes an 

identifier designation determining means for determining a designation 

of an identifier supplied by a prospective transactor in accordance 

with his circumstances; and a response means for implementing a 

predetermined response according to the designation of the identifier, in 

which the designation is "normal" or "duress" and in which the "duress" 

designation is "low duress", "medium duress" or "high duress". The 

response implemented can be to permit a normal suite of transactions 

if the designation of the identifier is "normal" or not to permit any 

transaction and to activate a duress procedure if the designation of 

the identifier is "duress" such as freezing the transactor's account or 

to permit predefined limited transactions and the duress procedure 

includes alerting duress personnel. The identifier is a code or a biometric 

such as a fingerprint. 

(21) 577676 (22) 15 Nov 2007 

(54) Authorising payments at a remote terminal by acquiring and 

transmitting account and biometric data 

(86) PCT/IB2007/054659 (87) WO2008/059458 

(51) IPC2012.01:G06Q20/00; G06K9/00; G07F7/10; G07G1/12 

(71) NET 1 UEPS TECHNOLOGIES, INC. 

(72) BELAMANT, Serge Christian Pierre 

(31) 06 09537 (32) 16 Nov 2006 (33) ZA 



(57) Disclosed is a system (11) for facilitating a financial transaction 

between a prospective transactor and a transactee. The system 

includes an identity and account verifying facility for verifying the identity 

of the prospective transactor and an account the prospective transactor 

has with a financial institution. The identity and account verifying facility 

is operated by an independent verifier and includes a storage means 

(20) which stores a biometric identifier of the prospective transactor and 

details of at least one account held by the transactor at the financial 

institution. The details of the account(s) have been checked by the 

financial institution. The identity and account verifying means further 

includes a receiving means (38) for receiving a biometric identifier and 

account details of a prospective transactor from a transactee, wherein 

the biometric identifier is verified by comparison with the corresponding 

biometric identifier stored against the account details. The identity and 

account verifying facility is also provided with a communicating means 

for communicating with the financial institution to confirm details of the 

account(s) with the relevant financial institution and a replying means 

(42) for replying to a transactee in response to a request to verify the 

biometric identifier and account details of the prospective transactor. 



(21) 577694 (22) 6 Dec 2007 

(54) METHODS AND SYSTEMS FOR ACCESS CONTROL USING A 

NETWORKED TURNSTELE 

(86) PCT/US2007/086651 (87) WO2008/070781 

(51) IPC2012.01:G06Q10/08; G07C9/02 

(71) Ticketmaster L.L.C. 

(72) DENKER, Dennis; HIROSE, Shigeki; WALL, Jonathan, Scott 

(31) 07 873324 (32) 7 Dec 2006 (33) US 



(57) A method of controlling venue access and a computer controlled 

turnstile system are disclosed. The turnstile system comprises a 

turnstile, including a computer interface; and a computer system 

coupled to the turnstile and to user terminals. The computer system 

includes program code configured to receive an order from a user for a 

plurality of admissions to an event; associate the plurality of admissions 

with a single first ticket; provide a user interface via which the user 

can re-associate a first quantity of the plurality of admissions with a 

second ticket; store in memory information related to the re-association; 

at least partly in response to information obtained from the second 

ticket at a venue associated with the event, access the information and 

enable the turnstile to admit a number of persons that corresponds 

to the first quantity. The order is received from a user terminal; Also 

disclosed is a networked access control system comprising a network 

interface configured to receive user communications over a network and 

to receive ticket data read from tickets via a ticket reader located at an 

event venue; and program code stored in a computer readable medium, 

configured to receive a request for a first plurality of admissions for an 

event from a user; cause, at least in part, a user interface to be presented 

via which the user can associate a second plurality of admissions, which 

is a first subset of the first plurality of admissions, with a first ticket, and 

a second subset of the first plurality of admissions with a second ticket; 

store a definition of the first subset and the second subset received from 

the user; receive data from a ticket reader corresponding to the first 

ticket; use the first ticket data read from the first ticket to determine how 

many admissions are associated with the first ticket; and at least in part 

enable a number of people that correspond to the determination as how 

many admissions are associated with the first ticket to gain admission 

to the event. 

(21) 577698 (22) 22 Nov 2007 

(54) Ampoules comprising an elongated neck portion which prevents 

suspended particles within the liquid from reaching the head of the 

ampoule 

(86) PCT/GB2007/004476 (87) WO2008/062203 

(51) IPC2012.01:A61J1/06 

(71) Breath Ltd 

(72) MCAFFER, Ian, Gardener, Cameron; TASKO, Peter, Ernest 

(31) 06 0623320 (32) 22 Nov 2006 (33) GB 

(31) 07 0709273 (32) 15 May 2007 (33) GB 

(74) CULLEN & CO, Level 32, 239 George Street, Brisbane, QLD 4001, 

Australia 

(57) Disclosed is an ampoule, comprising: a body comprising a reservoir 

for up to 50ml of liquid; a removable head portion comprising a bulb; 

and a neck portion, linking the body to the head portion, comprising 

a channel through which liquid in the reservoir can exit the ampoule 

when the head portion has been removed, wherein the neck portion 

comprises a trap to prevent suspended particles in the liquid which have 

settled from reaching the head portion, and wherein the bulb is in fluid 

communication with the channel of the neck portion. 

(21) 577767 (22) 18 Dec 2007 

(54) Use of Lactobacillus amylovorus cells in the manufacture of 

a medicament for improving or preventing periodontal disease by 

promoting IGA production 

(86) PCT/JP2007/074321 (87) WO2008/075685 

(51) IPC2012.01:A61K35/74; A61P37/04 

(71) Calpis Co., Ltd. 

(72) HACHIMURA, Satoshi; KANZATO, Hiroki; FUJIWARA, Shigeru 

(31) 06 344233 (32) 21 Dec 2006 (33) JP 



(57) Disclosed is the use of Lactobacillus amylovorus cells in the 

manufacture of a medicament for improving or preventing periodontal 

disease by promoting IGA production. 

(21) 577798 (22) 21 Dec 2007 

(54) 5-CYANO-4- (PYRROLO [2, 3B] PYRIDINE-3-YL) -PYRIMIDINE 

DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS 

(86) PCT/US2007/026190 (87) WO2008/079346 

(51) IPC2012.01:A61K31/506, 551; A61P35/00; A61P9/00; A61P11/06; 

A61P37/00, 08; A61P5/00; A61P29/00; A61P25/00, 28; A61P3/00; 

A61P19/00; A61P43/00 

(71) VERTEX PHARMACEUTICALS, INC. 

(72) MORTIMORE, Michael; YOUNG, Stephen, Clinton; EVERITT, 

Simon, Robert, Lorrie; KNEGTEL, Ronald; PINDER, Joanne, Louise; 

RUTHERFORD, Alistair, Peter; DURRANT, Steven; BRENCHLEY, 

Guy; CHARRIER, Jean, Damien; O'DONNELL, Michael 

(31) 06 876307 (32) 21 Dec 2006 (33) US 

(31) 07 922291 (32) 6 Apr 2007 (33) US 

(31) 07 947707 (32) 3 Jul 2007 (33) US 

(31) 07 989014 (32) 19 Nov 2007 (33) US 



(57) Disclosed is a 5-CYANO-4- (PYRROLO [2, 3B] PYRIDINE-3-YL) - 

PYRIMIDINE and derivatives that are useful as protein kinase inhibitors. 



(21) 577825 (22) 8 Jan 2008 

(54) SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC 

INHIBITORS 

(86) PCT/US2008/000221 (87) WO2008/088688 

(51) IPC2012.01:C07D491/10; A61K31/438; A61P3/00; C07D495/04 

(71) BANYU PHARMACEUTICAL CO., LTD.; MERCK SHARP & DOHME 

CORP. 

(72) IINO, Tomoharu; JONA, Hideki; SHIBATA, Jun; SHIMAMURA, 

Tadashi; YAMAKAWA, Takeru; YANG, Lihu 

(31) 07 880302 (32) 12 Jan 2007 (33) US 



(57) Disclosed are spirochromanone derivatives represented 

by formula (I). An example of a compound of formula 

(I) is 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1Htetrazol-5-yl)spiro[chroman-2,4'-piperidine 

]-4-one. The compounds are 

used to treat metabolic syndrome, fatty liver, hyperlipemia, obesity, 

diabetes, bulimia, malignant neoplasm and infectious diseases. 

(21) 577846 (22) 23 Nov 2007 

(54) POWER SUPPLY MONITORING SYSTEM 

(86) PCT/AU2007/001810 (87) WO2008/061321 

(51) IPC2012.01:H02H3/00; H02H11/00; G01D7/00 

(71) Jemena Asset Management (6) Pty Ltd 

(72) EDWARDS, Karl, Nathan 

(31) 06 906590 (32) 24 Nov 2006 (33) AU 


Australia 

(57) A system and method for detecting one or more predetermined 

fault conditions associated with the supply of AC electrical power to 

a consumer, where the supply has an active conductor and a neutral 

conductor with the neutral conductor connected to earth, is disclosed. 

The system comprises: a first current detector associated with the 

active conductor; a second current detector associated with the neutral 

conductor; means to determine a current ratio of a first current detected 

by the first current detector and a second current detected by the second 

current detector; a voltage detector to detect voltage between the active 

conductor and the neutral conductor; and a contactor switch in the active 

conductor. 

(21) 577863 (22) 21 Dec 2007 

(54) SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 

INHIBITORS 

(86) PCT/DK2007/000564 (87) WO2008/077404 

(51) IPC2012.01:C07D213/61; A61P31/00; A61P35/00; C07D413/12; 

A61P29/00; A61K31/44, 4427; C07D417/12; A61P25/00 

(71) LEO Pharma A/S 

(72) FELDING, Jakob; NIELSEN, Simon, Feldbaek 

(31) 06 871689 (32) 22 Dec 2006 (33) US 

(31) 07 945470 (32) 21 Jun 2007 (33) US 



(57) Disclosed are substituted acetophenone compounds of formula I 

and pharmaceutically acceptable esters, pharmaceutically acceptable 

salts, hydrates, N-oxides or solvates thereof, wherein the 

substituents are as described within the specification. Examples 

of compounds of formula I include: 2-(3,5-Dichloro-pyridin-4-yl)-1- 

(2-hydroxy-3,4-dimethoxy-phenyl)-ethanone; and {6-[2-(3,5-Dichloropyridin-4-yl)-acetly]-2,3-dimethoxy-phenoxy}-acetic 

acid ethyl ester. 

Further disclosed is a pharmaceutical composition comprising a 

compound of formula I, and the use of a compound of formula I in 

the manufacture of a medicament for the prophylaxis, treatment or 

amelioration of dermal diseases or conditions, or acute or chronic 

cutaneous wound disorders. Also disclosed is a method of preventing, 

treating or ameliorating dermal diseases or conditions, or acute or 

chronic cutaneous wound disorders in a non-human animal. 

(21) 577877 (22) 21 Nov 2007 

(54) Method and apparatus for connecting perpendicular reinforcing bars 

(86) PCT/US2007/085379 (87) WO2008/064307 

(51) IPC2012.01:B23P19/04; E04C5/16 

(71) Jon R. Kodi 

(72) KODI, Jon R 

(31) 06 860434 (32) 21 Nov 2006 (33) US 

(31) 07 622674 (32) 12 Jan 2007 (33) US 



(31) 07 911401 (32) 12 Apr 2007 (33) US 

(31) 07 778174 (32) 16 Jul 2007 (33) US 



(57) Disclosed is an apparatus and method for connecting bars. The 

apparatus includes a clip string having a terminal clip. The clip string 

has a plurality of connected clips. Each clip has a downwardly open 

lower seat, a downwardly open upper seat oriented transversely to the 

lower seat, and an upwardly open upper seat oriented parallel to the 

lower seat. The apparatus includes a barrel having a clip receiving 

cavity and an open distal end. The terminal clip is received in the 

clip receiving cavity with the downwardly open lower seat and the 

downwardly open upper seat open toward the open distal end of the 

barrel. The apparatus further includes a hammer received in the barrel. 

The hammer reciprocates longitudinally within the barrel for contacting 

and expelling the terminal clip from the barrel. 


(21) 577878 (22) 27 Dec 2006 

(54) OPTICAL FIBRE MANAGEMENT SYSTEM 

(86) PCT/GB2006/004906 (87) WO2008/078058 

(51) IPC2012.01:G02B6/44 

(71) PRYSMIAN CABLES & SYSTEMS LIMITED 

(72) HUBBARD, Paul; HINES, George; SMITH, Christopher; GRIFFITHS, 

Ian 



(57) Disclosed is an optical fibre management assembly (100) which 

includes a supporting element (2); at least one splice tray (4) mounted 

on the supporting element; and at least one distributing element (6) 

for routing the optical fibres through the assembly. The assembly is 

pivotable about a first axis of the distributing element and the at least 

one splice tray is pivotable about a second axis which is perpendicular 

to the first axis. 

(21) 577910 (22) 10 Jan 2008 

(54) PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL 

PENTANOIC ACID 

(86) PCT/EP2008/000142 (87) WO2008/083967 

(51) IPC2012.01:C07C227/22, 16, 32; C07C271/22; C07D207/26, 267, 

27, 277, 28, 38, 44; C07F7/18; C07C229/34; C07D227/02; C07C269/06 

(71) Novartis AG 

(72) HOOK, David; RUCH, Thomas; RISS, Bernhard; WIETFELD, 

Bernhard; SEDELMEIER, Gottfried; NAPP, Matthias; BANZIGER, 

Markus; HAWKER, Steven; CISZEWSKI, Lech; WAYKOLE, Liladhar 

Murlidhar 

(31) 07 07100451 (32) 12 Jan 2007 (33) EP 



(57) Disclosed are pyrrolidin-2-ones represented by general formula (I) 

methods for their preparation and their use in the preparation of NEPinhibitors, 

particularly in the preparation of N-(3-carboxyl-1 -oxopropyl)- 

(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl 

ester. 

(21) 577936 (22) 14 Dec 2007 

(54) AGENTS FOR CONTROLLING PARASITES ON ANIMALS 

(86) PCT/EP2007/01090 (87) WO2008/080541 

(51) IPC2012.01:A01N47/02; A01N25/02; A61K31/415; A61K47/08, 22; 

A01P7/02, 04; A01N43/56, 28 

(71) BAYER ANIMAL HEALTH GMBH 

(72) SIRINYAN, Kirkor; TURBERG, Andreas 

(31) 06 06061537 (32) 27 Dec 2006 (33) DE 


(57) Disclosed is a composition for controlling parasites 

on animals, which comprises an N-arylpyrazole such 

as fipronil or 5-amino-4-trifluoromethylsulphinyl-1-(2,6-dichloro-4trifluoromethylphenyl)-3-thiocarbamoylpyrazole 

in a formulation 

comprising: an aliphatic cyclic carbonate selected from ethylene 

carbonate or propylene carbonate and mixtures thereof; an aliphatic 

cyclic or acyclic polyether being an ether derived from a diol having 

up to 8 carbon atoms (such as diethylene glycol monoethyl ether, 

diethylene glycol monopropyl ether or dipropylene glycol monopropyl 

ether), or a 5- or 6-membered cyclic ether having a ring oxygen and 4 

or 5 ring carbon atoms and optionally carrying a alkyl substituent (such 

as tetrahydrofurfuryl alcohol); and one or more esters of a dihydric or 

trihydric alcohol having up to three carbon atoms with organic fatty acids 

having 6 to 18 carbon atoms. 

(21) 577937 (22) 14 Dec 2007 

(54) COMBINATION PRODUCT FOR CONTROLLING PARASITES ON 

ANIMALS 

(86) PCT/EP2007/010981 (87) WO2008/080542 

(51) IPC2012.01:A01N47/02; A01N25/02; A01N53/00; A61K31/415; 

A61K47/08, 22; A01P7/02, 04; A01N43/56, 28 

(71) BAYER ANIMAL HEALTH GMBH 

(72) SIRINYAN, Kirkor; TURBERG, Andreas 

(31) 06 06061538 (32) 27 Dec 2006 (33) DE 


(57) Disclosed is a composition for controlling parasites 

on animals, which comprises an N-arylpyrazole (such 

as fipronil or 5-amino-4-trifluoromethylsulphinyl-1-(2,6-dichloro-4trifluoromethylphenyl)-3-thiocarbamoylpyrazole) 

and a pyrethroid (such 



as flumethrin or permethrin) in a formulation comprising: an aliphatic 

cyclic carbonate selected from ethylene carbonate or propylene 

carbonate and mixtures thereof; an aliphatic cyclic or acyclic polyether 

being an ether derived from a diol having up to 8 carbon atoms (such as 

diethylene glycol monoethyl ether, diethylene glycol monopropyl ether 

or dipropylene glycol monopropyl ether), or a 5- or 6-membered cyclic 

ether having a ring oxygen and 4 or 5 ring carbon atoms and optionally 

carrying a alkyl substituent (such as tetrahydrofurfuryl alcohol); and one 

or more esters of a dihydric or trihydric alcohol having up to three carbon 

atoms with organic fatty acids having 6 to 18 carbon atoms. 

(21) 577974 (22) 18 Dec 2007 

(54) A packet for containing a tobacco product with a foldable web between 

the lid and packet 

(86) PCT/GB2007/004867 (87) WO2008/084189 

(51) IPC2012.01:B65D5/44, 66; A24F23/00 

(71) British American Tobacco (Investments) Limited 

(72) LEWIS, Stephen 

(31) 07 0700460 (32) 10 Jan 2007 (33) GB 


Australia 

(57) A packet (B) is disclosed for containing a tobacco product. The packet 

comprises a container portion having a top surface (10) with an opening 

(16) providing access to the inside of the container. A lid (12) is hingedly 

attached to the container portion and is operable to cover the opening 

(16) when the lid (12) is in a closed position and to be substantially 

coplanar with the top surface (10) when the lid (12) is in an open position. 

A web of panels (21-22) is attached to the lid (12) and when the lid is 

closed the web folds to be substantially contained between the lid (12) 

and the top surface (10). When the lid is open the web is unfolded to be 

substantially coplanar with the lid (12) and the top surface (10). A blank 

is also disclosed for use in forming such a packet (B). 

(21) 578077 (22) 12 Feb 2008 

(54) DIAGNOSIS OF PREECLAMPSIA USING FREE FOETAL 

HAEMOGLOBIN 

(86) PCT/EP2008/001051 (87) WO2008/098734 

(51) IPC2012.01:G01N33/569, 72, 68; A61P7/00; A61B5/00 

(71) Stefan Hansson; Bo Akerstrom 

(72) HANSSON, Stefan; AKERSTROM, Bo 

(31) 07 0700339 (32) 12 Feb 2007 (33) SE 

(74) FB RICE, Level 23, 44 Market Street, Sydney, NSW 2000, Australia 

(57) Disclosed is the use of free foetal haemoglobin as a marker for (i) 

diagnosing preeclampsia, (ii) monitoring the progression or regression 

of preeclampsia and (ii) assessing the efficacy of a treatment of 

preeclampsia. 

(21) 578163 (22) 4 Dec 2007 

(54) AUTONOMOUS SYSTEMS AND METHODS FOR STILL AND 

MOVING PICTURE PRODUCTION 

(86) PCT/US2007/086420 (87) WO2008/070687 

(51) IPC2012.01:H04N7/18; G01S3/786; H04N5/247, 262, 222, 232; 

A63B24/00 

(71) LYNX SYSTEM DEVELOPERS, INC. 

(72) DEANGELIS, Douglas, J; SIGEL, Kirk; EVANSEN, Edward, G 

(31) 06 872639 (32) 4 Dec 2006 (33) US 



(57) Autonomous picture production system comprises a location unit 

attached to each tracked object (106); an object tracking device (102) 

for receiving location information from each location unit; at least 

two motorized cameras (110); and a camera control device (104) for 

determining which of the motorized cameras has the best field of view 

of at least one of the tracked objects and for controlling, based upon the 

location information, the camera with the best field of view to capture 

image data of the at least one of the tracked objects. The camera control 

device determines the best field of view based upon factors including 

presence of another of the tracked objects blocking a view of the at least 

one of the tracked objects. Also disclosed is an autonomous picture 

production process comprising automatically determining location of 

each of a plurality of objects in or adjacent to an operational field; 

automatically determining whether each of a plurality of motorized 

cameras has a view of one of the objects obstructed by another of the 

objects and automatically controlling each of the motorized cameras in 

response to the location and obstructed views to capture image data of 

the one object. 


(21) 578165 (22) 3 Jan 2008 

(54) FOOD COMPOSITIONS INCORPORATING ADDITIONAL LONG 

CHAIN FATTY ACIDS 

(86) PCT/US2008/000051 (87) WO2008/085840 

(51) IPC2012.01:A23D9/00 

(71) MONSANTO TECHNOLOGY LLC 

(72) WILKES, Richard, S 

(31) 07 878300 (32) 3 Jan 2007 (33) US 



(57) Disclosed is a food product comprising an oil from a transgenic plant 

comprising at least 10% by weight stearidonic acid based on the total 

weight of fatty acids in the oil and a soybean oil comprising less than 3% 

by weight alpha-linolenic acid based on the total weight of fatty acids 

in the soybean oil, the food product exhibiting at least 5% longer shelflife 

against flavour degradation than an otherwise identical food product 

having eicosapentaenoic acid rather than stearidonic acid. 

(21) 578166 (22) 3 Jan 2008 

(54) FOOD COMPOSITIONS INCORPORATING STEARIDONIC ACID 

(86) PCT/US2008/000052 (87) WO2008/085841 



(51) IPC2012.01:A23D9/00 

(71) MONSANTO TECHNOLOGY LLC 

(72) WILKES, Richard, S 

(31) 07 878301 (32) 3 Jan 2007 (33) US 



(57) Disclosed is a food product comprising a soy protein and an oil from 

a transgenic plant comprising at least 10% by weight stearidonic acid 

based on the total weight of fatty acids in the oil, the food product 

exhibiting at least 5% longer shelf-life against flavor degradation than 

an otherwise identical food product having eicosapentanoic acid rather 

than stearidonic acid wherein the soy protein is selected from the 

group consisting of soyflour, defatted soyflour, soy protein concentrate, 

texturized soy protein concentrate, hydrolyzed soy protein, soy protein 

isolate, and spray-dried tofu. 

(21) 578200 (22) 14 Mar 2006 

(54) Nutritionally balanced food or beverage product 

(51) IPC2012.01:A23L1/29 

(71) Sapporo Holdings Limited 

(72) Ryan, Glenda 

(74) Pairman IP, 50A Dyers Pass Road, Cashmere, Christchurch, New 

Zealand 

(57) A food or beverage product containing the same relative proportions 

of the recommended daily intake of calories, protein, fat, carbohydrate, 

sugar and fibre as listed in the Australia-New Zealand Joint Foods 

Standards Code, in force 5 on 14 March 2006, the product being 

substantially homogenised throughout such that any portion of the 

product consumed will contain the same relative proportion of fat, 

protein, carbohydrate and fibre as any other. Also disclosed is a method 

of making the food or beverage product. 


(21) 578213 (22) 13 Dec 2007 

(54) Appetite supressant peptides 

(86) PCT/GB2007/004779 (87) WO2008/071972 

(51) IPC2012.01:C07K14/435; A61K38/26 

(71) IMPERIAL INNOVATIONS LIMITED 

(72) BLOOM, Stephen, Robert 

(31) 06 0624868 (32) 13 Dec 2006 (33) GB 

(31) 06 0625667 (32) 21 Dec 2006 (33) GB 

(31) 07 0700897 (32) 17 Jan 2007 (33) GB 



(57) Disclosed is a peptide comprising the amino acid sequence Xaa1 

Xaa2 Xaa3 G1y4 Thr5 Phe6 Thr7 Ser8 Asp9 Tyr10 Ser11 Lys12 Tyr13 

Leu14 Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 

Xaa24 Trp25 Leu26 Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 Lys33 

Asn34 Asn35 Ile36 Ala37. The peptide is used in the manufacture of a 

medicament for reducing appetite in a subject, reducing food intake in a 

subject or reducing calorie intake in a subject, reducing body weight in 

a subject, reducing body weight gain in a subject or increasing energy 

expenditure in a subject. 


(21) 578250 (22) 7 Jan 2008 

(54) Cooling containers in carton by removing top and inserting cooling 

substance such as ice, and carton and blank therefore 

(86) PCT/US2008/050367 (87) WO2008/083413 

(51) IPC2012.01:B65D5/54; B65D71/36 

(71) Graphic Packaging International, Inc. 

(72) BRAND, Kirsten, Laura 

(31) 07 878830 (32) 5 Jan 2007 (33) US 



(57) A blank (10), carton, package, and method for enclosing a plurality of 

containers in a carton is disclosed. The carton includes first and second 

top panels (16, 20; 36, 40), first and second side panels (24,32), and a 

bottom panel (28). The top panels each include separation lines (18,38) 

with one top panel disposed over the other top panel when formed as 

a carton. The carton is openable along the separation lines to expose 

the containers. The carton is capable of receiving a cooling substance 

therewithin when the top panels are separated, along the separation 

lines. The carton including at least two handle tear lines (44,46) with 

a handle (45) disposed therebetween. The handle capable of being 

engaged to move the carton or package as desired. 

(21) 578257 (22) 25 Jan 2008 

(54) METHODS AND APPARATUS FOR THE SELECTIVE REMOVAL 

OF CONSTITUENTS FROM AQUEOUS TOBACCO EXTRACTS 

(86) PCT/IB2008/001021 (87) WO2008/090477 

(51) IPC2012.01:A24B15/24 

(71) PHILIP MORRIS PRODUCTS S.A. 

(72) ZIMMERMAN, Stephen, G 

(31) 11/698146 (32) 26 Jan 2007 (33) US 



(57) Disclosed is a method of selectively removing soluble metal ions 

from an aqueous tobacco extract comprising the steps of : Preparing 

an aqueous tobacco extract; and Contacting the extract with a metal 

selective adsorption agent, wherein the metal selective adsorption agent 

is a functionalised resin and has a metal selectivity index of at least 

15. Further disclosed is an aqueous tobacco extract from which soluble 

metal ions have been removed by said process. 

(21) 578305 (22) 8 Oct 2010 

(54) Therapeutic composition and uses thereof 

(51) IPC2012.01:A61K35/20; A61K36/00; A61K31/05 

(71) NEW IMAGE GROUP LIMITED 

(72) Lehrke, Peter 



(57) Provided is a composition comprising colostrum and a sulfated 

fucose-containing polysaccharide (fucoidan). The composition may 

further include resveratrol. The composition is useful to treat conditions 

benefiting from an increase in stem cell activity, including cancer, stroke 

and diabetes. 

(21) 578371 (22) 18 Jan 2008 

(54) COATING COMPOSITION 

(86) PCT/JP2008/050585 (87) WO2008/090812 

(51) IPC2012.01:C09D167/00; C09D183/02; C09D7/12 

(71) DAIKIN INDUSTRIES, LTD.; DOW CORNING CORPORATION 

(72) NAGATO, Masaru; MAEDA, Masahiko; MASUTANI, Tetsuya; 

ONODERA, Satoshi; KITAURA, Eiji; SASAKI, Motoshi; HUPFIELD, 

Peter Cheshire 

(31) 07 013108 (32) 23 Jan 2007 (33) JP 



(57) Disclosed is a coating composition comprising (A) a polyester resin, 

(B) at least one of fluorine-containing organosilicon compound having 

a fluorine content of 5 to 30 percent by mass and represented by the 

formula (I) wherein R1, R2, R3 and R4 are the same or different and 

each is an alkyl group; "n" is an integer of 1 to 30; at least one of R1, R2, 



R3 and R4 has a fluorine atom, (C) at least one non-fluorine-containing 

monovalent aliphatic hydrocarbon compound having a hydroxyl group 

selected from the group consisting of propanol, isopropanol, butanol and 

octanol, and/or at least one non-fluorine-containing monovalent alkoxy 

compound selected from the group consisting of triethoxymethane, 

methyl orthoformate, ethyl orthoformate, methyl orthoacetate, ethyl 

orthoacetate, B(OC2H5)3 and PO(OC2H5)3, and (D) at least one 

organic solvent other than the compound (C) and selected from 

the group consisting of hydrocarbon solvents, ketone solvents, ester 

solvents, amide solvents and sulfonic acid ester solvents. 

(21) 578380 (22) 14 Dec 2007 

(54) METHOD FOR REPLICATING INFLUENZA VIRUS IN CULTURE 

(86) PCT/US2007/025636 (87) WO2008/076371 

(51) IPC2012.01:A61K39/145; C12N7/02 

(71) SCHERING-PLOUGH LTD 

(72) WASMOEN, Terri Lee; GAO, Peng; EDDY, Bradley, Allen; 

ABDELMAGID, Omar, Yousif 

(31) 06 875287 (32) 15 Dec 2006 (33) US 

(31) 06 882412 (32) 28 Dec 2006 (33) US 



(57) Disclosed is a method of selecting a human influenza virus for growth 

on tissue culture cells by limiting dilution cloning, the method comprising: 

a) serially diluting a quantity of human influenza virus to obtain a series 

of dilutions with decreasing concentrations of human influenza virus; b) 

contacting the human influenza virus of each of the series of dilutions 

with tissue cultured cells; c) growing the human influenza virus that were 

contacted in step b for a time sufficient to produce cytopathic effects 

(CPE); d) harvesting a human influenza virus grown in step c from tissue 

cultured cells that were contacted with human influenza virus from the 

highest dilution within the series of dilutions that causes CPE; and e) 

repeating steps a through d with a quantity of human influenza virus 

harvested in step d. Also disclosed is the use of the method in selecting 

canine influenza. 

(21) 578415 (22) 13 Dec 2007 

(54) METHOD FOR PRODUCING COMPOSITE MATERIALS FROM 

FUNGI COMPRISING HYPHAE AND DISCRETE PARTICLES 

(86) PCT/US2007/025475 (87) WO2008/073489 

(51) IPC2012.01:C12P1/02; C12N1/14 

(71) RENSSELAER POLYTECHNIC INSTITUTE; ECOVATIVE DESIGN 

LLC 

(72) BAYER, Eben; MCLNTYRE, Gavin; SWERSEY, Burt, L 

(31) 06 875243 (32) 15 Dec 2006 (33) US 

(31) 07 927458 (32) 3 May 2007 (33) US 

(31) 07 001556 (32) 12 Dec 2007 (33) US 



(57) Disclosed is a method of making a composite material comprising the 

steps of forming an inoculum including a preselected fungus: forming 

a mixture of a substrate of discrete particles and a nutrient material, 

said nutrient material being capable of being digested by said fungi; 

adding said inoculum to said mixture; and allowing said fungus to digest 

said nutrient material in said mixture over a period sufficient to grow 

hyphae and to allow said hyphae to form a network of interconnected 

mycelia cells through and around said discrete particles thereby bonding 

said discrete particles together to form a self- supporting material. 

Further disclosed are self-supporting composite materials comprising a 

substrate of discrete particles and a network of interconnected mycelia 

cells extending through and around said discrete particles and bonding 

said particles together. 

(21) 578541 (22) 20 Dec 2007 

(54) DNA VACCINES FOR FISH 

(86) PCT/EC2007/000004 (87) WO2008/077413 

(51) IPC2012.01:C07K14/08; A23K1/16; A61K39/12; C12N15/40 

(71) SOLUCIONES BIOTECNOLOGICAS INNOVACION LTDA; EWOS 

S.A.; CECILIA FALCONI PEREZ 

(72) KRIMAN, FLEIDERMAN, Salomon, Luis; REYES, HERNANDEZ, 

Miguel, Ernesto; OYARZUN, CAYO, Patricio, Alejandro; VILLEGAS, 

FERRARI, Claudio, Ricardo, Alfonso; NANCUCHEO, CUEVAS, Ivan, 

Patricio 

(31) 06 063767 (32) 22 Dec 2006 (33) CL 



(57) Provided is a fish vaccine based on Infectious Pancreatic Necrosis 

virus (IPNv) VP2 protein. The vaccine is formulated with liposome 

DOTAP. Further provided are methods of producing the vaccine, and 

foods containing the vaccine. 

(21) 578556 (22) 11 Jan 2008 

(54) ANTIVIRAL NUCLEOSIDE ANALOGS 

(86) PCT/US2008/050929 (87) WO2008/089105 

(51) IPC2012.01:C07H19/23; A61K31/706; A61P31/12; A61P35/00 

(71) BIOCRYST PHARMACEUTICALS, INC. 

(72) BABU, Yarlagadda S; CHAND, Pooran; KUMAR, V. Satish; KOTIAN, 

Pravin L; WU, Minwan 

(31) 07 880278 (32) 12 Jan 2007 (33) US 



(57) Disclosed is the use of a compound of formula (I) in the manufacture 

of a medicament for treating viral infections where in the substituents are 

as disclosed in the specification and examples of compounds of formula 

(I) are: (2S,3R,4R,5R)-2-(4-Aminopyrrolo[1,2-j][1,2,4]triazin-7-yl)-5- 

(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol; (2S,3R,4R,5R)-2-(4- 

(Dimethylamino)pyrrolo[1,2-j][1,2,4]triazin-7-yl)-5-(hydroxymethyl)-3methyltetrahydrofuran-3,4-diol; 

and (2S,3R,4R,5R)-2-(4-Amino-5bromopyrrolo[1,2-j][1,2,4]triazin-7-yl)-5-(hydroxymethyl)-3methyltetrahydrofuran-3,4-diol. 

Examples of the viral infection are 

from the group consisting of: hepatitis B, hepatitis C, human 

immunodeficiency virus, Polio, Coxsackie A and B, Rhino, Echo, small 

pox, Ebola, and West Nile virus. 


(21) 578613 (22) 9 Jan 2008 

(54) CHROMONES AS THERAPEUTIC AGENTS 

(86) PCT/US2008/050600 (87) WO2008/086403 



(51) IPC2012.01:A61K31/35 

(71) Unigen, Inc. 

(72) ZHAO, Ji-fu; TSENG-CRANK, Julie; YIMAM, Mesfin; JIA, Qi 

(31) 07 884107 (32) 9 Jan 2007 (33) US 



(57) Disclosed is the use of a chromone or a mixture of chromones for 

the preparation of a medicament for preventing or treating a disease 

selected from the group consisting of: insulin resistance, glucose 

intolerance, hyperglycemia, metabolic syndromes, dyslipidemia, and 

hypertriglyceridemia, wherein said chromone or a mixture of chromones 

are selected from the group of compounds having the structure of 

formula (I) wherein the substituents are as disclosed in the description. 

Also disclosed is a composition comprising a compound of formula (I) 

and aloe gel powder and a method for preparing the composition. 


(21) 578623 (22) 8 Nov 2007 

(54) Radiation diffraction sensor comprising an ordered array of particles 

and a solid matrix 

(86) PCT/US2007/084005 (87) WO2008/097397 

(51) IPC2012.01:G01N21/77, 47 

(71) PPG INDUSTRIES OHIO, INC. 

(72) PURDY, Sean; VANIER, Noel; U, Xiangling; CAVLOVICH, Robert 

(31) 07 672226 (32) 7 Feb 2007 (33) US 



(57) Disclosed is a radiation diffraction sensor comprising an ordered 

periodic array of particles formed on a substrate and a solid nonhydrogel 

matrix composition coated onto the array of particles. The 

matrix composition is selected to be responsive to an activator, such that 

exposure to the activator shifts the wavelength of radiation diffracted 

by the sensor from a first wavelength to a second wavelength. Also 

disclosed is a method of producing a sensor comprising forming an 

ordered periodic array of particles on a substrate, coating the array of 

particles with a matrix and curing the matrix to fix the array of particles 

within the matrix. The matrix is a solid non-hydrogel, and is selected 

to be responsive to an activator, such that exposure to the activator 

shifts the wavelength of radiation diffracted by the sensor to a shifted 

wavelength. Articles having the sensor include security cards/tags. 

(21) 578626 (22) 7 Dec 2007 

(54) FLOATING DISPERSANT PASTE 

(86) PCT/US2007/025100 (87) WO2008/094236 

(51) IPC2012.01:E02B15/04; C09K3/32 

(71) ExxonMobil Upstream Research Company 

(72) NEDWED, Timothy, J; CANEVARI, Gerard, P; CLARK, James, R 

(31) 07 898350 (32) 30 Jan 2007 (33) US 



(57) An oil spill treatment agent comprising: a viscous dispersant liquid 

formulated to disperse oil floating on the surface of a body of 

water, wherein the viscous dispersant liquid is opaque, has a density 

between about 0.80 grams per milliter (g/ml) and about 1.02 (g/ 

ml) and a viscosity between about 1,000 centipoise (cP) and about 

10,000cP and wherein the viscous dispersant liquid comprises sorbitan 

monooleate, polyoxyethylene sorbitan monooleate, polyoxyethylene 

sorbitan trioleate, and an alkali metal salt of dioctyl sulfosuccinate. Also 

disclosed is a method for manufacturing an oil spill agent and a method 

of dispersing oil on a body of water. 

(21) 578647 (22) 10 May 2005 

(54) Antibodies that bind to p-selectin glycoprotein ligand 1 

(51) IPC2012.01:A61K39/395; C12N15/13; C07K16/28 

(71) AbGenomics Cooperatief U.A. 

(72) Lin, Rong-Hwa; Chang, Chung Nan; Chen, Pei-Jiun; Huang, Chiu- 

Chen 

(31) M (32) 10 May 2004 (33) US 


Australia 

(57) Disclosed is an isolated antibody that binds specifically to amino acid 

residues 50 to 60 of human P-Selectin Glycoprotein Ligand 1, wherein 

the antibody, upon binding to P-Selectin Glycoprotein Ligand 1 on an 

activated T-cell, induces the death of the activated T-cell. 


(21) 578698 (22) 29 Jan 2008 

(54) SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS 

(86) PCT/US2008/052318 (87) WO2008/094912 

(51) IPC2012.01:C07D409/06; A61K31/403; A61P27/06 

(71) ALLERGAN, INC. 

(72) IM, Wha Bin; OLD, David, W 

(31) 07 887415 (32) 31 Jan 2007 (33) US 



(57) Disclosed herein are gamma lactam derivatives of the given 

formula, wherein the subustituents are as defined within the 

specification, processes for their preparation, compositions comprising 

said compounds. Said compounds are useful in the treatment of 

glaucoma or ocular hyperstension and also for growing hair or improving 

the appearance of hair. 

(21) 578721 (22) 27 Feb 2008 

(54) METHOD FOR ACTIVATION OF HELPER T CELL AND 

COMPOSITION FOR USE IN THE METHOD 

(86) PCT/JP2008/053417 (87) WO2008/105462 

(51) IPC2012.01:C12Q1/02; C07K14/82; C12N15/09, 00; A61K38/00; 

C07K16/32; G01N33/53; A61P35/00, 02; A61P43/00 

(71) INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. 

(72) SUGIYAMA, Haruo 

(31) 07 047317 (32) 27 Feb 2007 (33) JP 


(57) Disclosed is the use of a WT1 peptide comprising the amino 

acid sequence Lys Arg Tyr Phe Lys Leu Ser His Leu GIn Met 

His Ser Arg Lys His, a polynucleotide encoding said peptide, an 

expression vector comprising said polynucleotide, or a cell including 

said expression vector in the manufacture of a medicament for the 



treatment or prevention of cancer in a subject who is HLA-DRB1 *1501, 

HLA-DPB1 *0901 or HLA-DPB1 *0501 positive. Also disclosed is the 

use of an activated helper T cell produced by contacting an antigen 

presenting cell with a WTl peptide comprising the same amino acid 

sequence in the manufacture of a medicament for the treatment of 

cancer in a subject who is HLA-DRB1*1501, HLA-DRB1*0901 or HLA- 

DRB1*0501 positive. Further disclosed is a method for the determination 

of the presence or amount of a WT1-specific helper T cell in anyone 

of an HLADRB1*1501-positive, HLA-DRB1*0901-positive and HLA- 

DRB1*0501- positive subject, comprising: (a) reacting a complex of 

a WTl peptide comprising the amino acid sequence, and an HLA- 

DRB1*1501 molecule, HLA-DRB1*0901 molecule or HLA-DRB1**0501 

molecule with sample possibly containing a lymphocyte from the 

subject; and (b) determining the presence or amount of a helper T cell 

recognizing the complex contained in the sample. 


(21) 578722 (22) 29 Jan 2008 

(54) SKIN-BEAUTIFYING AGENT 

(86) PCT/JP2008/051257 (87) WO2008/093657 

(51) IPC2012.01:A61P17/00; A61K38/00; A61K35/20; A23L1/30; 

A23K1/16 

(71) MEGMILK SNOW BRAND Co., Ltd. 

(72) KATO, Ken; HARUTA, Yuko; WATANABE, Tatsuya; UENO, Hiroshi; 

UEDA, Noriko; YOSHIOKA, Toshimitsu 

(31) 07 019448 (32) 30 Jan 2007 (33) JP 


(57) Disclosed is a cosmetic method of beautifying skin, comprising 

administering a composition comprising a milk-derived phospholipid 

prepared from milk or milk material, wherein the composition comprises 

40 to 70 percent by weight of lipid in a total solid content and 30 percent 

or more by weight of milk derived phospholipid in the total solid content. 

(21) 578804 (22) 26 Feb 2008 

(54) Spirocyclic phosphodiesterase inhibitors 

(86) PCT/DK2008/000080 (87) WO2008/104175 

(51) IPC2012.01:C07D493/10; A61K31/36; A61P29/00; C07D495/10; 

C07D491/10 

(71) LEO Pharma A/S 

(72) FELDING, Jakob; NIELSEN, Simon, Feldbaek; LARSEN, Jens, 

Christian, Hojland; BABU, Bollu, Ravindra 

(31) 60/903849 (32) 28 Feb 2007 (33) US 

(31) 60/946849 (32) 28 Jun 2007 (33) US 



(57) Disclosed are PDE4 inhibiting compounds of formula (I) 

and pharmaceutically acceptable salts, hydrates, N-oxides, or 

solvates thereof, wherein the substituents are as described 

within the specification. Examples of compounds of formula (I) 

include: N-(3,5-Dichloropyridine-4-yl)-7-methoxy-2',3',5',6'-tetrahydrospiro[1,3-benzodioxole-2,4'(4H)-pyran]-4-carboxamide; 

and 2-(3,5- 

Dichloro-1-oxido-pyridine-4-yl)-1-(7-methoxy-2',3',5',6'-tetrahydrospiro[1,3-benzodioxole-2,4'-(4H)-pyran]-4-yl)ethanone. 

Further 

disclosed is a pharmaceutical composition comprising a compound of 

formula (I), and the use of a compound of formula (I) in the manufacture 

of a medicament for the prevention , treatment or amelioration of a 

disease or condition selected from dermal diseases or conditions, or 

acute or chronic cutaneous wound disorders. 

(21) 578813 (22) 11 Feb 2008 

(54) Energy efficient methods to produce alcohols and carboxylic acids 

(86) PCT/US2008/053611 (87) WO2008/098254 

(51) IPC2012.01:C12P1/00, 04; C12P7/00, 06, 44, 40, 50, 56, 54, 52, 16; 

C10J3/00 

(71) Zeachem, Inc. 

(72) VERSER, Dan, W; EGGEMAN, Timothy, J 

(31) 07 889165 (32) 9 Feb 2007 (33) US 



(57) A method for producing an alcohol or carboxylic acid from 

a carbohydrate containing material, wherein the chemical energy 

efficiency of the method is greater than the chemical energy efficiency 

of a solely biological conversion process, and is greater than a process 

in which all the material is initially subjected to a thermochemical 

conversion step. The method comprises the steps: (I) Converting a 

material that has less than 75 percent by weight of the carbon containing 

material as carbohydrate into two intermediates. One intermediate 

is produced by a biological fermentation, and the other intermediate 

is produced by a thermochemical conversion process selected from 

gasification, pyrolysis, reforming and partial oxidation; and (II) Reacting 

the two intermediates to form an alcohol, carboxylic acid, salt or ester of 

a carboxylic acid. The microorganism used in the biological conversion 

can be a homofermentative microorganism 

(21) 578867 (22) 5 Nov 2010 

(54) Trough made from a plurality of overlaping sheets the side walls held 

up by a wire in tension along the sides 

(51) IPC2012.01:A01K5/01, 00; B65D6/04 

(71) ROGER KENNETH ROY DALRYMPLE 

(72) Dalrymple, Roger Kenneth Roy 



(57) A trough is disclosed that may be extended to accommodate a 

large number of animals feeding at the same time. The trough has an 

elongate trough body (12) and at least one elongate support element 

(14, 15). The trough body comprises at least one longitudinal side 

wall portion (18,19) and a bottom portion (16) which are integral with 

one another, or attached to one another along respective longitudinal 

edges. The support element extends along the outer face of the side 

wall portion, lower than an upper edge of the side wall portion but 

higher than the bottom portion. The support element may be restrained 

from moving outward, away from a longitudinal trough centreline, by 

connecting a restraint (26) located inside the trough to the support 

element. The side wall portion is maintained upright partly by tension in 

the support element or in the restraint. In one embodiment, a plastics 

sheet material is bent into a U-shape with opposite side walls (18,19) 

supported upright by tension in longitudinal supporting wires (14,15) and 

transverse restraint wires (26), the ends of which connect to the support 

wires through respective perforations (30) in the side walls. 

(21) 578890 (22) 5 Feb 2008 

(54) TURBID WATER TREATMENT APPARATUS AND SYSTEM WITH 

A FLEXIBLE WATER IMPREMEABLE BAG FILLED WITH FILTER 

MATERIAL INSIDE A TANK 



(86) PCT/AU2008/000122 (87) WO2008/095230 

(51) IPC2012.01:C02F1/00; B01D24/00; B01D35/027; B01D39/06 

(71) Wobelea Pty Limited 

(72) BLISS, William 

(31) 07 900548 (32) 5 Feb 2007 (33) AU 

(74) EKM patent & trade marks, Level 1, 38 - 40 Garden Street, South 

Yarra, VIC 3141, Australia 

(57) Turbid water treatment apparatus and system with an internal flexible 

water impermeable bag surrounded by a reinforced cage, filled with filter 

material inside an external rigid water tank, the inner bag containing 

an inlet for dirty water at the top and an conduit outlet such as a hose 

or pipe for filtered or purified water that passes through the interior 

bag wall into the exterior storage tank. A valve mounted inline with 

the outlet conduit controls the water flow through the filter. The filter 

can consist of homogeneous filter material that is selected from the 

group consisting of palagonite, pearlite, silica sand, vermiculite, carbon, 

lignite, zeolite, rockwool and synthetic filtering agents. Additional water 

treatment is provided by chemical dosing and/or ultra violet radiation. 

The filter material can be backwashed. 

(21) 578970 (22) 28 Jan 2008 

(54) Antimicrobial peptides comprising one basic amino acid 

(86) PCT/GB2008/000283 (87) WO2008/093060 

(51) IPC2012.01:C07K7/06, 08; A61K38/06, 08 

(71) NovaBiotics Limited 

(72) O'NEIL, Deborah 

(31) 07 0702020 (32) 2 Feb 2007 (33) GB 

(31) 07 899283 (32) 2 Feb 2007 (33) US 


Australia 

(57) Disclosed is use of a peptide, or pharmaceutically acceptable salt 

thereof, in the manufacture of a medicament for the treatment or 

alleviation of a fungal infection wherein the peptide consists of a 

sequence of 9 to 15 amino acids wherein all the amino acids in said 

sequence are arginine subject to 0, 1 or 2 substitutions to the amino 

acid sequence. 

(21) 578977 (22) 14 Feb 2008 

(54) 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 

RECEPTOR 

(86) PCT/US2008/001950 (87) WO2008/100565 

(51) IPC2012.01:A01N43/40; A61K31/445 

(71) JANSSEN PHARMACEUTICA N.V. 

(72) CAI, Hui; CHAVEZ, Frank; EDWARDS, James, P; FITZGERALD, 

Anne, E; LIU, Jing; MANI, Neelakandha, S; WIENER, Danielle, K; 

RIZZOLIO, Michele, C; SAVALL, Brad, M; SMITH, Deborah, M; 

VENABLE, Jennifer, D; WEI, Jianmei; WOLIN, Ronald, L 

(31) 07 889798 (32) 14 Feb 2007 (33) US 



(57) Provided is a 2-aminopyrimidine modulator of histamine H4 receptor 

with the compound formula (I) with specified substituents. The 

compound can be used to treat a variety of diseases, including allergy, 

asthma, and other immunological disorders. 

(21) 579013 (22) 26 Feb 2008 

(54) AUTOMATIC PRESSURE CONTROLLED RELAY PUMP SYSTEM 

FOR A PLURALITY OF MEDICATION FLUID INPUTS AND A 

MULTIPLE OF LIQUID OUTPUTS WITH FLOW THROUGH REFLUX 

BARRIERS 

(86) PCT/US2008/002490 (87) WO2008/106108 

(51) IPC2012.01:A61M5/168 

(71) Carefusion 303, Inc. 

(72) REBOURS, Pierre 

(31) 07 891671 (32) 26 Feb 2007 (33) US 



(57) A continuous pump relay system for injecting medication fluids or 

discharging liquids into an intravenous (IV) line tube, comprising a 

plurality of at least two drivers to operate respective plungers with 

end seals located in syringe type containers; tubes are connected to 

the vessels and feed the liquid into and through a reflux barrier; each 

line has a pressure sensor to generate a input signal that goes to a 

controller, which in turn generates an output signal to move each driver 

independently, calculated from the respective pressure input signal. 

Valves are located in each line between the container and reflux barrier 

that open when a container is connected to the system and close when 

the container is removed. The pressure sensor measures the differential 

pressure across the valve. When the medicament has been discharged 

from the first container, the driver moves the plunger backwards to 

reduce pressure within the tube. A second driver then operates in a 

forward direction to increase the pressure in the tubing up to a setpoint or 

reference pressure value. A control loop within the controller varies the 

change in the rate of the pressure increase until the pressure setpoint 

is reached. 

(21) 579024 (22) 9 Nov 2010 

(54) Handheld bud remover brush using wire bristles that form a contiuous 

curved bristle surface 

(51) IPC2012.01:A46B7/04; A46B9/00, 02; A01G17/00; A46B15/00; 

A01G3/08 

(71) Carson Reginald Green 



(72) Green, Carson Reginald 

(74) ELLIS TERRY, Level 12, 45 Johnston Street, Wellington 6011, New 

Zealand 

(57) A bud removal tool for use on vines is disclosed. The tool has a 

handle (103) that is between 1.2 and 1.6 metres in length, a head (105) 

attached to one end of the handle and a bristles (203). The bristles are 

segmented into two or more replaceable bristle sections (201A, 201B, 

201C) that are attached to the head and together form a curved and 

continuous bristle surface. The bristle surface is used to removing buds 

from a trunk. An object of the present invention is to provide a vine bud 

removal tool that can remove newly grown vine buds with relative ease 

and with minimal effort by the user. 

(21) 579084 (22) 28 Feb 2008 

(54) Solid forms of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluromethyl-phenyl)amine 

(86) PCT/US2008/055227 (87) WO2008/140850 

(51) IPC2012.01:C07D401/14; A61K31/4439, 4184, 4178; A61P35/00 


(72) HASHASH, Ahmad; LIN, Kangwen, L; OKHAMAFE, Augustus, O 

(31) 07 904455 (32) 2 Mar 2007 (33) US 



(57) Disclosed is a solid form of 1-methyl-5-(2-(5-(trifluoromethyl)-1Himidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1Hbenzo[d]imidazol-2-amine. 

The solid form is used to treat cancer. 

(21) 579157 (22) 5 Mar 2008 

(54) NOVEL 2-HETEROARYL SUBSTITUTED BENZOTHIOPHENES 

AND BENZOFURANES 

(86) PCT/SE2008/050243 (87) WO2008/108730 

(51) IPC2012.01:C07D405/04; A61K31/443, 4436, 501; C07D409/04; 

C07D471/04 

(71) ASTRAZENECA AB 

(72) SWAHN, Britt-Marie; WENSBO, David; ARZEL, Erwan 

(31) 60/893149 (32) 6 Mar 2007 (33) US 



(57) Disclosed are 2-heteroaryl substituted benzothiophene and 

benzofurane compounds of formula (Ia), wherein the substituents are as 

described within the specification. Further disclosed is a pharmaceutical 

composition comprising a compound of formula (Ia), the use of a 

compound of formula (Ia) in a process for the preparation of a 

labelled compound, and the use of a compound of formula (Ia) in the 

manufacture of a medicament for use in in vivo metod for measuring 

amyloid deposits in a subject, wherein the subject is suspected of 

having a disease or syndrome selected form Alzheimer’s disease, 

familial Alzheimer’s disease, Down’s Syndrome and homozygotes for 

the apolipoprotein E4 allele. 

(21) 579204 (22) 22 Jan 2008 

(54) Improvement of cell growth in cells deficient in the enzyme 

dihydrofolate reductase 

(86) PCT/EP2008/050699 (87) WO2008/090148 

(51) IPC2012.01:C12N9/06; C12N15/66; C12N5/10 

(71) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 

(72) KAUFMANN, Hitto; FLORIN, Lore; BECKER, Eric 

(31) 07 07101070 (32) 24 Jan 2007 (33) EP 



(57) A method for improving cell growth of a cell line by the introduction 

of a dihydrofolate reductase (DHFR) expression cassette to increase 

the activity of DHFR, whereby the DHFR is not used as a selection or 

amplification maker. 

(21) 579230 (22) 19 Feb 2008 

(54) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use 

thereof 

(86) PCT/EP2008/001257 (87) WO2008/104306 

(51) IPC2012.01:C07D471/04; A61K31/437; A61P9/10 

(71) BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 

(72) BARFACKER, Lars; KOLKHOF, Peter; SCHLEMMER, Karl-Heinz; 

GROSSER, Rolf; NITSCHE, Adam; KLEIN, Martina; MUNTER, Klaus; 

ALBRECHT-KUPPER, Barbara; HARTMANN, Elke 

(31) 07 07009494 (32) 27 Feb 2007 (33) DE 


(57) The disclosure relates to novel substituted 4-aryl-1,4-dihydro-1,6naphthyridine-3-carboxamides 

of formula (I), a process for their 

preparation, their use for the treatment and/or prophylaxis of diseases, 

and their use for the manufacture of medicaments for the treatment and/ 

or prophylaxis of diseases, especially cardiovascular disorders. 

(21) 579238 (22) 22 Feb 2008 



(54) ACTIVATION OF HUMAN ANTIGEN-PRESENTING CELLS 

THROUGH CLEC-6 

(86) PCT/US2008/054785 (87) WO2008/103947 

(51) IPC2012.01:C07K14/11, 705; A61P37/04; C07K17/14; C12N5/0784, 

10; C07K16/28; A61K39/395, 39 


(72) BANCHEREAU, Jacques, F; OH, Sangkon; ZURAWSKI, Gerard; 

ZURAWSKI, Sandra; LI, Dapeng 

(31) 07 891418 (32) 23 Feb 2007 (33) US 



(57) Disclosed are antibodies directed against the C-type lectin-like 

receptor 6 (CLEC-6). The antibodies are used for activating antigen 

presenting cells. CLEC-6 is synonymous with CLEC4D (C-type lectin 

domain family 4 member D) and CLECSF8 (C-type lectin superfamily 

member 8). 


(21) 579244 (22) 28 Feb 2008 

(54) PROCESS FOR PREPARING ISOMERS OF CARMOTEROL 

(86) PCT/GB2008/000677 (87) WO2008/104781 

(51) IPC2012.01:C07D215/227 

(71) Cipla Limited 

(72) KANKAN, Rajendra, Narayanrao; RAO, Dharmaraj, Ramachandra; 

BIRARI, Dilip; SAWANT, Ashwini, Amol 

(31) 07MU 391 (32) 28 Feb 2007 (33) IN 



(57) Disclosed is a process for preparing the (R,R)-, (S,S)-, (R,S)- or 

(S,R)-diastereomer of a the trialkyl silyl ether carmoterol of formula 

(III) comprising condensing the R or S enantiomer of an oxiranyl 

compound of formula (I) with the R or S enantiomer of an pmethoxyphenyl-1-methylethyl 

amine of formula (II) or a salt thereof 

wherein the substituents are defined in the specification and wherein 

the process is carried out in the presence of a solvent. 

(21) 579262 (22) 22 Feb 2008 

(54) THERAPEUTIC APPLICATIONS OF ACTIVATION OF HUMAN 

ANTIGEN-PRESENTING CELLS THROUGH DECTIN-1 

(86) PCT/US2008/054798 (87) WO2008/118587 

(51) IPC2009.01:C12N5/06 


(72) BANCHEREAU, Jacques, F; OH, SangKon; ZURAWSKI, Gerard; 

ZURAWSKI, Sandra; NI, Ling 

(31) 07 891425 (32) 23 Feb 2007 (33) US 



(57) Disclosed is the use of an anti-Dectin-1-specific antibody or functional 

fragment thereof in conjunction with one or more antigens, wherein 

the anti-Dectin-1-specific antibody or functional fragment thereof is 

capable of activating a Dectin-1-expressing antigen presenting cell 

in the manufacture of a medicament for treating a disease selected 

from viral disease, bacterial diseases, fungal diseases, protozoa 

diseases, parasitic diseases, tumours, autoimmune diseases, allergies 

or graft rejection, wherein the one or more antigens are selected 

from the group consisting of viral antigens, bacterial antigens, fungal 

antigens, protozoal antigens, parasitic antigens, tumor antigens, 

antigens involved in autoimmune disease, antigens involved in allergy, 

and antigens involved in graft rejection. The effectiveness of antigen 

presentation by the antigen presenting cell is increased by contacting 

the antigen presenting cell with the anti-Dectin-1-specific antibody 

or functional fragment thereof, wherein the antigen presenting cells 

comprise an isolated dendritic cell, a peripheral blood mononuclear cell, 

a monocyte, a B cell, a myeloid dendritic cell, or combinations thereof. 

The anti-Dectin-1-specific antibody or fragment thereof is a specific for 

the ectodomain of Dectin-1. 


(21) 579274 (22) 12 Mar 2008 

(54) IMPROVED AQUEOUS-BASED INSULATING FLUIDS AND 

RELATED METHODS 

(86) PCT/GB2008/000868 (87) WO2008/110798 

(51) IPC2012.01:C10M173/02; C09K8/12 

(71) Halliburton Energy Services, Inc. 

(72) EZELL, Ryan; MILLER, Jeffrey, J; PEREZ, Gregory, P 

(31) 07 685909 (32) 14 Mar 2007 (33) US 

(31) 07 685923 (32) 14 Mar 2007 (33) US 



(57) Disclosed is an aqueous-based insulating fluid that (i) an aqueous 

base fluid, (ii) a water-miscible organic liquid, wherein the watermiscible 

liquid comprises at least one amine selected from the 

group consisting of diethyl amine, 2-(dimethylamino)ethanol, and any 

combination thereof, and (iii) a synthetic polymer, wherein at least a 

portion of the synthetic polymer is crosslinked in a reaction comprising 

at least one crosslinking agent selected from the group consisting 

of: polyalkylimines; polyalkyleneimines; polyethyleneimine; and any 

combination thereof. Also disclosed is a method for preparing a fluid, a 

method of using the fluid in pipes or tubes, for example as a well bore 

fluid, and a method of forming a gel or an annulus. 

(21) 579356 (22) 7 Mar 2008 

(54) CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE 

THEREOF 

(86) PCT/US2008/056229 (87) WO2008/109829 

(51) IPC2012.01:C07D491/048; A61P35/00; C07D215/06 

(71) Infinity Pharmaceuticals, Inc. 

(72) GROGAN, Michael, J; TREMBLAY, Martin 

(31) 07 893591 (32) 7 Mar 2007 (33) US 


Australia 

(57) Disclosed are cyclopamine lactam compounds represented by 

general formula 1. The compounds are used for the treatment of cancer. 

(21) 579361 (22) 7 Mar 2008 

(54) HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF 

USE THEREOF 

(86) PCT/US2008/003200 (87) WO2008/109184 

(51) IPC2012.01:C07D491/04, 10; A61K31/4355, 4747, 675 

(71) Infinity Discovery, Inc. 

(72) CASTRO, Alfredo C; GROGAN, Michael, J; TREMBLAY, Martin 

(31) 07 893595 (32) 7 Mar 2007 (33) US 


Australia 

(57) Disclosed are heterocyclic cyclopamine compounds represented by 

general formulae 1a and 1b. The compounds are used for the treatment 

of cancer. 

(21) 579389 (22) 24 Feb 2008 

(54) SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS 

INHIBITORS 

(86) PCT/US2008/054816 (87) WO2008/112407 

(51) IPC2012.01:C07D401/02; A61K31/47, 517; C07D403/02 



(71) ADVENCHEN LABORATORIES, LLC 

(72) CHEN, Guoqing, Paul 

(31) 60/894692 (32) 14 Mar 2007 (33) US 

(31) 60/941698 (32) 4 Jun 2007 (33) US 

(31) 12/036244 (32) 23 Feb 2008 (33) US 

(74) Acacia Law, Suite 3942, 24B Moorefield Road, Johnsonville, 

Wellington, New Zealand 

(57) Disclosed is a angiogenesis inhibiting compound of formula I, wherein 

the substituents are as described within the specification. An example of 

a compound of formula I includes: Benzyl 1-((4-(1H-indol-5-ylamino)-6methoxyquinolin-7-yloxy)methyl)cyclopropylcarbamate; 

and 7-((1- 

Aminocyclopropyl)methoxy)-N-(1H-indol-5-yl)-6-methoxyquinolin-4amine. 

Further disclosed is a method of producing a compound of 

formula I, a pharmaceutical composition comprising a compound of 

formula I, the use of a compound of formula I in the manufacture 

of a medicament for use in treating a neoplastic or proliferative or 

inflammatory disease, or a transplantation disorder, especially those 

caused by excess or inappropriate tyrosine kinases. 

(21) 579404 (22) 20 Feb 2008 

(54) MULTILAYER STRUCTURE FORMED BY NANOPARTICULAR 

LAMINA WITH UNIDIMENSIONAL PHOTONIC CRYSTAL 

PROPERTIES, METHOD FOR THE PRODUCTION THEREOF AND 

USE THEREOF 

(86) PCT/ES2008/070028 (87) WO2008/102046 

(51) IPC2012.01:G02B1/02 

(71) CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS 

(72) Ocana Jurado, Manuel; COLODRERO PEREZ, Silvia; MIGUEZ 

GARCIA, Hernan Ruy 

(31) P200700481 (32) 23 Feb 2007 (33) ES 


(57) Disclosed is a mesoporous nanoparticulate multilayer structure, 

having pores whose average size is in the range comprised between 

1 nm and 100nm, with the properties of a Bragg reflector or 

unidimensional photonic crystal, characterised in that it comprises 

periodically alternating laminae composed of nanoparticles, the laminae 

having different refractive indices and a thickness between 1 nm 

and 200 nm. Further disclosed is the a process for obtaining the 

nanoparticulate multilayer structure, characterised in that it comprises 

the following stages: a) preparation of suspensions of nanoparticles, 

the composition of which is that of any material that can be obtained 

in the form of a nanoparticle, where the suspension medium is any 

liquid wherein these particles can become dispersed, and where 

the concentration thereof is comprised between 1 percent and 99 

percent by weight; and b) formation of a multilayer structure of a high 

interconnected porosity and with the properties of a unidimensional 

photonic crystal through the alternating deposition, on any substrate, 

of laminae of controlled thickness of nanoparticles based on the 

suspensions described in a), in such a manner as to create an 

alternation in refractive index value and wherein the thickness of each 

of the laminae of nanoparticles that forms the multilayer is comprised 

between 1 nm and 1 micron, and where the number of nanoparticulate 

laminae present in the multilayer may vary between 1 and 100 layers. 

Also disclosed is the use of said nanoparticulate multilayer structure in 

the manufacturing of optical elements. 

(21) 579415 (22) 5 Mar 2008 

(54) METHOD OF PREPARING MORE DIGESTIBLE ANIMAL FEED 

(86) PCT/US2008/002940 (87) WO2008/109111 

(51) IPC2012.01:A23K1/12, 165; D21C3/02 

(71) ARCHER-DANIELS-MIDLAND COMPANY 

(72) ABBAS, Charles; BAO, Wuli; BEERY, Kyle E; CECAVA, Mike J; 

DOANE, Perry H; DUNN, James L; HOLZGRAEFE, David P 

(31) 07 904938 (32) 5 Mar 2007 (33) US 



(57) Disclosed is a process for making an animal feed comprising: 

contacting an edible fiber source in a mixture with an inorganic fiber 

hydrolyzing agent in a continuous process in a mixing device having 

at least one rotating member that shears the edible fiber and wherein 

the pressure is about 14 psig to about 50 psig the temperature is about 

100°C to 110 °C, and the time is between about 1 second to less than 5 

minutes to solubilize a first portion of carbohydrates from lignocellulosic 

material in the edible fiber source; contacting the edible fiber source with 

an enzyme fiber degrading agent selected from the group consisting of 

cellulases, hemicellulases, esterases, phytases, laccases, peroxidases 

and proteases for a time sufficient to solubilize a second portion of 

carbohydrates from lignocellulosic material in the edible fiber source; 

and drying the contacted edible fiber source to form a dried mixture 

having an insoluble fiber fraction and a soluble carbohydrate fraction 

derived from a common edible fiber source and wherein the soluble 

carbohydrate fraction is at least 45% wt/wt of the total carbohydrates 

contributed by the insoluble fiber fraction and soluble carbohydrate 

fraction. 

(21) 579431 (22) 6 Mar 2008 

(54) Substituted dihydro and tetrahydro oxazolopyrimidinones, 

preparation and use thereof 

(86) PCT/US2008/056002 (87) WO2008/112483 

(51) IPC2012.01:A61K31/519; A61P25/06, 18, 24; A61P29/00; 

C07D498/04 


(72) CAO, Bin; GURUNIAN, Vieroslava; KONGSAMUT, Sathapana; 

KOSLEY, Raymond W; SHER, Rosy; HARTUNG, Ryan E 

(31) 07 893991 (32) 9 Mar 2007 (33) US 



(57) Disclosed is a dihydro and tetrahydro oxazolopyrimidinones 

compound of formula (I) wherein the substituents are 

as disclosed in the description. Examples of compounds 

of formula (I) include: 2-{4-isopropyl-phenoxymethyl)-2,3-dihydrooxazoIo[3,2-a]pyrimidin-7-one;2-{3-tert-butyl-phenoxymethyl)-2,3dihydro-oxazolo[3,2-a 

]pyrimidin-7-one and 2-[ 4-(1-methyl-lphenyl-ethyl)-phenoxymethyl]-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7 

– 

one. Also disclosed is a pharmaceutical composition comprising a 

compound of formula (I) and the use of a compound of formula (I) for the 

preparation of a pharmaceutical composition for modulating one or more 

metabotropic glutamate receptor functions for treating neurological 

or psychiatric disorders for treating anxiety, migraine, schizophrenia, 

epilepsy and pain. 



(21) 579490 (22) 11 Mar 2008 

(54) Growth hormone secretion stimulator comprising milk-derived basic 

fraction 

(86) PCT/JP2008/054338 (87) WO2008/111573 

(51) IPC2012.01:A61K38/00; A61P5/06 

(71) Megmilk Snow Brand Co., Ltd 

(72) ONO, Aiko; MATSUYAMA, Hiroaki; MORITA, Yoshikazu; 

SERIZAWA, Atsushi; HIGURASHI, Satoshi 

(31) 07 062372 (32) 12 Mar 2007 (33) JP 



(57) Provided is the use of a milk-derived basic protein fraction for the 

manufacture of a medicament for promoting growth hormone secretion 

in patients with abnormal/pathological growth hormone secretion, 

wherein the milk-derived basic protein fraction comprises proteins in an 

amount of 95 weight % with a molecular weight in the range of from 

3,000 to 80,000, the proteins comprising lactoferrin and lactoperoxidase 

and wherein the amino acid composition of the proteins is at least 15 

weight % basic amino acids. 

(21) 579521 (22) 11 Mar 2008 

(54) SHOE INSERT INCLUDING INNER WEB WITH FUNCTIONAL 

PARTICLES 

(86) PCT/CN2008/070464 (87) WO2008/110113 

(51) IPC2012.01:A43B13/00; A43B7/00; A43B1/00; A43B23/00; 

A43B17/00 

(71) Noveko Trading 2008 LLC 

(72) CHEN, Hung-Jen 

(31) 07 072010 3806 (32) 12 Mar 2007 (33) CN 



(57) A multi-function health care self-cleaning shoe material includes a 

shoe material main body 10 which has a peripheral contour area 11, an 

inner area 12 and at least a sheet-form web body 120 located in the 

inner area 12 of the main body 10. The web body 120 is fixed on the 

peripheral contour area 11 and is a web-form fabric having plural fibers 

in both the warp and weft directions. Many functional particles (130) 

are contained in the fibers. The functional particles may be particles 

of submicron tourmaline, various metal oxides and metals, and other 

substances. 

(21) 579524 (22) 25 Feb 2008 

(54) Lubrication of a chainsaw using sensors to detect conditions of the 

saw and supplying lubrication to suit 

(86) PCT/FR2008/000245 (87) WO2008/122717 

(51) IPC2012.01:B27B17/12; F16N29/02; F16N7/38 

(71) PELLENC 

(72) PELLENC, Roger 

(31) 07 0701357 (32) 26 Feb 2007 (33) FR 

(74) P L BERRY & ASSOCIATES, 15B Byron Street, Sydenham, 

Christchurch 8023, New Zealand 

(57) A lubrication mechanism for a chain saw (1). The chainsaw has an 

endless cutting chain fitted around a drive pinion and a chain guide (6) 

that is equipped with a guiding rail. A motor drives the cutting chain, by 

means of the pinion. A lubricant storage tank is connected to a pump 

for sending the lubricant towards the chain guide/cutting chain. Unlike 

the prior art chainsaws, where the pump is driven by the motor that 

turns the drive pinion, this pump is coupled to an electric drive motor 

which is independent from the main motor and powered by a battery. 

The same battery may drive the main motor. Sensors are able to sense 

the condition of the chainsaw and adjust the lubrication as needed now 

that the pump is not directly driven by the motor, making the lubrication 

tailored to the state of the machine and not determined by the main 

motor speed. 

(21) 579630 (22) 1 May 2008 

(54) SYNERGISTIC PESTICIDAL MIXTURES 

(86) PCT/US2008/005613 (87) WO2009/134224 

(51) IPC2012.01:A01N37/40; A01N47/40; A01N53/00; A01N57/16; 

A01N43/22; C07D419/04; A61K31/44; C07D213/28, 89; A01P7/04 

(71) Dow AgroSciences LLC 

(72) MEADE, Thomas; HUANG, Jim X; BABCOCK, Jonathan M; 

FARROW, Marc 

(31) 07 927119 (32) 1 May 2007 (33) US 

(74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street, 

Melbourne, Victoria 3000, Australia 

(57) Disclosed herein is a process comprising applying a synergistic 

composition comprising a mixture of [1-(6-trifluoromethylpyridin-3yl)ethyl](methyl)-oxido-ë4-sulfanylidenecyanamide, 

and one or more 

of: spinosad, spinetoram, gamma-cyhalothrin, methoxyfenozide or 

chlorpyrifos; to a locus to control pests. 


(21) 579693 (22) 10 Mar 2008 

(54) SYSTEM AND METHOD FOR DRIVING AND RECEIVING DATA 

FROM MULTIPLE TOUCH SCREEN DEVICES 

(86) PCT/US2008/003155 (87) WO2008/115365 

(51) IPC2012.01:G06F3/14, 048 

(71) Savant Systems LLC 

(72) ALLEN, James, F; MADONNA, Robert, P; JACOBSON, Arthur, A 

(31) 07 687435 (32) 16 Mar 2007 (33) US 



(57) Disclosed is an apparatus for driving a plurality of touch screen 

devices from a single graphics signal. The apparatus includes a general- 



purpose computer configured to provide a graphics signal of a particular 

display resolution. The graphics signal has a plurality of graphics 

frames. The apparatus also includes a display segmentor configured 

to divide a first portion of each graphics frame into a plurality of pixel 

groups, while a second portion of each graphics frame is not a part 

of any pixel group of the plurality of pixel groups. Each pixel group 

is associated with a particular touch screen device of the plurality 

of touch screen devices. The display segmentor is further configured 

to generate an individual graphics signal for each pixel group. Each 

individual graphics signal has a display resolution that is lower than the 

particular display resolution. The apparatus further includes one or more 

interfaces configured to transmit each individual graphics signal to one 

of the plurality of touch screen devices. 

(21) 579764 (22) 22 Mar 2008 

(54) 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 

RECEPTOR MODULATORS 

(86) PCT/EP2008/002316 (87) WO2008/116620 

(51) IPC2012.01:C07D413/14; A61K31/4709; C07D405/14; A61P29/00; 

C07D401/14; C07D417/14; C07D409/14 

(71) JERINI AG 

(72) GIBSON, Christoph; TRADLER, Thomas; SCHNATBAUM, Karsten; 

PFEIFER, Jochen; LOCARDI, Elsa; SCHARN, Dirk; PASCHKE, 

Matthias; REIMER, Ulf; RICHTER, Uwe; HUMMEL, Gerd; REINEKE, 

Ulrich 

(31) 07 006089 (32) 23 Mar 2007 (33) EP 



(57) Disclosed are 8-oxy quinoline compounds of 

formula I, salts thereof, and methods for their 

preparation. Specific examples of compounds of formula 

I include: 1-{4-Chloro-3-[4-(4-fluoro-pyrazol-1-yl)-2-methyl-quinolin-8yloxymethyl]-6-methylpyridin-2-ylmethyl}-2-oxo-1,2-dihydro-pyridine-3carbonitrile,1-{3-[4-(5-Chloro-thiazol-4-yl)-2-methyl-quinolin-8yloxymethyl]-4-methyl-pyridin-2-ylmethyl}-3-trifluoromethyl-1Hpyridin-2-one,N-(5-{8-[4-Chloro-2-(2-oxo-3-trifluoromethyl-2Hpyridin-1-ylmethyl)-pyridin-3-ylmethoxy]-2-methyl-quinolin-4-yl}-1Hpyrazol-4-ylmethyl)-acetamide, 

and 1-{4-Chloro-3-[4-(4-hydroxy-1Hpyrazol-3-yl)-2-methyl-quinolin-8-yloxymethyl]-6-methyl-pyridin-2ylmethyl}-2-oxo-1,2-dihydro-pyridine-3-carbonitrile. 

Also disclosed is 

the use of compounds of formula I for inhibiting binding of BK to a BK 

B2 receptor and the use of detectably labelled compounds of formula 

I for localizing or detecting a BK B2 receptor in a tissue. Compounds 

of formula I are useful for treating skin disorders; eye diseases; 

ear diseases; mouth, throat and respiratory diseases; gastrointestinal 

diseases; liver, gallbladder and pancreatic diseases; urinary tract 

and kidney diseases; diseases of male genitale organs and female 

genitale organs; diseases of the hormone system; metabolic diseases; 

cardiovascular diseases; blood diseases; lymphatic diseases; disorders 

of the central nervous system; brain disorders; musculoskeletal system 

diseases; allergy disorders; pain; infectious diseases; inflammatory 

disorders; injuries; immunology disorders; cancers; hereditary diseases; 

or edema. 

(21) 579767 (22) 21 Mar 2008 

(54) Acetyl L-carnitine, optionally combined with an antihypertensive drug 

or a statin, for the prevention of type 2 diabetes and its complications in 

pre-diabetic patients with insulin resistance 

(86) PCT/EP2008/053437 (87) WO2008/113862 

(51) IPC2012.01:A61K31/205, 22, 24, 366, 405; A61K45/06; A61P3/00 

(71) SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. 

(72) CAVAZZA, Claudio; CARMINATI, Paolo 

(31) 07104624.7 (32) 21 Mar 2007 (33) EP 



(57) Disclosed is the use of acetyl L-carnitine, or a pharmaceutically 

acceptable salt thereof, in combination with an antihypertensive drug, 

for preparing a medicament for the prevention or delay of onset of 

type 2 diabetes and its clinical complications in pre-diabetic subjects 

with insulin resistance. Further disclosed is the use of acetyl L-carnitine 

for preparing a medicament for the reduction of high systolic blood 

pressure or high pulse blood pressure, in pre-diabetic subjects already 

in treatment with an anti hypertensive drug. 

(21) 579781 (22) 27 Mar 2008 

(54) SCAFFOLDING PROP WITH CONNECTING ASSEMBLY 

INCLUDING PIVOTING LOCK ELEMENT 

(86) PCT/DE2008/000538 (87) WO2008/128500 

(51) IPC2012.01:E04G7/30; E04G1/14; E04G5/14 

(71) WILHELM LAYHER VERWALTUNGS-GMBH 

(72) KRELLER, Helmut 

(31) 10 2007 018 314 (32) 18 Apr 2007 (33) DE 


(57) A prop (32.1) for a three-dimensional framework, particularly a 

scaffold, comprising a fastening mechanism for attaching a railing 

device (28.1, 28.2) to the prop. The fastening mechanism comprises a 

locking element (45) which can be swiveled about a swivel pin. In the 

locked position, the locking surface of the locking element lies across 

from a bearing surface of a support element (42) that is mounted on the 

prop. Furthermore, in the locked position and in the operational position 

of the prop, the locking surface of the locking element is disposed at a 

vertical distance above the bearing surface of the support element, and/ 

or in the operational position of the prop, the swivel pin is placed at a 

vertical distance above the locking surface that is in the locking position, 

preferably also at a vertical distance above the bearing surface of the 

support element. 



(21) 579802 (22) 22 Feb 2008 

(54) Compounds for improving the efficacy of other drugs 

(86) PCT/US2008/054788 (87) WO2008/103949 

(51) IPC2012.01:C07D277/28; A61K31/427; A61P31/12; C07D417/14 

(71) GILEAD SCIENCES, INC. 

(72) DESAI, Manoj C; HONG, Allen Y; HUI, Hon C; LIU, Hongtao; VIVIAN, 

Radall W; XU, Lianhong 

(31) 07 903228 (32) 23 Feb 2007 (33) US 

(31) 07 958716 (32) 6 Jul 2007 (33) US 



(57) Disclosed is a pharmaceutical composition which 

comprises a compound of formula (a) which 

is ((thiazol-5-yl)methyl) (2R,5R)-5-(((S)-(3-((isopropylthiazol-4yl)methyl)-3-methylureido)-2-(morpholinoethyl)ethyl)amido)-1,6diphenylhexan-2-ylcarbamate, 

tenofovir disoproxil fumarate, 

emtricitabine and elvitegravir for the treatment of HIV infection. 


(21) 579815 (22) 10 Mar 2008 

(54) Electrolysis cells where the cathode bars have a combination of 

vertical and horizontal outlets 

(86) PCT/NO2008/000087 (87) WO2008/120993 

(51) IPC2012.01:C25C3/16 

(71) NORSK HYDRO ASA 

(72) OVSTETUN, Frank; DROSTE, Christian 

(31) 20071766 (32) 2 Apr 2007 (33) NO 

(74) P L BERRY & ASSOCIATES, 15B Byron Street, Sydenham, 

Christchurch 8023, New Zealand 

(57) A method for operating electrolysis cells connected in series, where 

electrical current is led into one first cell via an anode arrangement 

arranged in the upper part of the cell, through an electrical conducting 

electrolyte and further through a substantially horizontal cathode, and 

further to an anode arrangement of a neighbouring cell, via one or more 

risers 6 and where electric current is led vertically out of the cell from 

at least one intermediate position of the cathode by means of at least 

one connection and further downstream the cathode is connected to the 

one or more risers 6 where current is conducted from the cathode via 

at least one collector bar 12 integrated therein. The current is led out 

of the cathode via the at least one intermediate position in combination 

with at least one horizontal end of a collector bar 12. 

(21) 580043 (22) 29 Feb 2008 

(54) IMPROVEMENT OF PROTEIN PRODUCTION THROUGH 

INCREASED EXPRESSION OF MUTATED START DOMAIN 

PROTEIN CERT 

(86) PCT/EP2008/052493 (87) WO2008/107388 

(51) IPC2012.01:C12N15/67 

(71) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 

(72) KAUFMANN, Hitto; FLORIN, Lore; BECKER, Eric; OLAYIOYE, 

Monilola; HAUSSER, Angelika; FUGMANN, Tim 

(31) 07 07103406 (32) 2 Mar 2007 (33) EP 

(31) 07 07104226 (32) 15 Mar 2007 (33) EP 

(31) 07 07116358 (32) 13 Sep 2007 (33) EP 



(57) Disclosed is the use of increased expression of a protein having 

ceramide transfer protein (CERT) to produce heterologous proteins of 

interest. Also disclosed are vectors comprising a first polynucleotide 

encoding for a protein having an amino acid comprising CERT sequence 

and a second polynucleotide encoding for a polynucleotide of interest. 

Also disclosed are pharmaceutical compositions comprising inhibitors 

and suppressors of a protein having a CERT sequence and a method 

for identifying a modulator of ceramide transfer protein (CERT) function. 

(21) 580247 (22) 21 Apr 2008 

(54) MANIPULATION OF PLANT SENESCENCE USING MODIFIED 

ARABIDPOSIS MYB PROMOTERS 

(86) PCT/AU2008/000556 (87) WO2008/128293 

(51) IPC2012.01:C12N15/11, 63; A01H1/00; A01H3/00; A01H5/00 

(71) La Trobe University; Agriculture Victoria Services Pty Ltd 

(72) SPANGENBERG, German; RAMAGE, Carl. McDonald; 

PALVIAINEN, Melissa Ann; PARISH, Roger W; HEAZLEWOOD, 

Joshua 

(31) 07 789526 (32) 24 Apr 2007 (33) US 

(74) JONES TULLOCH, 484 Glenferrie Road, Hawthorn, Victoria 3122, 

Australia 

(57) A method of manipulating senescence in a plant and enhancing plant 

biomass. The method comprises transforming a plant with a genetic 

construct that has a cytokinin biosynthesis gene operably linked to a 

myb gene promoter that has at least one root specific or pollen specific 

motif deleted or inactivated from the promoter. The myb promoter can 

be from Arabidopsis and the root specific motif can be the sequence 

ATATT or AATAT and the pollen specific motif can be the sequence 

TTCT or AGAA. 



(21) 580415 (22) 21 Apr 2008 

(54) Dosing regimen for (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol 

(86) PCT/EP2008/003178 (87) WO2008/128740 

(51) IPC2012.01:A61K31/137; A61P25/04 

(71) Grunenthal GmbH 

(72) LANGE, Claudia; ROMBOUT, Ferdinand 

(31) 07 07008218 (32) 23 Apr 2007 (33) EP 



(57) Disclosed is the use of tapentadol chemical name for which is 

(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol for the 

manufacture of a medicament comprising: at least one administration 

unit A containing dose a of tapentadol adapted for administration during 

a first administration interval, and at least one administration unit B 

containing dose b of tapentadol adapted for administration during a 

second administration interval following the first administration interval, 

where dose a is less than dose b, for the treatment of pain. 

(21) 580429 (22) 2 Jun 2008 

(54) PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE 

REUPTAKE INHIBITORS 

(86) PCT/US2008/065571 (87) WO2008/151156 

(51) IPC2012.01:A01N43/00 

(71) SEPRACOR, INC. 

(72) SHAO, Liming; WANG, Fengjiang; MALCOLM, Scott, Christopher; 

HEWITT, Michael, Charles; MA, Jianguo; RIBE, Seth; VARNEY, Mark, 

A; CAMPBELL, Una; ENGEL, Sharon, Rae; HARDY, Larry, Wendell; 

KOCH, Patrick; SCHREIBER, Rudy; SPEAR, Kerry, L 

(31) 07 941242 (32) 31 May 2007 (33) US 



(57) Disclosed are phenyl substituted cycloalkylamines represented 

by general formula (IV). The compounds are used for treating a 

neurological disorder, an eating disorder or for inhibiting reuptake of at 

least one monoamine from a cell in a mammalian subject. 

(21) 580487 (22) 26 Mar 2008 

(54) BACTERIALLY-DERIVED, INTACT MINICELLS THAT 

ENCOMPASS PLASMID-FREE FUNCTIONAL NUCLEIC ACID FOR IN 

VIVO DELIVERY TO MAMMALIAN CELLS 

(86) PCT/IB2008/002984 (87) WO2009/027830 

(51) IPC2012.01:C12N15/11, 87; A61K48/00 

(71) EnGeneIC Molecular Delivery Pty. Ltd. 

(72) BRAHMBHATT, Himanshu; MACDIARMID, Jennifer; HULF, Toby 

(31) 07 909074 (32) 30 Mar 2007 (33) US 



(57) Disclosed is a composition comprising (a) a plurality of intact, 

bacterially-derived minicells, wherein each minicell of said plurality 

encompasses regulatory RNA that is packaged in said minicell, and 

(b) a pharmaceutically acceptable carrier therefor, wherein there is an 

absence from said minicells of a construct for in situ expression of said 

regulatory RNA, wherein said regulatory RNA is selected from the group 

consisting of siRNA, miRNA and shRNA, and wherein said plurality 

contains a therapeutically effective amount of said regulatory RNA. Also 

disclosed is the use of the said composition in the preparation of a 

medicament for the treatment of cancer. 

(21) 580530 (22) 3 Jun 2008 

(54) ANTI VEGF POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS 

AND ANTAGONISTS 

(86) PCT/GB2008/050404 (87) WO2008/149147 

(51) IPC2012.01:C07K16/00, 22, 28 

(71) DOMANTIS LIMITED 

(72) STEWARD, Michael; PUPECKA, Malgorzata; TOMLINSON, Ian; 

ENEVER, Carolyn; JESPERS, Laurent; BATUWANGALA, Thil Dinuk 

(31) 07 933632 (32) 6 Jun 2007 (33) US 


(57) Disclosed is an anti-VEGF antagonist comprising an amino acid 

sequence that is identical to the amino acid sequence of DOM 

15-26-593 or differs from the amino acid sequence of DOM 15-26-593 

at no more than 10 amino acid positions and has a CDR2 sequence 

that is at least 50% identical to the CDR2 sequence of DOM 15-26-593, 

wherein the amino acid sequence of DOM 15-26-593 is as set out in 

Figure 5. 

(21) 580550 (22) 21 Apr 2008 

(54) BIOFERTILIZER FORMULATION 

(86) PCT/US2008/005131 (87) WO2008/130701 

(51) IPC2012.01:C12N1/20 

(71) MANUEL GIDEKEL; ANA GUTIERREZ; LETICIA BARRIENTOS; 

GUSTAVO CABRERA; GRACIELA BERRIOS; IVAN MIHOVILOVIC 

(72) GIDEKEL, Manuel; GUTIERREZ, Ana; BARRIENTOS, Leticia; 

CABRERA, Gustavo; BERRIOS, Graciela; MIHOVILOVIC, Ivan 

(31) 07 925444 (32) 21 Apr 2007 (33) US 



(57) Provided is a biofertilizer composition, comprising psychrophilic 

bacterial strains isolated from rhizosphere of Deschampsia antarctica, 

wherein the composition contains one or more bacterial strains selected 

from the group consisting of Pseudomonas antarctica DaBact TI-8 (PTA 

8990), Pseudomonas trivialis DaBact 2H (PTA 8988) and Arthrobacter 

ssp. DaBact MII-9 (PTA 8989). 

(21) 580591 (22) 7 May 2008 

(54) IMPROVEMENTS IN THE PRODUCTION OF FERRO-ALLOYS 

(86) PCT/AU2008/000637 (87) WO2008/134822 

(51) IPC2012.01:C21C5/52, 56; C21B11/10; C21B13/12; C22C33/00 

(71) NewSouth Innovations Pty Limited 

(72) SAHAJWALLA, Veena 

(31) 07 902386 (32) 7 May 2007 (33) AU 



(57) A method for producing a ferro-alloy in an electric arc furnace, the 

method comprising the steps of: (i) removing steel from a comminuted 

carbon-containing organic material that comprises steel, wherein the 

carbon-containing organic material is a rubber material or a polymer 

from a steel reinforced polymer composite, and wherein the material is 

comminuted by one or more of slitting, shredding, chipping, grinding or 

crumbing the material; and (ii) charging the furnace with the comminuted 

carbon-containing organic material that is produced in step (i). 

(21) 580623 (22) 26 Mar 2008 

(54) TRANSGENIC PLANTS CONTAINING SOLUBLE CELL WALL 

POLYSACCHARIDES 

(86) PCT/IL2008/000419 (87) WO2008/120194 

(51) IPC2012.01:C12N15/82; A01H5/00; C12P7/08 

(71) FUTURAGENE ISRAEL LTD; YISSUM RESEARCH 

DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF 

JERUSALEM LTD. 

(72) SHOSEYOV, Oded; SHANI, Ziv; ABRAMSON, Miron; BARIMBOIM, 

Noga; DEKEL, Mara; LAPIDOT, Shaul 

(31) 07 907344 (32) 29 Mar 2007 (33) US 




(57) Disclosed is a transgenic plant expressing cellobiose dehydrogenase 

(CDH) and a signal peptide which directs expression of the CDH to the 

plant cell wall. Also disclosed are products containing material from the 

transgenic plant and methods of making products. 


(21) 580731 (22) 21 Apr 2008 

(54) COATED ORAL NICOTINE FORMULATION BUFFERED WITH 

AMINO ACID 

(86) PCT/SE2008/000278 (87) WO2008/140372 

(51) IPC2012.01:A61K47/18; A24B15/16; A61P25/34; A61K9/20, 68; 

A61K31/465 

(71) MCNEIL AB 

(72) ANDERSSON, Sven-Borje; BERGENGREN, Gunnar; BOSSON, 

Bengt; HUGERTH, Andreas; NICKLASSON, Fredrik; OLSSON, Roland 

(31) 0701177-8 (32) 16 May 2007 (33) SE 



(57) Disclosed is a coated pharmaceutical product for intraoral delivery of 

nicotine comprising at least one buffered or non-buffered core, nicotine 

in any forn and/or a nicotine mimicking agent selected from one or 

more of capsaicin, piperine and zingerone, at least one coating layer 

and optionally one or more other additive(s), wherein said at least one 

coating layer comprises a buffering agent comprising at least one amino 

acid selected from the group consisting of Arginine, Aspargine, Glutamic 

acid, Glutamine, Histidine, Isoleucine, Leucine, Lysine, Methionine, 

Phenylalanine, Serine, Threonine, Valine, Cysteic acid, N-Glycylglycine 

and Ornithine, and salts of any of the foregoing, and wherein the 

product further comprises a pH-adjusting compound when the pHadjusting 

capacity of said at least one amino acid and/or a salt thereof 

is insufficient to increase the pH of the saliva of a subject to whom 

the product is administered to at least about 7. Further disclosed is the 

use of said product in the preparation of a medicament for delivering 

nicotine in any form to a subject, wherein the medicament is for oral 

administration such that the nicotine is released in the saliva in the oral 

cavity and absorbed into the systemic circulation of the subject. Also 

disclosed is a system for delivering nicotine in any form to a subject, 

comprising said coated product and at least one other product for 

obtaining reduction of the urge to smoke or use tobacco. Also disclosed 

is a method for producing said coated product, wherein the product is a 

chewing gum or a tablet. Also disclosed is the use of said product for use 

in the treatment of nicotine dependence, Alzheimer’s disease, Crohn’s 

disease, Parkinson’s disease, Tourette’s syndrome, ulcerous colitis and 

post-smoking-cessation weight control. 

(21) 580783 (22) 27 Jun 2008 

(54) Stable water in oil in water double emulsions comprising two 

emulsifiers of differing molecular weights 

(86) PCT/EP2008/058318 (87) WO2009/003960 

(51) IPC2012.01:A61K9/113; A23D7/005; B01F17/00; A61K8/06; 

A23L1/035, 48 

(71) Nestec S.A. 

(72) FOLMER, Britta; MICHEL, Martin; GEHIN-DELVAL, Cecile; 

ACQUISTAPACE, Simone; LESER, Martin; SYRBE, Axel; MARZE, 

Sebastien 

(31) 07 07111403 (32) 29 Jun 2007 (33) EP 



(57) Disclosed is a double emulsion comprising an internal aqueous 

phase dispersed in an oil phase forming a water-in-oil emulsion, 

said water-in-oil emulsion being dispersed in an external aqueous 

phase, wherein the water-in-oil emulsion comprises at two different 

emulsifiers having different molecular weights, whereby one emulsifier 

is glycerol monooleate (GMO) and a second emulsifier is a polyglycerol 

polyricinoleic acid (PGPR) having a molecular weight of more than 

1200 g/mol, wherein at least the internal aqueous phase comprises 

solutes, and wherein the external aqueous phase comprises whey 

protein isolate, amidated low methoxy pectin, egg yolk or a mixture 

thereof. 

(21) 580967 (22) 1 May 2008 

(54) COMPOSITION COMPRISING A BILE SALT AND AN 

EFFERVESCENT EXCIPIENT COMPONENT FOR TRANSMUCOSAL 

DELIVERY OF POLYPEPTIDES 

(86) PCT/US2008/005655 (87) WO2008/137054 

(51) IPC2012.01:A61K38/11, 21, 22, 23, 26, 28, 29; A61K31/575; 

A61K9/08, 14, 46 

(71) Cephalon, Inc 

(72) DURFEE, Steve L; THURMAN, Gary B 

(31) 07 927006 (32) 1 May 2007 (33) US 



(57) Disclosed is an oral transmucosal composition comprising: a) A 

therapeutically effective amount of a biologically active polypeptide; b) 

An effervescent component; and c) A bile salt. Further disclosed is 

the use of said compositions in the manufacture of oral transmucosal 

pharmaceutical compositions. 

(21) 580980 (22) 18 Apr 2008 

(54) ENZYMATIC ANTICANCER THERAPY 

(86) PCT/US2008/060733 (87) WO2008/131163 

(51) IPC2012.01:C12Q1/68 

(71) SIGMA-TAU RARE DISEASES, S.A. 

(72) FILPULA, David R; SAPRA, Puja 

(31) 07 913039 (32) 20 Apr 2007 (33) US 



(57) Provided is the use of adenosine deaminase in the preparation of a 

medicament for treating a patient having a tumor, wherein the adenosine 

deaminase is conjugated to a substantially non-antigenic polymer. The 

polymer may by polyethylene glycol. 

(21) 580995 (22) 15 Apr 2008 

(54) ENERGY SAVING LUMENS SETTABLE DEVICE FOR 

FLUORESCENT LAMPS 

(86) PCT/NZ2008/000081 (87) WO2008/140330 

(51) IPC2012.01:H05B37/02; H05B41/02, 14, 28 

(71) ADVANCED ENVIRONMENTAL TECHNOLOGIES LIMITED 

(72) SIRAJUDDIN, Mohamed 

(31) 07 555103 (32) 10 May 2007 (33) NZ 



(57) Disclosed is an apparatus and method for providing a supply voltage 

to an AC load. The apparatus is connected to an AC supply and 

provides the AC current to a transformer (109) which is under repetitively 

switched control, the transformer output is rectified and supplies a half 

bridge inverter which has at least two output transistors (146, 154) in 

half bridge arrangement. The inverter has a current output including a 

transformer winding (141), the transformer winding is coupled to two 

other windings (139, 140) which are operable to drive the inverter. If 

no output current can be provided from the inverter, the inverter will 

not operate. The two other windings (139, 140) drive the bases of the 

half bridge transistors (146, 154) and are DC isolated. The base to 

emitter voltage of the transistors in the turn off direction is limited by a 

unidirectional component network (148, 149, 156, 157). The frequency 

of operation of the inverter is set by inductors (145, 152) in series with 

the two other windings (139, 140) each in configuration with a series 

capacitor (142, 143). 

(21) 581126 (22) 12 May 2008 

(54) METHODS FOR USING VASOPRESSIN ANTAGONISTS WITH 

ANTHRACYCLINE CHEMOTHERAPY AGENTS TO REDUCE 

CARDIOTOXICITY AND/OR IMPROVE SURVIVAL 



(86) PCT/US2008/063374 (87) WO2008/144269 

(51) IPC2012.01:A61K31/55, 553, 554; A01N43/00 

(71) OTSUKA PHARMACEUTICAL CO., LTD. 

(72) LIU, Yongge; KAMBAYASHI, Junichi 

(31) 60/938,089 (32) 15 May 2007 (33) US 



(57) Provided is the use of a V2 selective vasopressin antagonist 

compound or a pharmaceutically acceptable salt thereof in the 

preparation of medicament for reducing cardiotoxicity and/or improving 

survival from doxorubicin chemotherapy wherein the medicament is for 

administering simultaneously with or prior to doxorubicin administration. 

(21) 581200 (22) 30 Apr 2008 

(54) RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF 

BETA-CATENIN 

(86) PCT/EP2008/055365 (87) WO2008/132234 

(51) IPC2012.01:C12N15/11; A61K31/7088 

(71) SANTARIS PHARMA A/S; ENZON PHARMACEUTICALS, INC. 

(72) WORM, Jesper 

(31) 60/915,371 (32) 1 May 2007 (33) US 

(31) 61/023,244 (32) 24 Jan 2008 (33) US 



(57) Disclosed is an oligomer of between 16 - 24 nucleobases in length, 

wherein said oligmer comprises a gapmer nucleobase sequence of SEQ 

ID NO: 58 (ccatcttgtatccat), and wherein the oligomer is capable of 

inhibiting the expression of beta-catenin gene or mRNA in a cell which 

is expressing beta-catenin gene or mRNA. 


(21) 581210 (22) 19 Jul 2007 

(54) Self-assembling amphiphilic biocompatible copolymers as anticancer 

agents 

(86) PCT/US2007/073880 (87) WO2009/011702 

(51) IPC2012.01:A61K31/74, 4375; A61K47/48 

(71) Allexcel, Inc. 

(72) DIWAN, Anil, R; ONTON, Ann, Louise; TATAKE, Jayant G 



(57) Disclosed is the use of an anticancer drug in the preparation of a 

medicament for the treatment of cancer, wherein the anticancer drug 

is encapsulated within a comb polymer, said comb polymer consisting 

essentially of the structure shown herein, which comprises a backbone 

formed of alternating branch-point moieties B and hydrophilic, watersoluble 

polymer blocks A; and having hydrophobic side chains C and 

targeting moieties Z attached to the branch-point moieties, wherein: 

each hydrophobic side chain C is independently selected from the 

group consisting of C6-C30 linear or branched hydrocarbons optionally 

substituted with one or more hydrophilic substituents; C6-C30 cyclic 

or polycyclic hydrocarbons optionally substituted with one or more 

hydrophilic substituents; and hydrophobic amino acids, peptides and 

polymers; each targeting moiety Z is independently a ligand having 

specific binding affinity for the surface of said cancer cells; s is a bond or 

a spacer moiety; the value of n ranges from 1 to about 100; the average 

value of p ranges from greater than one to four; and the average value 

of r ranges from 0 to 8. 

(21) 581245 (22) 2 May 2008 

(54) Water treatment containing DBNPA for use in sanitizing recreational 

water 

(86) PCT/US2008/005699 (87) WO2008/137085 

(51) IPC2012.01:A61L2/00 

(71) ARCH CHEMICALS, INC. 

(72) UNHOCH, Michael, Joseph; CHOI, Sungmee; ROBERTS, Kathrine, 

P; O'MALLEY, Leon, Peter 

(31) 12/150,592 (32) 29 Apr 2008 (33) US 

(31) 60/927,804 (32) 4 May 2007 (33) US 



(57) Disclosed is a composition for reducing the levels of microorganisms 

in recreational water systems, comprising: (1) a biocidal effective 

amount of dibromonitrilopropionamide (DBNPA) , wherein said biocidal 

effective amount ranges from 0.1 per cent to 40 per cent by weight 

as liquid or 1 per cent to 99 per cent by weight as solid, based 

on the total weight of said composition; (2) a biocidal effective 

amount of an algaecide selected from the group consisting of 

didecyldimethylammonium chloride (DDAC), zinc, and copper, wherein 

said biocidal effective amount ranges from 1 per cent to 75 per cent by 

weight as liquid or 5 per cent to 75 per cent by weight as solid, based 

on the total weight of said composition; and (3) a compound capable 

of in situ activation to form an oxidizing agent selected from the group 

consisting of sodium persulfate (persulphate), potassium persulfate, 

ammonium persulfate, and combinations thereof and in an amount 

ranging from 0.1 wt per cent to 50 wt per cent, based on the total weight 

of said composition; wherein said composition is effective for reducing 

the levels of microorganisms in recreational water systems. 

(21) 581255 (22) 22 May 2008 

(54) A CONNECTOR FOR A BLIND CONTROL MECHANISM 

ASSOCIATED WITH TWO CO-AXIAL SHAFTS 

(86) PCT/AU2008/000722 (87) WO2008/141389 

(51) IPC2012.01:E06B9/42, 34, 40, 44, 56, 60, 62, 50 

(71) LICCIARDI DI STEFANO, Carmelo Joseph 

(72) LICCIARDI DI STEFANO, Carmelo, Joseph 

(31) 2007902784 (32) 24 May 2007 (33) AU 

(74) Mallesons Stephen Jaques, Level 50 Bourke Place, 600 Bourke 

Street, Melbourne, VIC 3000, Australia 

(57) A connector (122) for a blind control mechanism, the mechanism 

including: i) a cylinder rotatable relative to two or more different shafts; 

ii) drive means connected to the cylinder and being operable to rotate 

the cylinder in either a blind extending direction or a blind direction; and 

iii) at least two biasing means (108, 110) connected to the cylinder, each 

biasing means being responsive to rotation of the cylinder in a blind 

extending direction to store energy and being responsive to rotation of 

the cylinder in a blind retracting direction to release stored energy and 

thereby apply a turning force to the cylinder, the turning force acting 

in the blind retracting direction. The connector has a body (116) for 

coupling an end portion of one of the biasing means to one of the shaft 

portions, and for coupling respective end portions of two adjacent the 

shafts together. 

(21) 581355 (22) 20 Jun 2008 

(54) POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2,5- 

DIHYDRO-4-IMIDAZO[1,2-A]PYRIDINE-3-YL-2,5-DIOXO-1H- 

PYRROL-3-YL)-9-FLUORO-1,2,3,4-TETRAHYDRO-2-(1- 

PIPERIDINYL-CARBONYL)-PYRROLO[3,2,1-JK] 

[1,4]BENZODIAZEPINE 

(86) PCT/US2008/067614 (87) WO2009/006043 



(51) IPC2012.01:A61P35/00; A61K31/4745, 555, 4985, 704, 513, 7068, 

5517, 724, 4188, 437, 407, 551; A61K33/24; C07D471/04; C07D487/06 

(71) ELI LILLY AND COMPANY 

(72) ABURUB, Aktham; CHEDID, Marcio; ENGLER, Thomas, Albert; 

VASUDEVAN, Venkatraghavan 

(31) 60/947,512 (32) 2 Jul 2007 (33) US 



(57) Disclosed is 7-(2,5-dihydro-4-(imidazo[1,2-a]pyridine-3-yl)-2,5dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(piperidin-1ylcarbonyl)-pyrrolo[3,2,1-jk][1,4]-benzodiazepine 

or a pharmaceutically 

acceptable salt or solvate thereof in combination with a 

chemotherapeutic agent selected from CPT-11, 5-fluorouracil, 

pemetrexed, gemcitabine, etoposide, doxorubicin, and platinum 

chemotherapeutic agents such as cisplatin or carboplatin; for use in 

the treatment of ovarian cancer, non-small cell lung cancer, colorectal 

cancer or gastric cancer. 


(21) 581410 (22) 20 May 2008 

(54) HOLDER ASSEMBLY FOR POWDERED DRINK INCLUDING 

SCREW CONVEYOR AND SHUT-OFF VALVE 

(86) PCT/NL2008/050297 (87) WO2008/143505 

(51) IPC2012.01:A47J31/40 

(71) BRAVILOR HOLDING B.V. 

(72) KOOPMAN, Carlos Nicolaas Jozef Maria; HUIBERTS, Johannes 

Theodorus Emerentia; VERHOEVEN, Romanus Eduard 

(31) 2000662 (32) 24 May 2007 (33) NL 


(57) A holder assembly for a powdered ingredient (4) for preparing an 

instant drink. The assembly comprises a holder, a conveyor screw (6), 

an outflow channel (7) provided on the holder for dispensing ingredient, 

a threshold plate (9) extending into the outflow channel, and also a shutoff 

valve (10) for shutting off the outflow channel. The shut-off valve 

comprises a shut-off body (11) which can be moved back and forth 

in the longitudinal direction of the conveyor screw between a release 

position and a shut-off position. In the release position the shut-off body 

is located downstream of the threshold plate, set apart therefrom. In the 

shut-off position the shut-off body is located next to the threshold plate 

in such a way that the shut-off body and the threshold plate together 

shut off the shut-off channel. 

(21) 581487 (22) 21 May 2008 

(54) WATER-SOLUBLE IRON-CARBOHYDRATE DERIVATIVE 

COMPLEXES, PREPARATION THEREOF AND MEDICAMENTS 

COMPRISING THEM 

(86) PCT/EP2008/056276 (87) WO2008/145586 

(51) IPC2012.01:C08B31/18; A61K33/26 

(71) VIFOR (INTERNATIONAL) AG 

(72) REIM, Stefan; PHILIPP, Erik; FUNK, Felix; MULLER, Hans-Martin; 

GEISSER, Peter 

(31) 07109081.5 (32) 29 May 2007 (33) EP 

(74) J D Hardie & Co, 14th Floor, 44-48 Emily Place, Auckland Central 


(57) Disclosed is a water-soluble iron-carbohydrate derivative complex 

obtained from an aqueous iron(llI) salt solution and an aqueous 

solution of the product of the oxidation and subsequent derivatisation 

of one or more maltodextrins, wherein the oxidation is carried out 

with an aqueous hypochlorite solution at a pH value in the alkaline 

range, wherein one maltodextrin is used its destrose equivalent is 

from 5 to 20 and when a mixture of a plurality of maltodextrins is 

used the dextrose equivalent of the mixture is from 5 to 20 and the 

dextrose equivalent of the individual maltodextrins in the mixture is 

from 2 to 40, and the subsequent derivatisation is carried out with a 

suitable reagent. Further disclosed is a process for the preparation 

of an iron-carbohydrate complex as defined above, and wherein the 

derivatisation of the oxidised maltodextrin is carried out by one of the 

following processes: a) esterification with organic or inorganic acids or 

derivatives thereof, b) oxidation, c) carboxylalkylation, d) etherification, 

e) amidation, f) carbamate formation or g) anhydride formation. Further 

disclosed is a medicament which comprises an aqueous solution of an 

iron-carbohydrate derivative complex as defined above for the treatment 

or prophylaxis of iron deficiency states or anaemias. 

(21) 581703 (22) 30 May 2008 

(54) MULTIGENE PROGNOSTIC ASSAY FOR LUNG CANCER 

(86) PCT/US2008/065409 (87) WO2008/151072 

(51) IPC2012.01:C12Q1/68 

(71) The Regents of the University of California 

(72) RAZ, Dan J; JABLONS, David M 

(31) 60/941,550 (32) 1 Jun 2007 (33) US 



(57) Provided is a method of providing a prognosis for lung cancer 

in a subject, the method comprising the steps of: (a) contacting a 

biological sample from the subject with eight different reagents that each 

specifically binds to a different nucleic acid comprising one of ctnnb 1, 

wnt3a, tp53, kras, erbb3, muc1, erbb2, and dusp6, and (b) determining 

whether or not all of the eight nucleic acids are differentially expressed 

in the sample in comparison to a non-cancer cell; thereby providing a 

prognosis for lung cancer. The markers can be quantified using PCR 

amplification with oligonucleotide probes. 




(21) 581801 (22) 12 Jun 2008 

(54) METABOLITES OF THE JANUS KINASE 

INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- 

PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE 

(86) PCT/US2008/066658 (87) WO2008/157207 

(51) IPC2012.01:C07D487/04; A61K31/519 

(71) Incyte Corporation 

(72) RODGERS, James D.; ARVANITIS, Argyrios G.; SHI, Jack Guoen 

(31) 60/943,695 (32) 13 Jun 2007 (33) US 



(57) Disclosed are compounds 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1Hpyrazol-1-yl)-3-(3- 

hydroxycyclopentyl)propanenitrile (I), 3-(4-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(2hydroxycyclopentyl)propanenitrile 

(II) and 3-(4-(7H-pyrrolo[2,3d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(3-oxocyclopentyl)propanenitrile 

(III). The compounds are used to treat diseases which are associated 

with JAK activity. 

(21) 581824 (22) 15 May 2008 

(54) Natural d-limonene based cleaning composition 

(86) PCT/US2008/063765 (87) WO2009/023327 

(51) IPC2012.01:C11D3/38; C11D1/66 

(71) The Clorox Company 

(72) OCHOMOGO, Mana; KAARET, Thomas W; GARABEDIAN, Aram; 

HOOD, Ryan, K 

(31) 11/765,516 (32) 20 Jun 2007 (33) US 



(57) Disclosed is a hard surface cleaning composition comprising:(a) 0.5 

to 5% alkyl polyglucoside; (b) 0.5 to 5% ethanol;(c) 0.05 to 1% glycerol; 

(d) 0.01 to 0.4% lemon oil or essential oil comprising d-limonene;(e) less 

than 0.2% builder wherein the builder comprises a builder selected from 

the group consisting of alkali metal carbonate, alkali metal bicarbonate, 

alkali metal hydroxide, alkali metal silicate and combinations thereof;(f) 

water; and (g) optionally dyes, colorants, and preservatives. 

(21) 581957 (22) 13 Jun 2008 

(54) TARGETED OXYGEN DELIVERY VIA INTRAVENOUS OR 

INTRA-ARTERIAL INFUSION OF OXYGENATED POLYMERIZED 

HEMOGLOBIN SOLUTIONS 

(86) PCT/US2008/007445 (87) WO2008/156699 

(51) IPC2012.01:A61K38/42; A61P9/10 

(71) OPK BIOTECH LLC 

(72) ZAFIRELIS, Zafiris, G; DUBE, Gregory, P; LACCETTI, Anthony, J; 

BAQAI, Javed 

(31) 60/934,448 (32) 13 Jun 2007 (33) US 


(57) The use of an oxygenated haemoglobin solution for treating an organ 

under an ischemic condition that is formulated to be administered to 

the organ by retrograde infusion. The oxygenated haemoglobin solution 

includes polymerized haemoglobin wherein 80 percent by weight or 

greater is oxyhaemoglobin. 

(21) 582132 (22) 19 Jun 2008 

(54) A VACCINE COMPOSITION COMPRISING A WATER IN OIL 

EMULSION WHEREIN AQUEOUS COMPONENT COMPRISES AN 

ACRYLIC POLYMER AND DDA 

(86) PCT/US2008/067433 (87) WO2008/157659 

(51) IPC2012.01:A61K39/00, 145 

(71) Wyeth LLC 

(72) RODENBERG, Jeffrey Harold; KUMAR, Mahesh; LUTZ, David Leon; 

DIEHL, Evan James 

(31) 60/936,571 (32) 20 Jun 2007 (33) US 



(57) Disclosed is a vaccine composition comprising a water-in-oil 

emulsion, wherein said emulsion comprises an oil component and an 

aqueous component; and wherein said aqueous component comprises 

at least one antigen and at least one adjuvant, wherein said at least one 

adjuvant is selected from an acrylic polymer or both an acrylic polymer 

and dimethyl dioctadecyl ammonium bromide (DDA). 

(21) 582216 (22) 20 Jun 2008 

(54) IDENTIFYING VEGETATION ATTRIBUTES FROM LIDAR DATA 

(86) PCT/US2008/067710 (87) WO2009/002859 

(51) IPC2012.01:G01S17/89, 88; G06Q10/08; A01G23/00; G06Q50/02; 

G06K9/00 

(71) Weyerhaeuser NR Company 

(72) MCKINNEY, Robert, K; BIRDSALL, Earl T; WELTY, Jeffry J 

(31) 11/767,084 (32) 22 Jun 2007 (33) US 



(57) A computer system for identifying the species of an item of vegetation 

comprises a memory that stores LiDAR data for selected item of 

vegetation and one or more species attribute templates that store data 

collected from different species and a processor that is configured 

to execute a sequence of programmed instructions that cause the 

processor to: identify coordinate positions and intensity values in 

the LiDAR data that are generated from an item of vegetation in 

response to being contacted with a LiDAR laser pulse; identify a 

species of the item of vegetation by selecting a species attribute 

template with data that describes one or more attributes of a known 

species; comparing attributes of the LiDAR data that a generated from 

the item of vegetation with the data stored in the selected species 

attribute template; and identifying a species of the item of vegetation 

by determining a species attribute template that stores data that most 

closely matches the attributes of the LiDAR data that are generated 

from the item of vegetation. Further disclosed is a method of operating 

a computer system to process LiDAR data to identify the species of 

an item of vegetation comprising identifying with the computer system 

LiDAR data that are associated with an item of vegetation; determining 

with the computer system, an average intensity of the LiDAR data 

associated with the item of vegetation; selecting with the computer 

system, a hardwood or conifer species attribute template based on 

the determined average intensity of the LiDAR data associated with 

the item of vegetation and analysing with the computer system, the 

LiDAR data associated with the item of vegetation and the data in 

the selected species attribute template to identify a species that most 

closely matches the item of vegetation. The species attribute templates 

store data collected from different species. 



(21) 582250 (22) 3 Jul 2008 

(54) Anti CD20 antibody formulations 

(86) PCT/US2008/069125 (87) WO2009/009407 

(51) IPC2012.01:A61K39/395 

(71) GLAXOSMITHKLINE LLC 

(72) Lashmar, Ulla Tove; Brisbane, Charlene E; Ketkar, Amol Sharad 

(31) 60/948/220 (32) 6 Jul 2007 (33) US 



(57) Disclosed is an anti-CD20 antibody formulation comprising a 

therapeutically effective amount of an antiCD20 antibody, wherein the 

formulation further comprises 10 to 100 mM sodium acetate, 25 to 100 

mM sodium chloride, 0.5 to 5% w/v (weight/volume) arginine free base, 

0.02 to 0.2 mM EDT A, 0.01 to 0.2 % w/v polysorbate 80 and adjusted 

to pH 5.0 to 7.0. 

(21) 582293 (22) 17 Jul 2008 

(54) Method for treating a food, feed or agricultural product with natamycin 

composition 

(86) PCT/EP2008/059349 (87) WO2009/010547 

(51) IPC2012.01:A01N43/90; A23B4/20; A23C19/11; A23L3/3463; 

A01P3/00 

(71) DSM IP Assets B.V. 

(72) HEE, VAN, Pim; SANTEN, VAN, Laurentius Cornelis Adrianus; 

FARAGHER, John Mark 

(31) 60/929,944 (32) 19 Jul 2007 (33) US 

(31) 07113455.5 (32) 30 Jul 2007 (33) EP 

(31) 07114406.7 (32) 16 Aug 2007 (33) EP 



(57) Disclosed is an aqueous antifungal composition comprising 

natamycin in an amount of from 50 to 400,000 ppm, xanthan gum in 

an amount of from 0.02% to 10% (w/w) , citric acid in an amount of 

from 0.05% to 5% (w/w) and lactate in an amount of from 0.05% to 

7.5% (w/w) , said composition being free of chloride salts, wherein 

the composition may further comprise at least one compound selected 

from the group consisting of additional antimicrobial compounds, flow 

agents, surfactants and buffering agents. Said composition is stable 

after storage for at least 12 weeks at a temperature of 20 Deg. C; and 

it is suitable for the treatment of a food such as a cheese or a sausage 

product, feed or agricultural product for the prevention of mould growth, 

fungal growth and yeast growth, and it is also suitable for preventing 

corrosion of process equipment used during the treatment of food, feed 

or agricultural products with an aqueous antifungal composition. 

(21) 582314 (22) 2 Jul 2008 

(54) PIRENZEPINE AND DERIVATIVES THEREOF AS ANTI-AMYLOID 

AGENTS 

(86) PCT/EP2008/058527 (87) WO2009/004038 

(51) IPC2012.01:A61K31/551, 553, 554; A61P25/28 

(71) PROTEOSYS AG; AC IMMUNE S.A. 

(72) Pfeifer, Andrea; Schrattenholz, Andre; Muhs, Andreas 

(31) 07111491.2 (32) 2 Jul 2007 (33) EP 



(57) Disclosed is the use of pirenzepine derivative represented by general 

formula (I), such as clozapine, for the treatment of a disease or condition, 

which is caused by or associated with the formation of beta-amyloid 

plaques in the brain, in an animal suffering from said disease or condition 

by (a) reducing the beta-amyloid plaque load, and/or (b) inhibiting the 

formation of beta-amyloid plaques and/or (c) retarding the increase of 

amyloid load in the brain of the treated animal, thereby retaining or 

increasing cognitive memory capacity in said animal. Such diseases 

can include Guam Parkinson-Dementia complex; diseases based on 

or associated with amyloid-like proteins; Creutzfeld Jacob disease, 

Parkinson's disease, HIV-related dementia, ALS (amyotropic lateral 

sclerosis), Adult Onset Diabetes; senile cardiac amyloidosis; endocrine 

tumors, macular degeneration, drusen-related optic neuropathy and 

cataract due to beta-amyloid deposition. 


(21) 582346 (22) 3 Jul 2008 

(54) NOVEL TRIAZINE COMPOUNDS FOR TREATMENT OF CANCER 

(86) PCT/EP2008/058600 (87) WO2009/004060 

(51) IPC2012.01:C07C245/24; A61P35/04; C07C309/15; C07D233/54; 

A61K31/655 

(71) TriN Therapeutics GmbH 

(72) REITER, Rudolf; KALBE, Jochen; FORSTER, Heinz 

(31) 07111716.2 (32) 4 Jul 2007 (33) EP 

(74) J D Hardie & Co, 14th Floor, 44-48 Emily Place, Auckland Central 


(57) Disclosed is a compound of formula (I) where the substituents are 

as disclosed in the specification. An example of a compound of formula 

(I) is 3-{4-{4-[(1E)-3,3-dimethyl-1-triazenyl]-benzoyl}-phenoxy}propionic 

acid. Also disclosed is a process for preparing a compound of formula 

(I) and the use of a compound of formula (I) in the preparation of a 

medicament for the treating of cancer. 

(21) 582360 (22) 11 Jul 2008 

(54) INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING 

HEMAGGLUTININ PRODUCED WITHIN A PLANT 

(86) PCT/CA2008/001281 (87) WO2009/009876 

(51) IPC2012.01:A61P31/16; C12N7/01, 02; A61K39/145; C12N15/82, 

29, 44; A61P37/04; C07K14/11 

(71) Medicago Inc. 

(72) D'AOUST, Marc-Andre; COUTURE, Manon; ORS, Frederic; 

TREPANIER, Sonia; LAVOIE, Pierre-Olivier; DARGIS, Michele; 

VEZINA, Louis-Philippe; LANDRY, Nathalie 

(31) 60/959,414 (32) 13 Jul 2007 (33) US 

(31) 60/990,603 (32) 27 Nov 2007 (33) US 

(31) 61/013,272 (32) 12 Dec 2007 (33) US 

(31) 2,615,372 (32) 21 Jan 2008 (33) CA 

(31) 61/022,775 (32) 22 Jan 2008 (33) US 

(74) Adams Pluck, 2710/24B Moorefield Road, Johnsonville, Wellington 


(57) Disclosed is a method for synthesizing influenza virus-like particles 

(VLPs) within a plant or a portion of a plant is provided. The method 

involves expression of influenza HA in plants and the purification by size 

exclusion chromatography. The invention is also directed towards a VLP 



comprising influenza HA protein and plants lipids. The invention is also 

directed to a nucleic acid encoding influenza HA as well as vectors. The 

VLPs may be used to formulate influenza vaccines, or may be used to 

enrich existing vaccines. 

(21) 582425 (22) 5 Jun 2007 

(54) EMAGNETODYNAMIC MACHINE WITH CIRCULAR ARRAY 

PERMANENT MAGNET STATOR AND COMPOSITE MAGNETIC 

POLE ROTOR 

(86) PCT/IB2007/052113 (87) WO2008/149182 

(51) IPC2012.01:H02K53/00 

(71) EZEKIEL IZUOGU 

(72) IZUOGU, Ezekiel 



(57) A so-called self-sustaining emagnetodynamic machine includes a 

stator with a circular array of equally spaced and magnetically isolated 

permanent magnets 18, 19, 20 with poles of like polarity directed to 

the centre of the circle, and a rotor with a composite magnet having 

a leading pole and a trailing pole, the leading pole leading the trailing 

pole during rotation of the rotor, the composite magnet being attached 

to a central journalled shaft 11,so that the composite magnet rotates 

closely past the inner stator poles and rotates the shaft as it does 

so. The stator includes a release electromagnet 22 to magnetically 

cooperate with the composite magnet of the rotor, by developing a 

magnetic polarity similar to the array of permanent magnet poles of the 

stator and timed to switch off at the point that the trailing magnetic pole 

of the composite magnet is to be released. Apparently the composite 

magnet provides a rotational force on the rotor when the composite 

magnet becomes proximate each to the permanent magnets in the 

stator array, the direction of the rotational force being that produced 

when the polarity of the composite pole is similar to that of the stator 

poles. An energy feedback loop transfers energy from the rotor to the 

release electromagnet. The feedback loop includes a current generator 

coupled to the rotor and a current pulse generator and a booster which 

supplies power from the current pulse generator to operate the release 

electromagnet. 

(21) 582534 (22) 17 Jun 2008 

(54) MARKING EAR TAG COMPRISING A TISSUE SAMPLING DEVICE 

(86) PCT/FR2008/000841 (87) WO2009/010658 

(51) IPC2012.01:A01K11/00; G06K19/00 

(71) CHEVILLOT SAS 

(72) HILPERT, Jean Jacques; DECALUWE, Johan 

(31) 07 04466 (32) 22 Jun 2007 (33) FR 

(74) ELLIS TERRY, Level 12, 45 Johnston Street, Wellington 6011, New 

Zealand 

(57) An ear tag 1 for identifying an animal, enables a sample of biological 

tissue to be taken when the tag is applied to the animal. The tag includes 

a male part 2 and a female part 3 which are assembled by irreversible 

interlocking between the male part on one side of the animal’s ear and 

the female part on the other side of the ear. The stem 22 of the male part 

includes a detachable head 23 having a hollow distal part 29 provided 

with a cutting edge 25 for cutting out a biological sample when the head 

perforates the ear of the animal. The female part includes a central tube 

31 for receiving the head and at least partially receiving the stem when 

the ear tag is applied, and a detachable sample container 32 arranged in 

the axial extension of the tube. The proximal end 35 of the container has 

a first opening 33 for receiving the head 23 of the stem when the ear tag 

is applied, and the distal end 36 of the container has a second open end 

34 enabling the inside of the sample container to be reached. Once the 

tag is applied, the sample container with the head including the sample 

attached, can be removed from the tag and placed within a protection 

tube including a closing cover so that the sample taken can be stored in 

a closed space bathed in appropriate substances and analysed later. 

(21) 582676 (22) 30 Jun 2008 

(54) METHODS FOR N-DEMETHYLATION OF MORPHINE AND 

TROPANE ALKALOIDS 

(86) PCT/CA2008/001179 (87) WO2009/003272 

(51) IPC2012.01:C07D489/02; B01J23/44, 72; C07B43/04 

(71) Brock University 

(72) CARROLL, Robert; LEISCH, Hannes; HUDLICKY, Tomas 

(31) 11/771,227 (32) 29 Jun 2007 (33) US 

(74) EKM patent & trade marks, Level 1, 38 - 40 Garden Street, South 

Yarra, VIC 3141, Australia 

(57) Disclosed is a one pot method for the N-dementhylation fo a tertiary 

N-methylate heterocycle comprising mixing the teriary N-methylated 

heterocycle with a metal catalyst in the presence of an oxidizing agent, 

wherein the metal catalyst is Pd(OAc)2 (Palladium (II) acetate). 

(21) 582679 (22) 18 Jul 2008 

(54) CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN 

DERIVATIVES AND THEIR THERAPEUTIC USE 

(86) PCT/IB2008/002869 (87) WO2009/016516 

(51) IPC2012.01:C07D487/04; A61K31/5517; A61P35/00 


(72) COMMERCON, Alain; BOUCHARD, Herve; CHARI, Ravi V.J; DENG, 

Yonghong; GAUZY, Laurence 

(31) 07290904.7 (32) 19 Jul 2007 (33) EP 



(57) Disclosed are cytotoxic tomaymycin derivatives of formula 

(I), wherein the substituents are as described within the 

specification. An example of a compound of formula 

(I) includes 4-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11atetrahydro-pyrrolo[2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]phenoxy)-butyric 

acid. Further disclosed is a conjugate comprising one 

or more compounds of formula (I) covalently linked to a cell binding 

agent through the linking group of the linker of the compound, wherein 



said cell binding agent is chosen from antibodies or a fragment of an 

antibody, lymphokines, hormones, growth factors, or nutrient-transport 

molecules, and the process for the preparation of said conjugate. Also 

disclosed is a pharmaceutical composition comprising said conjugate or 

a compound of formula (I), and the use of said conjugate or compound 

of formula (I) in the preparation of a medicament for the treatment of 

cancer. 

(21) 582708 (22) 17 Jul 2008 

(54) HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE 

INHIBITORS 

(86) PCT/US2008/008749 (87) WO2009/014637 

(51) IPC2012.01:C07D487/04; C07D413/14; A61K31/444, 497; 

C07D401/14; C07D471/04; C07D417/14; A61P43/00 

(71) SCHERING CORPORATION 

(72) SIDDIQUI, M. Arshad; GUZI, Timothy, J; CAUBLE, David, F; 

TORRES, Luis, E; TANG, Shuyi; WONG, Tzu, Tshin; TADIKONDA, 

Praveen, K; ZHAO, Lianyun; REDDY, Panduranga, Adulla, P 

(31) 60/950,709 (32) 19 Jul 2007 (33) US 



(57) The disclosure relates to heterocyclic amide compounds of formula 

depicted herein and pharmaceutically acceptable salt thereof. Also 

disclosed are compositions comprising said compounds, and methods 

for using said compoundsfor treating or preventing a proliferative 

disease, an anti-proliferative disorder, inflammation, arthritis, a 

neurological or neurodegenerative disease, a cardiovascular disease, 

alopecia, a neuronal disease, an ischemic injury, a viral disease or a 

fungal disease. 

(21) 582764 (22) 21 Dec 2010 

(54) Rotor or stator with magnets contacting flux returns 

(51) IPC2012.01:H02K15/03; H02K1/06 

(71) WELLINGTON DRIVE TECHNOLOGIES LIMITED 

(72) Howell, David James; Hatz, Andreas Hartmut 



(57) Disclosed is a rotor or stator for an electrodynamic machine and a 

method for its production. The method includes providing a cylindrically 

arranged series of magnets (103) and a cylindrically arranged series of 

items of magnetic material (109) in a mould (115). The magnets (103) 

and items of magnetic materials (109) are concentrically arranged and 

in loose contact with each other. The movement of the magnets (103) 

is limited by abutment with a wall of the mould (115). Plastic material is 

then injected under pressure against one of the cylindrically arranged 

series of items of magnetic material (109) and subsequently against the 

magnets (103) and the mould wall (115). The injection pressure of the 

plastic material against the items of magnetic material (109) dynamically 

maintains them substantially in contact with the magnets (103) and 

maintains the magnets (103) substantially in contact with the mould wall 

(115) during injection and setting of the plastic material. As a result of 

this, the flow of plastic material does not substantially penetrate between 

the magnets (103) and the items of magnetic material (109). 

(21) 582810 (22) 7 Aug 2008 

(54) NOVEL HERBICIDES 

(86) PCT/EP2008/006496 (87) WO2009/019015 

(51) IPC2012.01:C07D493/04; A01N43/02 

(71) Syngenta Limited 

(72) TYTE, Melloney; JEANMART, Stephane, Andre, Marie; MATHEWS, 

Christophe, John; ROBINSON, Louisa 

(31) 071 557 6.5 (32) 9 Aug 2007 (33) GB 



(57) Disclosed are tricyclic bridged cyclopentanedione 

derivatives represented by general formula (I). 

An example of a compound of formula (I) 

includes (1RS,2SR,6RS,7SR)-4-(3,5-dimethylbiphenyl-4-yl)-5-oxo-10oxa-tricyclo[5.2.1.02.6]dec-3-en-3-yl-2,2-dimethylpropionate. 

The 

compounds are used to control grasses and weeds in crops. 

(21) 582823 (22) 25 Jul 2008 

(54) COMPOSITION OF TUMOUR-ASSOCIATED PEPTIDES AND 

RELATED ANTI-CANCER VACCINE 

(86) PCT/EP2008/006152 (87) WO2009/015841 

(51) IPC2012.01:A61K39/00; A61K38/08, 16; A61P35/00 

(71) immatics biotechnologies GmbH 

(72) SINGH, Harpreet; SCHOOR, Oliver; TRAUTWEIN, Claudia; HILF, 

Norbert; WEINSCHENK, Toni; WALTER, Steffen; LEWANDROWSKI, 

Peter 

(31) EP07014796.2 (32) 27 Jul 2007 (33) EP 

(31) 60/953,109 (32) 31 Jul 2007 (33) US 

(31) 60/981,241 (32) 19 Oct 2007 (33) US 



(57) Disclosed is a pharmaceutical composition comprising at least 

two peptides that have the ability to bind a molecule of the human 

histocompatibility complex (MHC) class I or class II and are between 8 

and 100 amino acids long. The pharmaceutical composition is used in 

the manufacture of a medicament for treating or preventing cancer. 

(21) 582844 (22) 25 Jul 2008 

(54) A VORTEX FLOW CONTROL DEVICE DESIGNED TO INDUCE 

TURBULENCE AT ITS INLET 



(86) PCT/GB2008/002548 (87) WO2009/013509 

(51) IPC2012.01:F15D1/00, 02; E03F5/10; E03F1/00 

(71) Hydro International plc 

(72) FARAM, Michael, Guy; ANDOH, Robert, Yaw, Gyamfi; LECORNU, 

Jeremy, Paul; HUTCHINGS, Keith, Garry; JARMAN, Daniel, Stuart 

(31) 0714594.9 (32) 26 Jul 2007 (33) GB 



(57) Disclosed is a vortex flow control with a template unit (2) having 

end walls (4, 6), of which the wall (4) has an outlet opening (5), and a 

partial outer wall (8). The partial outer wall comprises a curved portion 

which extends about an axis perpendicular to the end walls and has an 

opening (16). A plate (26) is subsequently secured to the template unit 

to partially close the opening to leave an inlet. The inlet is configured 

so that fluid entering the vortex chamber through the inlet induces a 

circulating flow within the vortex chamber about the axis. The size of the 

plate is selected so as to result in an inlet sized to achieve required flow 

characteristics for the finished device. The plate is inclined to a planar 

portion (14) on the opposite side of the inlet at an angle in the range 85° 

to 95°, so as to induce turbulence in the region of the inlet. 


(21) 582881 (22) 25 Jul 2008 

(54) BACULOVIRAL VECTORS COMPRISING REPEATED CODING 

SEQUENCES WITH DIFFERENTIAL CODON BIASES 

(86) PCT/NL2008/050512 (87) WO2009/014445 

(51) IPC2012.01:C12N15/864, 63, 67, 68; C07K14/015, 075 

(71) AMSTERDAM MOLECULAR THERAPEUTICS B.V. 

(72) BAKKER, Andrew, Christian; HERMENS, Wilhelmus, Theodorus, 

Johannes, Maria, Christiaan 

(31) 60/952,081 (32) 26 Jul 2007 (33) US 

(31) 07113257.5 (32) 26 Jul 2007 (33) EP 


(57) Disclosed are insect cells that comprise a nucleotide sequence 

encoding a parvoviral Rep52 or 40 protein and a parvoviral Rep 78 or 

68 protein. The two Rep proteins have a common amino acid sequence 

of at least 100 amino acids with at least 90 percent sequence identity 

and the nucleotide sequences encoding the common sequence share 

less than 90 percent sequence identity. The cells have improved stability 

and expression of the viral rep proteins and increase the productivity of 

the production of paroviral vectors. The nucleotide sequences can have 

optimised codon usage to further increase the productivity of the insect 

cells. 

(21) 582888 (22) 23 Mar 2006 

(54) CHARGED LIPOPROTEIN COMPLEXES AND THEIR USES 

(51) IPC2012.01:A61K9/127; A61P3/06 

(71) CERENIS THERAPEUTICS HOLDING SA 

(72) DASSEUX, Jean-Louis 

(31) 60/665,180 (32) 24 Mar 2005 (33) US 



(57) Disclosed are charged lipoprotein complexes that include a negatively 

charged phospholipid that is expected to impart the complexes with 

improved therapeutic properties. An apolipoprotein fraction and a lipid 

fraction, said lipid fraction consisting essentially of 0.2 to 3 wt% of one or 

5 more negatively charged phospholipids, sphingomyelin, and lecithin. 


(21) 582948 (22) 25 Jul 2008 

(54) POLYMER NETWORKS COMPRISING ACTIVE INGREDIENTS, 

PROCESS FOR THEIR PRODUCTION, AND THEIR USE 

(86) PCT/EP2008/059780 (87) WO2009/016112 

(51) IPC2012.01:A01N25/10, 18; A61L9/04 

(71) BASF SE 

(72) TERRENOIRE, Alexandre; LEININGER, Hartmut; BULLOCK, James; 

QURESHI, Mohammed Shoaib; SCHMIDT, Hans-Werner; GIESA, 

Reiner; RANFT, Meik; LAFUENTE CERDA, Oscar 

(31) 07113711.1 (32) 2 Aug 2007 (33) EP 



(57) Disclosed is a process for producing an actives-comprising polymeric 

network by mixing polymerizable oligomers and actives and also, 

optionally, further monomers and/or auxiliaries, followed by thermal or 

photochemical polymerization of the mixture, wherein the polymerizable 

mixture comprises the following components: (A) 19.9 to 99.8 percent 

by weight of at least one oligomer containing mono(meth)acrylate 

groups and having an average molar mass of 350 to 5000 grams per 

molecule, selected from the group of epoxy (meth)acrylates, polyester 

(meth)acrylates, urethane (meth)acrylates or polyether (meth)acrylates, 

the arithmetic average of the number of (meth)acrylate groups per 

oligomer molecule being 2.1 to 5; (B) 0 to 49.8 percent by weight of 

at least one monomer containing olefinic groups and having a molar 

mass of less than 350 grams per molecule; (C) 0.1 to 8 percent by 

weight of at least one polymerization initiator which is soluble in the 

photopolymerizable mixture; (D) 0.1 to 80 percent by weight of at least 

one active which is dispersible or soluble in the photopolymerizable 

mixture; and (E) 0 to 20 percent by weight of further auxiliaries and/or 

additives. Further disclosed is an actives-comprising polymeric network 

obtainable by said process, and the use of said actives-comprising 

polymeric network for protecting industrial materials, films, paints and 

dispersions, crops, and for controlling plant growth. 

(21) 582969 (22) 12 Apr 2008 

(54) METHOD FOR ROASTING AND SURFACE PASTEURIZATION OF 

PARTICULATE FOOD PRODUCTS 

(86) PCT/EP2008/002906 (87) WO2009/003545 

(51) IPC2012.01:A23B9/02; A23L3/16; A23N12/08 

(71) BUHLER BARTH AG 

(72) PERREN, Rainer; FISCHER, Jurgen 

(31) 10 2007 030 661.1 (32) 2 Jul 2007 (33) DE 

(31) 10 2008 015 063.0 (32) 19 Mar 2008 (33) DE 



(57) Disclosed is a method for roasting and for the surface pasteurization 

of food product pieces, wherein the method is performed in a roasting 

system and comprises a roasting phase and a pasteurization phase, and 

during the pasteurization phase a pasteurization treatment is performed 

at a temperature less than 100°C in a humid atmosphere having a 

humidity greater than the humidity of the atmosphere during the roasting 

phase, wherein during the pasteurization phase the temperature on the 

product surface is maintained below the dewpoint temperature of the 

humid atmosphere, the pasteurization treatment being performed for 1 

to 30 min, and wherein in the course of advancing or continued roasting 

the condensation water on the surface of the food products is removed 

and the water absorption of the latter is minimized. 

(21) 582995 (22) 25 Jul 2008 

(54) DERIVATIVES OF 1-OXO-1,2-DIHYDROISOQUINOLINE-5- 

CARBOXAMIDES AND OF 4-OXO-3,4-DIHYDROQUINAZOLINE-8- 

CARBOXAMIDES, PREPARATION THEREOF AND APPLICATION 

THEREOF IN THERAPEUTICS 

(86) PCT/FR2008/001109 (87) WO2009/044018 

(51) IPC2012.01:C07D217/24; A61K31/472, 498; A61P25/00; 

C07D239/88 




(72) MALLERON, Jean-Luc; KARLSSON, Andreas; GENEVOIS- 

BORELLA, Arielle; EVERS, Michel 

(31) 0705500 (32) 27 Jul 2007 (33) FR 



(57) Disclosed are derivatives of 1-oxo-1,2-dihydro#isoquinoline-5carboxamides 

and of 4-oxo-3,4-dihydroquinazoline-8-carboxamides, of 

general formula (I), wherein the substituents are disclosed in the 

specification. Also disclosed is the method of producing said derivatives 

and the application thereof in therapeutics as â-secretase for treating 

neurodegenerative disorders such as Alzheimer's disease. 

(21) 583024 (22) 31 Jul 2008 

(54) An agonist of miR-29a, miR-29b or miR-29c that prevents tissue 

fibrosis and uses thereof 

(86) PCT/US2008/071839 (87) WO2009/018493 

(51) IPC2012.01:A61P9/00, 10; A61K38/00; A61K31/7105; C07K5/00; 

A61K48/00; C12N15/11 

(71) Board of Regents, The Univeristy of Texas System 

(72) OLSON, Eric; VAN ROOIJ, Eva 

(31) 60/952,917 (32) 31 Jul 2007 (33) US 

(31) 60/980,303 (32) 16 Oct 2007 (33) US 

(31) 61/047,014 (32) 22 Apr 2008 (33) US 



(57) Disclosed is the use of an agonist of miR-29a-c for the preparation 

of a medicament for treating or preventing a tissue fibrosis in a subject 

in need thereof, wherein the agonist of miR-29a-c is a polynucleotide 

comprising a pri-miRNA, pre-miRNA, or mature sequence of miR-29a, 

miR-29b, and/or miR-29c. 


(21) 583033 (22) 6 Aug 2008 

(54) TRICYCLIC BRIDGED CYCLOPENTANEDIONE DERIVATIVES AS 

HERBICIDES 

(86) PCT/EP2008/006467 (87) WO2009/019005 

(51) IPC2012.01:C07D493/08; A01N43/08 

(71) SYNGENTA LIMITED 

(72) TYTE, Melloney; MATHEWS, Christopher, John; HALL, Gavin, 

John; WHITTINGHAM, William, Guy; WAILES, Jeffrey, Steven; SCUTT, 

James, Nicholas; JEANMART, Stephane, Andre, Marie; VINER, Russell 

(31) 0715454.5 (32) 8 Aug 2007 (33) GB 



(57) Disclosed are tricyclic bridged cyclopentanedione derivatives 

represented by general formula (I). An example of a compound of 

formula (I) includes carbonic acid (1RS,2SR,6RS,7SR)-5-oxo-4-(2,6diethyl-4-methylphenyl)-10-oxatricyclo[5.2.1.02.6]-dec-3-en-3yl 

ester 

ethyl ester. The compounds are used to control grasses and weeds in 

crops. 

(21) 583062 (22) 22 Aug 2008 

(54) An interface device for a wind turbine control system and a method 

for inputting commands to a wind turbine controller 

(86) PCT/EP2008/061019 (87) WO2009/033931 

(51) IPC2012.01:G08C17/00; G10L15/22 

(71) SIEMENS AKTIENGESELLSCHAFT 

(72) JENSEN, Michael 

(31) 07017914.8 (32) 12 Sep 2007 (33) EP 



(57) An interface device for a wind turbine control system, in particular 

provided for a service or maintenance procedure, where the interface 

device is connected to a controller of the wind turbine control system 

for user communication with the controller, is disclosed. The interface 

device comprises: a controller interface; a processor; a speech 

recognition unit; a microphone; and an output unit. The controller 

interface is connected to the controller for sending commands and/ 

or data to and receiving commands and/or data from, the controller. 

The processor is connected to the controller interface to produce 

commands and/or data for the controller and to interpret commands and/ 

or data received from the controller and to provide an output a signal 

representing the interpreted data. The speech recognition unit translates 

electrical signals representing orally input commands or data into an 

input command signal or input data signal and which is connected to 

the processor. The microphone allows an oral command input and/ 

or an oral data input to the interface device. An electrical signal from 

the microphone is input to the speech recognition unit. The output unit 

is connected to the processor for receiving commands or data. The 

processor comprises: a command manager to: produce, upon receipt 

of an input command signal, a reproduction signal representing the 

received input command signal in a form which is appropriate to be 

recognised by the user and a confirmation request signal, to deliver the 

reproduction signal and the confirmation request signal to the output 

unit, and to further process the received input command signal only 

upon receipt of a confirmation by the user. The interface device provides 

an inactive state, an idle state, a watchdog state representing a dead 

man button function, an error state, an operator information state and 

a command state. 

(21) 583147 (22) 8 Aug 2008 

(54) DEHYDROEPIANDROSTERONE COMPOSITIONS FOR 

TREATING MENOPAUSE 

(86) PCT/CA2008/001444 (87) WO2009/021323 

(51) IPC2012.01:A61K31/5685, 453, 56; A61P15/12; A61P5/26, 32 

(71) ENDORECHERCHE, INC. 

(72) LABRIE, Fernand 

(31) 60/964,270 (32) 10 Aug 2007 (33) US 

(31) 60/964,673 (32) 13 Aug 2007 (33) US 



(57) Disclosed is the use of a sex steroid precursor selected from the 

group consisting of dehydroepiandrosterone, dehydroepiandrosteronesulfate, 

androst-5-ene-3beta,17beta-diol, and 4-androsten-3,17-dione, 

optionally combined with a Selective Estrogen Receptor Modulator 

(Acolbifene), in the manufacture of a medicament for treating 

or reducing the likelihood of acquiring vaginal diseases or 

problems selected from urinary incontinence, vaginal atrophy, 

atrophic vaginitis, vaginal dryness, dyspareunia and sexual 

dysfunction in postmenopausal women, wherein said medicament 

is formulated for intravaginal administration of said sex steroid 

precursor at a therapeutic amount of 13 mg per day or 

less. Further disclosed is a pharmaceutical composition for 

intravaginal administration comprising a sex steroid precursor 

selected from dehydroepiandrosterone, dehydroepiandrosteronesulfate, 

androst-5-ene-3beta,17beta-diol, and 4-androsten-3,17-dione 

and further comprising a pharmaceutically acceptable excipient, 

diluent or carrier. Also disclosed is a vaginal suppository comprising 

dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androst-5ene-3beta,17beta-diol, 

and 4-androsten-3,17-dione and an excipient 

comprising saturated fatty acid asters or Witepsol H-15. 




(21) 583284 (22) 14 Aug 2008 

(54) CYCLIC DEPSIPEPTIDES FROM ISOLATED CHONDROMYCES 

CROCATUS USEFUL AS INHIBITORS OF KALLIKREIN 7 AND 

HUMAN NEUTROPHIL ELASTASE 

(86) PCT/EP2008/060689 (87) WO2009/024527 

(51) IPC2012.01:C07K11/02; A61K38/15 


(72) KRASTEL, Philipp; LIECHTY, Brigitta-Maria; MEINGASSNER, Josef 

Gottfried; SCHMITT, Esther; SCHREINER, Erwin Paul 

(31) 07114507.2 (32) 17 Aug 2007 (33) EP 



(57) Disclosed herein is a cyclic depsipeptide having the structure of 

formula (I), wherein an ester bond is formed between the carboxy 

group of A7 and the hydroxyl group of A2, wherein the acyl residue 

X is CH3CH2CH(CH3)CO or (CH3)2CHCO, A1 is glutamine, glutamic 

acid, or a derivative thereof, A2 is threonine,A3 is leucine, A4 is Ahp, 

3-amino-piperidine-2-one, proline, 5-hydroxy-proline or a derivative 

thereof, A5 is isoleucine, A6 is tyroxine, N-Me-tyrosine or a derivative 

thereof, A7 is isoleucine or valine;or a pharmaceutically acceptable salt 

thereof. Also disclosed is the extraction of said compound from isolated 

Chondromyces microorganism from the strain Chrondromyces crocatus 

(DSM 19329) as well as an alternative process for its preparation. 

(21) 583334 (22) 15 Aug 2008 

(54) Lighting assembly, enclosure and method for growing plants using 

specific wavelength LED's 

(86) PCT/EP2008/060776 (87) WO2009/022016 

(51) IPC2012.01:A01G7/04; F21V29/02; F21Y101/02; A01G9/20 

(71) Lemnis Lighting Patent Holding B.V. 

(72) ROOYMANS, Johannes Otto 

(31) 07114397.8 (32) 15 Aug 2007 (33) EP 



(57) Disclosed is a lighting assembly for growing plants. The lighting 

assembly has a first light source emitting light in a first wavelength 

range of 600 to 750 nm; a second light source emitting light in a second 

wavelength range of 375 to 500 nm; and a controller for controlling the 

output of the first light source independent from the output of the second 

light source. Disclosed are also an enclosure for growing plants, and a 

method for growing plants. 

(21) 583449 (22) 25 Jul 2008 

(54) THE APPLICATION OF 3, 5-DIHYDROXYTOLUENE OR 

DERIVATIVES THEREOF IN THE PREPARATION OF MEDICINE 

AND FUNCTIONAL FOR TREATING OR PREVENTING 

DEPRESSION 

(86) PCT/CN2008/071752 (87) WO2009/018747 

(51) IPC2012.01:A61K31/05, 085, 7032; A23L1/30; A61P25/24 

(71) KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY 

OF SCIENCES; KUNMING INSTITUTE OF ZOOLOGY, CHINESE 

ACADEMY OF SCIENCES; KUNMING JINGBIAO BIOSCIENCES R & 

D CO., LTD. 

(72) CHEN, Jijun; XU, Lin; ZHOU, Jun; LU, Jun; MAO, Rongrong; TIAN, 

Meng; ZHOU, Qixin; ZHANG, Xuemei; SHEN, Yong; JIANG, Zhiyong; 

ZUO, Aixue 

(31) 200710066088.7 (32) 3 Aug 2007 (33) CN 



(57) Disclosed herein is the use of 5-methyl-1,3-benzenediol derivatives 

as represented by the compounds of formula I-IV in the manufacture 

of a medicament of a functional food for use in treating or 

preventing depression or its symptoms, in particular, circadian rhythm 

disorders, sleep disorders, chronic stress, anxiety, acute stress-induced 

impairment, or cognitive functional impairment or disorders. 

(21) 583475 (22) 24 Dec 2008 

(54) A TRAILER HWERE THE TRAILER BED IS RAISED AND 

LOWERED BY AN ACTUATING MEANS IN THE PLANE OF THE 

WHEEL 

(86) PCT/AU2008/001907 (87) WO2009/086586 

(51) IPC2012.01:B60P1/02, 34; B60G3/14, 20; B62D63/06, 08; B60P3/07, 

12 

(71) Innovare Motion Pty Ltd 

(72) FANKHAUSER, Jason; MCKAY, Colin 

(31) 2008900040 (32) 4 Jan 2008 (33) AU 

(31) 2008905593 (32) 30 Oct 2008 (33) AU 

(74) WADESON, Level 27 101 Collins Street, Melbourne, Vic 3000, 

Australia 

(57) A trailer is disclosed including a draw bar (12), a trailer frame (15’), 

a wheel carrying structure (30’) and an actuating means (40’, 44’). The 

wheel carrying structure (30’) carries at least one wheel (22’) and is 

located laterally inward of the wheel (22’). The actuating means (40’, 

44’) can be actuated to exert a force on the wheel carrying structure 

(30’) to raise or lower the trailer frame (15’) and is located substantially 

in the plane of rotation of the wheel (22’).

Patent abridgements Part 1 - Intellectual Property Office of New ...

Create successful ePaper yourself

Delete template?

Save as template?